Balancing tissue homeostasis and inflammatory responses against Candida albicans infections: is it a matter of mast cells&apos; immunological memory? by DE ZUANI, Marco
	 
PhD course in Biomedical Sciences and Biotechnology  
 
 
XXX Cycle 
 
 
 
 
 
Balancing tissue homeostasis and inflammatory 
responses against Candida albicans infections: 
is it a matter of mast cells' immunological 
memory? 
 
 
 
 
 
 
 
 
PhD Candidate:  
Marco De Zuani, MSc  
 
    Supervisor:  
    Prof. Carlo E.M. Pucillo, MD  
 
    Tutor: 
    Dr. Barbara Frossi, PhD 
 
 
 
Academic year 2017-2018 
University of Udine
Department of Medicine
PhD course in Biomedical Sciences and
Biotechnology – XXX Cycle
Balancing tissue homeostasis and
inflammatory responses against
Candida albicans infections: is it
a matter of mast cells’ immuno-
logical memory?
PhD Candidate:
Marco De Zuani, MSc
Supervisor:
Prof. Carlo E.M. Pucillo, MD
Tutor:
Dr. Barbara Frossi, PhD
Academic year 2017-2018

Personalmente penso che le qualità
dell’uomo vengono esaltate dalla
sua capacità di elevarsi nella
conoscenza, più che nel suo talento
di coltivare antiche illusioni.
Per far questo, purtroppo, è però
necessario rinunciare a un certo
mondo incantato; è necessario cioè
uscire dalla stanza delle fiabe e dei
racconti fantastici. Ciò può essere
scomodo e anche deludente.
Personalmente non lo penso. Penso
che l’avventura dell’intelligenza sia
molto più stimolante di quella della
credulità. E che il desiderio di
scoprire sia più eccitante di quello
di rimanere nella stanza delle fiabe.
E credo che, comunque, sia difficile
rimanerci quando la porta è ormai
aperta.
Piero Angela - Viaggio nel mondo del
paranormale, 1978

CONTENTS
1 abstract 1
I theoretical background 3
2 introduction 5
2.1 Why do we have mast cells? 5
2.1.1 A peculiar cell in our bodies: MCs biology. 6
Evolutionary aspects. 7
Mast cell development. 7
Mast cell biology. 10
Approaches to study mast cells in vivo 12
2.1.2 Mast cells: tissue-resident ”rabbit ears”. 14
FceRI activation 16
Toll-like receptors. 19
C-type lectin receptors. 25
Other receptors 27
2.1.3 MCs (social) networks: crosstalk with other immune
system cells. 27
2.1.4 Do we really need mast cells? Roles in health and dis-
ease. 29
2.2 Hold the door! Immunity to fungal infections. 32
2.2.1 Candida albicans. 34
2.2.2 Innate sensing 35
CLRs 35
TLRs 36
NLRs 36
2.2.3 Innate immunity to fungal infections 37
Immunity at the epithelial barrier 37
Neutrophils 38
Monocytes and macrophages 38
Dendritic cells and T-cell activation 38
2.2.4 Are mast cells playing the game? 39
2.3 Innate immune memory. 41
2.3.1 Innate immune memory in vertebrates. 42
2.3.2 Endotoxin tolerance: the other side of the coin? 43
2.3.3 Mechanisms of innate immune memory. 44
Studies in lower taxa. 44
Molecular mechanisms of trained immunity in verte-
brates. 46
Molecular mechanisms of endotoxin tolerance. 47
2.3.4 MASTer memory: a changing concept in MC biology. 49
3 aim of the work 51
II experimental studies and results 53
4 results 55
V
VI Contents
4.1 Mast cell - Candida interactions. 55
4.1.1 MC - Candida immunological synapse. 55
4.1.2 MCs degranulation in response to fungal challenge. 57
4.1.3 Cytokine release in response to fungal challenge. 57
4.1.4 MCs activation status affects macrophage behaviour. 59
Macrophage crawling is increased in the presence of
activated MCs. 59
Resting MCs partially inhibit macrophage phagocyto-
sis ability. 60
Impaired phagocytosis of Candida by macrophages is
not dependent on MCs soluble mediators. 62
4.2 Mast cells training by microbial PAMPs. 64
4.2.1 MCs priming affect their response to secondary inflam-
matory stimuli. 65
4.2.2 MCs training by microbial products does not affect
MCs phenotype. 65
Histochemical comparison. 65
Surface markers expression. 67
4.2.3 LPS conditioning impairs the PI3K-AKT pathway. 69
4.2.4 LPS conditioning modulates TNF-α transcription. 72
5 discussion 75
6 experimental procedures 81
III back matter 89
L I ST OF TABLES
Table 2.1.1 Murine and human MC subtypes. 13
Table 2.1.2 Murine models to study mast cells in vivo 15
VII

L I ST OF F IGURES
Figure 2.1.1 200 Deutsche Mark banknote. 5
Figure 2.1.2 Transmission electron microscopy image of mast cells. 6
Figure 2.1.3 Evolution of mast cells and basophils. 8
Figure 2.1.4 Model of MC lineage development. 9
Figure 2.1.5 Serglycin structure. 11
Figure 2.1.6 Timing of mast cell response to challenges. 16
Figure 2.1.7 Signaling in FceRI-induced activation. 18
Figure 2.1.8 TLRs structure and activation pathways. 21
Figure 2.1.9 TLR4 signaling. 23
Figure 2.1.10 Dectin-1 structure. 25
Figure 2.1.11 Dectin-1 signaling network. 26
Figure 2.2.1 Published papers about “microbiota” from 1956 to
2017. 32
Figure 2.2.2 The human mycobiota. 33
Figure 2.2.3 Morphology and structure of Candida albicans. 35
Figure 2.2.4 Recognition of Candida by innate immune cells. 37
Figure 2.3.1 Proposed model of differential programming of in-
nate immunity. 41
Figure 2.3.2 Classical immunological memory and innate immune
memory. 42
Figure 2.3.3 Epigenetic regulation of innate immune memory. 48
Figure 4.1.1 Dectin-1-/- BMMC differentiation. 55
Figure 4.1.2 Mast cells can tightly interact with C. albicans hyphae. 56
Figure 4.1.3 MCs degranulation and cytokine release in response
to C. albicans. 58
Figure 4.1.4 Peritoneal macrophages purification. 60
Figure 4.1.5 Mast cell activation influence peritoneal macrophage
behaviour. 61
Figure 4.2.1 Schematic representation of the experimental proto-
col. 64
Figure 4.2.2 BMMCs priming modulate the response to secondary
challenges. 66
Figure 4.2.3 MCs phenotype after the conditioning period. 68
Figure 4.2.4 LPS-primed MCs differentially activate the PI3K-AKT
pathway. 70
Figure 4.2.5 TNF-α expression is skewed after LPS priming. 72
Figure 5.0.1 Proposed model of MCs activation during fungal in-
fections. 80
IX

1 ABSTRACT
Mast cells (MC) are long lived immune cells widely distributed at mucosal
surfaces among the first immune cell type that can get in contact with the
external environment. This study aims to unravel the mechanisms of recipro-
cal influence between mucosal mast cells, the human commensal Candida al-
bicans and microbial bioproducts. Stimulation of bone marrow-derived mast
cells (BMMC) with live forms of C. albicans induced the release of TNF-α,
IL-6, IL-13 and IL-4. Quite interestingly, BMMC were able to engulf C. albi-
cans hyphae, rearranging their α-tubulin cytoskeleton accumulating LAMP1+
vesicles at the phagocytic synapse with the fungus. Infected MCs failed to
promote macrophage chemotaxis but instead increased their crawling abil-
ity. On the other side, resting MCs inhibited macrophage phagocytosis of C.
albicans in a contact-dependent manner.
Several microbial ligands are known to induce immune memory on mac-
rophages and natural killer cells. To determine whether this is true also for
MCs and if their training could afford protection against fungal infections,
BMMCs were stimulated for 24 hour with microbial ligands, washed and
allowed to rest for 6 days and then restimulated with LPS or C. albicans. LPS-
primed cells showed a decreased release of TNF-α and IL-6 upon restimula-
tion with LPS (a condition known as endotoxin tolerance) but an increased
release of TNF-α during fungal challenge. The impaired response during
endotoxin tolerance relied on the impaired activation of the PI3K-AKT-p38
pathway, which led to a decreased NF-κB activation and TNF-α expression.
On the other side, the training effect of LPS was mediated by the enhanced
activation of NF-κB and the sustained basal transcription of TNF-α.
These results indicate that MCs are important gatekeeper of tissue home-
ostasis. Signals received from the microbiota can shape their immune mem-
ory, dampening the inflammation in response to bacterial LPS but affording
protection during fungal infections.
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Part I
THEORET ICAL BACKGROUND

2 INTRODUCT ION
2.1 why do we have mast cells?
The first thing that comes to mind when trying to describe mast cells(MCs) is ”Those cells responsible for your itching, sneezing and allergies”.
The reason for such a bad reputation needs to be searched in history: these
neglected cells have been described as principal effectors in anaphylaxis
(and, later, allergy) since the beginning of the twentieth century.
Figure 2.1.1: German 200 DeutscheMark banknote. The banknote, depict-ing Paul Ehrlich and the chemical struc-ture of Arsphenamine, was issued by theDeutsche Bundesbank in 1989. Fromthe Paul-Ehrlich-Institut website. http:
\www.pei.de
MCs are granulated, tissue resi-
dent cells that belong to the innate
arm of the immune system. These
cells were firstly observed in 1863
by Friedrich von Recklinghausen
which described them as granular
cells found in frog mesentery1. 14
years later, MCs were identified and
characterized also in human tissues
by the medical student Paul Ehrlich
in his thesis on the use of aniline
dyes on microscopic specimens. He
described MCs as aniline-positive
cells localized around blood vessels
in connective tissues, which gran-
ules content stained metachromatic-
ally with aniline dyes2. These cells were named ”Mastzellen” after the ger-
man word ”mast” (i.e. “fattening”), by virtue of their granules which were
thought to have a nutritional function. Paul Ehrlich studies on MCs led him
to be awarded in 1908, together with Ilya Ilyich Mechnikov, of the Nobel
Prize in Physiology or Medicine. Later in 1902, Paul Portier and Charles
Richet introduced the concept of anaphylaxis (even though analogous obser-
vations were made earlier in 1873 by Charles Blakely) as the symptoms of
anaphylactic shock caused by the extract of the jellyfish Phycalia tentacles
on dogs that were already challenged with the same extract several days
earlier3,4. Further studies on the mechanisms of anaphylaxis led Richet to
be awarded with the Nobel Prize in Physiology or Medicine five years after
Ehrlich. Only four years later, in 1906, a similar concept was introduced by
Clemens von Pirquet during his studies on smallpox vaccine administration
as he noted that some patients showed worse adverse effects following the
re-administration of the vaccine5. These observations led him to coin the
word allergy (after the greek allos, diverse, and ergia, energy) to describe the
phenomenon. Starting form 1910, when Dale and Laidlaw described for the
first time histamine, different studies were performed to unravel the nature
of anaphylaxis6. Albeit being supposed for many years, it was only in dur-
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Figure 2.1.2: Transmission electron microscopy image of mast cells. Restingand degranulated rat peritoneal MCs. The resting cell show an homogenousdistribution of granules which contain electron-dense material. During the de-granulation process, granules are fused together and released from the cell. Longarrows indicate two regions where multiple granules have extensively fused; theshort arrow indicates an exocytosed membrane-free granule remnant. Adaptedfrom Wernersson and Pejler 15 .
ing the 50’s that the presence of histamine in MCs granules was confirmed7.
In the same years, different studies determined that MCs were the predom-
inant source of this molecule and, moreover, that different compounds (e.g.
stilbamidine, compound 48/80) were able to induce the release of histamine
by MCs eventually inducing anaphylactic shock8,9. Finally, a connection be-
tween MCs, histamine and anaphylaxis was defined.
A key point was still missing: which mechanism was responsible for MCs
activation during allergy? Albeit primitive answers were already given dur-
ing the 20’s, it was only in 1959 that Ishizaka and Campbell determined how
antigen-antibody complexes were able to induce passive cutaneous anaphy-
laxis in guinea pigs10. In a follow-up study, Ishizaka and Ishizaka finally
identified the specific reaginic antibody as γE-antibodies (IgE)11. From thisIgE is an independent class
of immunoglobulin
characterized by the e heavy
chain. IgE antibodies are
monomeric soluble proteins
of ∼180kDa and are a minor
component of the Ig pool
under normal conditions
(<0.01% in human
serum)12,13.
day on, many different studies have been performed to identify and charac-
terize the putative IgE receptor on MCs surface. Finally, in 1989, the high
affinity IgE receptor FceRI and its subunits were cloned and characterized14.
2.1.1 A peculiar cell in our bodies. MCs origin, development and biology.
MCs are tissue-resident cells widely distributed through the body and
are particularly abundant in the skin, gut and airways. They are generally
localized close to epithelial cell, venules, nerves and smooth muscle cells,
and thus are one of the first immune cell type that can get in contact with
signals from the external environment. The ability to detect and respond to
external signals is ensured by the wide plethora of receptors expressed by
these cells and by their ability to release many different soluble mediators.
MCs possess a high number of cytoplasmic granules which contain a great
number of preformed immunomodulatory compounds (Fig. 2.1.2). Various
signals can trigger MCs activation and degranulation, i.e. a rapid release
of granule content, but can also induce the synthesis of many biologically
active molecules.
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Evolutionary aspects.
It is believed that MCs may derive from a leukocyte ancestor which shared
functional characteristics similar to those of actual invertebrate granular
haemocytes. These cells were presumably involved in the protection of the
host by encapsulation, phagocytosis and killing of pathogens16. A puta-
tive MC-basophil ancestor has been described in the ascidian Styela plicata
(Fig. 2.1.3). These organism possess circulating granular haemocytes which Ascidian (class Ascidiacea,
subphylum Tunicata,
phylum Chordata) are a
group of marine invertebrate
organism which are closely
related to vertebrates and
have probably arisen ≈550
million years ago during the
“Cambrian explosion”17.
ultrastructurally resemble vertebrate MCs and contain both histamine and
heparin. In the same organism were also reported accessory cells termed
“test cells” which contain histamine and tryptase, and can be activated by
the vertebrate MCs secretagogue Compound 48/8018,19. MC-like cells can be
found in many Perciformes and have been described to contain histamine20.
Also zebrafish (Danio rerio Hamilton, order Cypriniformes) possess granu-
Perciformes (class
Actinopterygii, phylum
Chordata) are the largest
order of vertebrates and
represent the most
evolutionarily advanced
clade of teleost fish21.
lated cells mainly localized in the gills and in the intestine. These cells are
very similar to murine MCs, can be stained metachromatically with tolui-
dine blue and stain positively for tryptase and KIT, the stem cell factor (SCF)
receptor. Strikingly, these cells express a FceRI-like receptor22,23. Albeit be-
ing described in zebrafish MCs, FceRI is believed to be a recent acquisition
in MCs evolution seen that IgE (and IgG) originated in mammals probably
from an IgY-like ancestor16,24,25. Moreover, there is still no evidence of a
specific IgY or IgM receptor on avian, reptile or amphibian MCs, nor about
the possible role of these antibodies in MCs activation. During mammal
evolution, and particularly during primate speciation, a great number of
mutations occurred in the chymase and tryptase gene locus, leading to an
enormous gene diversification in different mammalian species26,27. The fact
that these ancient cells persisted trough 500 million years of evolution indi-
cates that they still play a role in the maintenance of host immunity. Their
role clearly changed from a mere effector against pathogens to a more com-
plex player in the regulation of both the innate and the adaptive arms of
immunity, as well as many different non-immunological processes.
Mast cell development.
MCs originate in the bone marrow from an hematopoietic progenitor
through a myeloid lineage but, unlike other myeloid-derived cells, MCs pro-
genitors leave the bone marrow at an early stage of differentiation to enter
the circulation. Once in the blood stream, they rapidly migrate to peripheral
tissues (so rapidly that they are barely detectable in peripheral blood) and
complete their differentiation into mature MCs with tissue-specific pheno-
types29. This uncommon developmental process is one of the peculiar trait
of these unique cells.
MCs lineage development has been studied mostly in mice but is still
rather debated. Early studies in the 70s by Kitamura et al. indicated that
MCs were originated in the bone marrow (BM) but only in recent years
it was demonstrated that MCs develop through the myeloid lineage from
a Kit+ Sca1+ hematopoietic stem cell (HSC), to a Kit+ Sca1lo FcγRII/IIIlo
common myeloid progenitor (CMP), and finally to a Kit+ Sca1- FcγRII/IIIhi
granulocyte monocyte progenitor (GMP) (Fig. 2.1.4)30,31. This GMP is sup-
posed to be shared by MCs, basophils, eosinophils, neutrophils and mono-
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Figure 2.1.3: Evolution of mast cells and basophils. The first putative ancestorfor MCs and basophil was found in the ascidian Styela plicata. This urochor-date possess mast cell/basophil like (MCBL) granular cells and test cells, bothcontaining histamine and heparin. With the divergence of teleost fish and rep-tiles, also MCs and basophil lineages separated. Both cells express activatingFcR-like receptors and reptile basophils can degranulate in response to FcRtriggering. With the comparison of mammals and IgE these cells acquired thecomplete Fc receptor while the protease gene family underwent a great diver-sification. Adapted from Voehringer 28 .
cytes. In addition, it appears that the commitment of this GMP to MCs or
basophils is tightly regulated by the expression levels of the transcription fac-
tors GATA-binding protein 2 (GATA2) and CCAAT/enhancer-binding pro-
tein α (C/EBPα)32. On the contrary, two recent works demonstrated that
mast cell progenitors (MCP) may derive directly from a CMP. The authors
identified a rare population of Kit+ Sca1- β7 integrin+ FcγRII/IIIlo MCP de-
rived from a Kit+ Sca1lo CMP that sorted with the megakaryocite-erithroid
lineage33,34. Increasing the complexity of this picture, a LIN- CD34+ Kit+
FcRIα- β7 integrinhi FcγRII/IIIhi bipotent basophil/mast cell progenitor
(BMCP) was identified in the spleen of adult C57BL/6 mice and appeared
to fill an intermediate step between GMP and MCP. Again, GATA2 and
C/EBPα regulate the commitment of this progenitor at least in vitro, as the
complete deletion of C/EBPα favors the development of MCs while the over-
expression of the same transcription factor give rise to a basophil popula-
tion35. The role of GATA2 and C/EBPα transcription factor in the decision of
MCs fate was confirmed also by two works recently published36,37. Ohmori
et al. showed that deletion of GATA2 in differentiated bone marrow-derived
mast cells (BMMC) resulted in a loss of MCs phenotype and to the upregula-
tion of C/EBPα; likewise, the re-expression of C/EBPα in mature MCs led to
an equivalent loss of phenotype36. Similarly, the overexpression of C/EBPα
in differentiated BMMC suppressed granule formation and downregulated
the expression levels of different mast cell proteases (e.g. Mcpt-1, Mcpt-2,
Mcpt-4)37.
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Figure 2.1.4: Model of murine MC lineage development. MC progenitors(MCP) originate in the bone marrow from hematopoietic stem cells (HSC), toa common myeloid progenitor (CMP) and a granulocyte monocyte progenitor(GMP) - which also gives rise to neutrophils, eosinophils, monocytes and ba-sophils. It is also proposed that MCP originate directly from a CMP that sortswith the megakaryocite-erithroid lineage. Moreover, a bipotent basophil/mastcell progenitor (BMCP) which can further differentiate in vitro to MCs or ba-sophils, was identified in the spleen. Once released in the blood stream, MCsquickly migrate to peripheral tissues where they complete their differentiation.
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After entering the blood stream, MCP quickly leave it to enter into tis-
sues by transendothelial migration. Nowadays it is known that many inte-
grins and chemokines are involved in the recruitment of MCs at peripheral
site. For instance, α4β7 integrin, its ligands mucosal vascular addressin cell
adhesion molecule 1 (MAdCAM-1) and vascular cell adhesion molecule 1
(VCAM-1), and the CXC chemokine receptor 2 (CXCR2) are fundamental
for the homing of MCP to the intestine38. Moreover, mice lacking integrin
αMβ2 and αIIbβ3 have an impaired number of MCs in the peritoneum while
injection of the chemokine CCL2 recruited MCP to the skin39–41. Recent data
show that peritoneal MCs and -to a lower extent- skin MCs stained positive
for the proliferation marker Ki67 suggesting that this cells might also locally
proliferate42.
Contrarily from most hematopoietic lineages, cKit expression is not lost
with MCs differentiation. As a general rule, MCs development, survival and
proliferation is dependent on stem cell factor (SCF), which binds cKit, and IL-
3 signaling. However, in vitro stimulation with IL-3 is sufficient for murine
BMMC development and addition of SCF synergizes for optimal MCs prolif-
eration43. Surprisingly, Il-3-deficient mice are able to develop MCs despite
their impaired IL-3 signaling44. Recent studies determined that also hu-
man CD34+ mast cell progenitors could functionally develop in vitro in the
absence of IL-3 or in the absence of SCF and KIT signaling45,46. This last ob-
servation might somehow reflect the fact that in MC-deficient KitW/W-v mice
(which harbor a mutated version of cKit, see Tab. 2.1.2) MCs deficiency can
be partially reverted by chronic inflammatory stimuli as idiopathic chronic
dermatitis47,48.
Differential stimulation of MCs during their maturation leads to the devel-
opment of MCs with peculiar phenotypes. This concept is of fundamental
importance because in vivo MCs terminal differentiation occurs at periph-
eral sites where the microenvironment signals (cytokines, growth factors,
cell-cell contact) are specific for all the distinct anatomical localizations, thus
giving rise to MCs with tissue-specific phenotypes29. Moreover, MCs can
dynamically change their phenotype also after being fully matured as the
microenvironmental condition change - a process which is likely to occur
since MCs are long lived cell and can survive in tissues for up to 12 weeks49.
This concept of plasticity will be thoroughly discussed in the next section.
Mast cell biology.
Albeit their plasticity, murine mature MCs can be divided into two main
categories on the basis of their localization and granule content: connective-
tissue mast cells (CTMCs) and mucosal mast cells (MMCs). CTMCs are
constitutively present in tissues and are mainly localized in serosal cavities,
around venules and nerves. On the other side, MMCs are predominantly
present in the mucosal tissues of the gut and in the respiratory tract mu-
cosa29,50. MMCs are lower in number and expand during infection in a T-cell
dependent manner seen that athymic mice fail to induce MMCs expansion
during Trichinella spiralis infections51. At “baseline”, MCs subpopulations
can be distinguished on the basis of their protease and proteoglycan content
(Tab. 2.1.1). MMCs express transcripts for the chymases MCPT1 and MCPT2,
2.1 why do we have mast cells? 11
Figure 2.1.5: Serglycin structure. Serglycin core protein is characterized bya ∼20 aa Ser-Gly repeat region, in which every repeat constitute a potentialattachment site for GAG chains (heparin or chondroitin sulphate). GAG: gly-cosaminoglycan. Adapted from Wernersson and Pejler 15 .
and contain serotonin but no (or little) histamine. On the contrary, CTMCs
express the chymase MCPT4, the elastase MCPT5, the tryptases MCPT6 and
MCPT7 (except for C57BL/6 mice which present a point mutation on the
Mcpt7 gene52) and Carboxypeptidase A4 (CPA3)53–56. CTMCs also contain
serotonin and high levels of histamine57. Most importantly, the protease
content of both MCs subsets can vary with the different anatomical localiza-
tion of the cells. For instance, MMCs in the intestine of T. spiralis infected
mice expressed only MCPT1, while CTMCs expressed both MCPT4, MCPT5,
MCPT6, MCPT7 and CPA355,56. On the other side, in an allergic inflamma-
tion model both tracheal MMC and CTMC expressed all the six proteases,
while in the proximal bronchi MMC expressed only MCPT1, MCPT6 and
MCPT7 while CTMCs were still positive for all the six proteases58. A re-
cent work by Dwyer et al. compared different subsets of murine MCs puri-
fied from different anatomical compartments and demonstrated that these
cells had considerable tissue-specific gene expression: among the most dif-
ferentially expressed genes the authors found proteases, G protein-coupled
receptors and homing markers as integrins42.
A better marker which can be used to distinguish among MMCs and
CTMCs, is the proteoglycan content of their granules. These heavily glycosy-
lated proteins are fundamental for MCs granule development, homeostasis
and for the storage of several MCs proteases59. Serglycin is a peculiar pro-
teoglycan core protein highly expressed by MCs, which present an extended
region of Ser-Gly repeats (∼20 aa in mouse and human) with every Ser-
Gly repeat constituting a potential attachment site for glycosaminoglycans
(GAG) chains60. The high anionic charge of GAG is believed to interact elec-
trostatically with the net positive charge of several MCs proteases such as
MCTP4, MCPT5, MCPT6 and CPA3 (Fig. 2.1.5)61. MCs contain two differ-
ent GAG: heparin and chondroitin sulphates (di-B, A and E). In particular,
MMCs contain mainly chondroitin sulphate di-B, A and E, while CTMCs
contain both chondroitin sulphate E and high amounts of heparin (which
allow them to be stained with Safranin)62–64.
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Taken together this data increase the complexity of the picture and in-
dicates that MCs maturation in peripheral tissues can give rise to a great
number of MCs-subset with small or moderate differences in their pheno-
type, thus making it harder to make generalizations about MCs role indepen-
dently of their localization. This concept of plasticity is further confirmed by
in vitro studies. BMMC are considered partially immature MCs (if compared
with mature in vivo isolated MCs) and their phenotype is thought to be an in-
termediate form between MMCs and CTMCs: they express MCPT5, MCPT6
and CPA3 (which is a CTMC-like phenotype) but the proteoglycan content
is more similar to those of MMCs (low levels of histamine and heparin)59,65.
Anyway, culturing BMMC on a monolayer of fibroblast and in presence of
IL-3, increased the granule content of heparin and histamine and led to the
development of MCs more similar to CTMCs66. This mechanism seems to
be mediated by the release of SCF by fibroblast and culturing BMMC with
IL3 and SCF phenocopied MCs obtained by the culture with fibroblast but
without a full maturation of granules, suggesting that cell-cell contact is in-
deed fundamental for the maturation process67. In terms of protease content,
BMMC obtained with IL-3 stimulation alone expressed MCPT5, MCPT6 and
CPA3. Interestingly, these cells could be induced to express also MCPT4,
MCPT1, MCPT2 or higher levels of MCPT6 by the addition of SCF, IL-9,
IL-10 or IL-33 respectively68–70.
Human MCs can also be divided into three main categories on the ba-
sis of the proteases stored in their granules: tryptase-positive MCs (MCT),
tryptase- and chymase-positive MCs (MCCT), and chymase-positive MCs
(MCC) (see Tab. 2.1.1). MCCT can be considered the human counterpart of
murine CTMCs and are mainly localized in the skin, gastro-intestinal submu-
cosae and esophageal subepithelium, while MCT are more similar to murine
MMC and are particularly abundant in the lung and in the gastro-intestinal
mucosae71,72. On the contrary, MCC are quite infrequent and have no pecu-
liar localization72. Also human MCT are thought to require T-cell for their
expansion seen that patients with acquired or congenital T-cell deficiencies
also show reduced number of MCT 73. Both MCT and MCCT subpopulations
contain heparin and chondroitin sulphate (A ad E)74.
Approaches to study mast cells in vivo
Over the past decades several animal models of MCs-deficiency have been
developed in order to study MCs roles in vivo (Tab. 2.1.2). The first MCs de-
ficient mice described, harbored naturally occurring loss-of-function muta-
tions at the KIT-encoding locus (known as white spotting locus W). The two
main models used are KitW/W-v and KitW-sh/W-sh. KitW/W-v mice carry one allele
(W) with a point mutation which encodes a truncated version of KIT, and
one allele (W-v) with a point mutation in the tyrosine kinase domain of KIT.
This mutations causes the depletion of all MCs populations but also cause
many important defects due to the loss of KIT: mice are sterile due to the
lack of germ cells, are profoundly anemic and neutropenic, lack interstitial
cells of Cajal in the small intestine and have an impaired γδ-T cells develop-
ment in the gut78. The other model, KitW-sh/W-sh, present a 3 Mb inversion in
chromosome 5 ∼70 kb upstream of the KIT gene, causing abnormal KIT ex-
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MC subtypes
Murine Human
MMC CTMC MCT MCTC
Anatomical
localization
Respiratory
tract; gastric,
small intestinal
and colonic
mucosae50,75–77
Skin; tongue;
trachea; large
airways; serosal
cavities50,75–77
Lung alveoli
and bronchi;
gastric, small
intestinal and
colonic mu-
cosae71,72
Skin; breast
parenchima
and skin;
axillary
lymph nodes;
esophageal
subepithe-
lium; gastric,
small intestinal
and colonic
mucosae71,72
Proteases MCPT1, 253–56 MCPT4, 5, 6, 7
and CPA353–56
Tryptase, CPA3
and cathepsin
G
Tryptase, chy-
mase, CPA3
and cathepsin
G
Proteoglycans Chondroitin
sulphate di-B,
A, E59
Heparin, Chon-
droitin sul-
phate E59
Heparin, Chon-
droitin sul-
phate A, E59,74
Heparin, Chon-
droitin sul-
phate A, E59,74
Biogenic
amines
Histamine
(low), sero-
tonin57
Histamine
(high), sero-
tonin57
Histamine Histamine,
serotonin (low)
Histochemical
staining
Alcian blue+,
toluidine
blue+ 57,76
Alcian blue+,
safranin+, tolui-
dine blue+ 57,76
Tryptase+, tolu-
idine blue+ 72
Tryptase+,
chymase+, tolu-
idine blue+ 72Table 2.1.1: Murine and human MC subtypes. This table summarize the mainphenotypic characteristics of murine and human MCs at ”baseline”. MurineMCs can be classified in two main subpopulations based on the granule content.While the protease content can vary during infections or with the anatomical lo-calization, the proteoglycan content remains almost fixed. Connective tissue MCs(CTMC) are rich in heparin (which positively stain with Safranin red) while mu-cosal MCs (MMC) contain mainly chondroitin sulphates. Human MCs can alsobe dived in two categories, based on the protease content: tryptase-positive MCs(MCT), tryptase- and chymase-positive MCs (MCCT). MCT can be consideredthe human counterpart for murine MMC (and are both T cell-dependent) whileMCCT are more similar to CTMC. All the references are indicated in the table.
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pression. Despite the fact that these mice present less hematological and non-
hematological abnormalities, the large inversion in Chr5 contains 27 genes
which are thought to be responsible for aberrant myelopoiesis, splenomegaly,
neutrophilia, megakaryocytosis and thrombocytosis. Moreover, these mice
suffer mild hypertension and cardiac hypertrophy due to the lack of the
cardiac protease corin79,80. To overcome this multitude of non-MCs-related
abnormalities, and thus confirming that a specific in vivo reaction is only
due to the lack of MCs, BMMC are engrafted in Kit mutant mice in order
to restore MCs population (the so-called “MCs knock-in mouse”)81. Albeit
this approach have been considered the gold standard to study MC function
in vivo, it is clear now that the reconstitution of Kit mutant mice can lead
to non-physiological accumulation and distribution of MCs in the animal,
thus limiting the interpretation of experimental results82. In recent years,
several groups generated new strains of MC-deficient mice independent on
Kit mutations. Most of them were able to deplete MCs population by gen-
erating transgenic mice which harbor a Cre recombinase under the control
of specific MCs genes (i.e. Mcpt5, Cpa3 and FceRIβ)83–86. These mice can be
constitutively depleted of MCs (as in the case of Cpa3Cre, Cpa3-Cre ×Mcl1fl/fl
and Mcpt5-Cre × R-DTA) or induced by the injection of diphtheria toxin
(Mcpt5-Cre × iDTR and RMB mice). Differently from Kit mutant mice, these
animals show far less hematological abnormalities and can thus be consid-
ered better models to study MCs roles in vivo, opening the scenario to a
more rigorous evaluation of specific MCs gene functions87.
The analysis of MCs role in human health is made more challenging by
the fact that, apart from patients with T-cell deficiencies which show reduced
number of MCT, no MCs deficiency in humans have been reported73,87. The
more likely explanation is that the lack of MCs does not cause any immun-
odeficiency or deviation of the immune response, so that these individuals
might be unconscious of their status87.
2.1.2 Mast cells: tissue-resident ”rabbit ears”.
The ability of MCs to respond to different pathogens rely on their abil-
ity to detect the presence of “non-self” antigens and other danger signals.
According to their localization and their role of tissue-resident sentinels,
MCs express a wide plethora of receptors aimed to interact with and detect
pathogens such as toll-like receptors (TLRs), C-type lectin receptors (CLRs),
complement receptors and several cytokine- and chemokine-receptors89. Ac-
tivation of MCs can lead to a two-phased response in which a fast release of
granule-stored mediators (the so-called degranulation process) is followed
by the de novo synthesis and exocytosis of a variety of compounds (Fig.
2.1.6)90. Mast cells can release their granule content by means of three
distinct mechanism: the classical exocytosis, where secretory granules are
singularly extruded by fusion with the plasma membrane; the compound
exocytosis, where multiple granules are fused together and then released
as a single unit; and finally through the piecemeal degranulation, a pecu-
liar secretion pattern (common also to basophils and eosinophils) in which
granule containers are not fused together nor with the plasma membrane
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Mouse strain MCs deletion mechanism Strain characteristics Ref.
KitW/W-v
(W/Wv)
KitW allele: point mutation
produces a truncated cKit
protein which cannot be ex-
pressed on the cell surface;
KitW-v allele: encodes for cKit
with impaired kinase activity
due to a point mutation in the
Tyr-kinase domain.
Depletion of 99% MCs and
75%-90% basophils. Mice
are sterile, present macrocytic
anaemia, impaired γδ+-T cells,
neutropenia, lack of interstitial
cells of Cajal and melanocytes.
MC-deficiency can be partially
rescued by chronic inflamma-
tion.
48,78
KitW-sh/W-sh
(W-sash)
Reduced expression of cKit
due to a large inversion of
chromosome 5, ∼75 kb up-
stream the cKit locus.
Depletion of 99% MCs. Mice
present aberrant myelopoiesis,
splenomegaly, neutrophilia,
megakaryocytosis and throm-
bocytosis.
79,80,86,88
Mcpt5-Cre Diphtheria toxin-induced dele-
tion
Mice lack >90% CTMC. MMC
and basophils are not deleted.
83
Cpa3Cre (Cre-
master)
Cre-mediated cytotoxicity Depletion of both CTMC and
MMC and 60% deletion of
splenic basophils.
84
Cpa3-Cre
(Hello Kitty)
Cross to Mcl1fl/fl, knock out of
the intracellular anti-apoptotic
factor Mcl1
Depletion of >90% CTMC
and MMC, and 60-80% of ba-
sophils. Mice present macro-
cytic anaemia and splenic neu-
trophilia.
85
RMB Diphtheria toxin-induced dele-
tion. The 3′-UTR of the Ms4a2
gene encoding the FceRIβ in-
cludes a red td-Tomato (tdT)
cassette and the human diph-
theria toxin receptor (hDTR).
95% MCs and basophils are
depleted within 2 days. Ba-
sophil population is restored
12 days after DT injection
while MCs levels remains low
even after 6 months.
86
Table 2.1.2: Murine models to study mast cells in vivo. This table summarizethe key features of the most used mice models of MCs deficiency. Kit mutant micehave been so far the most used models but show also many hematological andnon-hematological abnormalities unrelated with MCs deficiency which can limitthe interpretation of experimental results. In recent years, different new models ofKit-independent MCs deficiency have been generated. These new breed presentfar less phenotypic abnormalities and represent better alternatives to study MCsfunctions in vivo. All the references are indicated in the table.
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Figure 2.1.6: Timing of mast cell response to challenges. MCs earliest responsebegins with the release - within seconds - of granule-stored preformed mediators.Soon after, MCs are able to synthesize and release arachidonic acid-derived lipidmediators as leukotrienes and prostaglandins. A second phase of response isdependent on the release of de novo synthesized mediators comprising a greatnumber of cytokines and chemokines. By virtue of being long-lived cells, MCscan survive after the stimulation and replenish their granules, thus allowing theirresponse to further challenges. Adapted from Abraham and St John 90.
but are emptied and kept intact in the cytoplasm, allowing also a partial
release of granule content91,92. A recent elegant report by Gaudenzio et al.
demonstrated that MCs employ distinct degranulation strategies upon stim-
ulation through G-protein coupled receptors (GPCR) or by the anaphylactic
IgE/antigen (Ag) triggering. While the first stimulation induced MCs to
quickly and briefly release small and spherical granules, the latter induced a
partially retarded but sustained secretion of larger and more heterogeneous
particles93. Interestingly, the larger granules released following IgE/Ag stim-
ulation were found to be transported to draining lymph nodes, causing their
enlarging. Such results are consistent with prior observations by Kunder
et al. and suggest that transport of granules released by compound exocyto-
sis might enable the diffusion of their content, thus promoting or sustaining
the adaptive immune response even at distant loci93,94.
FcRI activation
Consistent with their well known role in allergy and anaphylaxis, the
signaling cascades initiated by the cross-linking of IgE/Ag complexes on
MCs’ surface FcRI are by far the most studied. FcRI is a tetrameric re-Lipid rafts are specialized
plasma membrane
microdomains enriched in
cholesterol, sphingolipids
and several membrane-bound
signaling proteins. These
microdomains serve as
“docking stations” which
allow the interaction among
kinases and adaptor proteins
and are believed to be crucial
for the initiation of receptor
signaling cascades.
ceptor which comprises the IgE-binding α-chain, a membrane-tetraspanning
β-chain and a disulphite-linked homodimer of the γ-chain95. Antigen recog-
nition by FcRIα-bound IgE induces receptor aggregation on lipid rafts,
activation of SRC family kinases (SFKs) and tyrosine phosphorylation of the
receptor subunits96–98. Four main SRC kinases have been described in FcRI
activation: LYN, SYK, FYN and HRC. These SFKs simultaneously initiate in-
dependent signaling cascades which interconnect and give rise to a complex
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signalosome that regulate MC activation. Albeit being extremely complex
and tightly regulated, two mayor signaling axis can be described, the first
one being initiated by LYN and SYK, and other one relying uniquely on
FYN95,99.
the lyn-fyn axis. After receptor triggering, aggregated FceRI associate
with LYN in lipid rafts which phosphorylates the immunoreceptor tyrosine-
based activation motifs (ITAM) on the receptor subunits β and γ (Fig. 2.1.7A).
Phosphorylated ITAMs provide high-affinity docking sites for LYN and the
tyrosine kinase SYK, which is now trans- and auto-phosphorylated100. Both
LYN and SYK promote the phosphorylation of the transmembrane adap-
tor molecule LAT, which in turn recruits many different signal molecules
serving as a scaffold for protein-protein interactions101. Among the pro-
tein recruited to LAT, phospholipase-γ (PLCγ) and the guanine-nucleotide-
exchange factors SOS and VAV are the most important for MC degranulation
and cytokine production in response to Ag stimuli. Active PLCγ catalyzes
the hydrolysis of phosphatidylinositol diphosphate (PIP2) to inositol triphos-
phate (IP3) and diacylglycerol (DAG). IP3 is responsible for a “first wave” of
Ca++ mobilization from endoplasmic reticulum stores, and this in turn in-
duces a “second wave” of intracellular calcium influx99. On the other side,
DAG is responsible for the activation of the protein kinase C (PKC). Both
the signals from calcium influx and PKC activation are fundamental for the
complex process of degranulation95.
The induction of cytokine transcription requires the activity of guanine-
exchange-factors SOS and VAV to shift the activation state of RAS. RAS then
activates the RAF-dependent pathway which leads to the activation of the
mitogen-activated protein kinases (MAPK) extracellular-signal-regulated ki-
nase 1 (ERK1), ERK2, JUN aminoterminal kinase (JNK) and p3895,102. To-
gether with the calcium influx induced by IP3 (and the subsequent nuclear
translocation of nuclear factor of activated T cells (NFAT) due to calcineurin-
dependent dephosphorylation), these pathways lead to the activation of NF-
κB, the activator protein 1 (AP1) members JUN and FOS and thus to cytokine
expression95,99,103.
the complementary fyn-gab2-pi3k axis. The existence of a compli-
mentary signaling pathway for IgE/Ag activation was inferred after a series
of studies which demonstrated that a novel SFK, FYN, was required for
MC activation independently of LAT and PLCγ (Fig. 2.1.7B)104. Instead,
this pathway leads to the activation of phosphatidylinositol 3-kinase (PI3K)
through the phosphorylation of the adaptor molecule GAB2105. PI3K phos-
phorylates membrane-bound PIP2 to phosphatidylinositol 3,4,5-triphosphate
(PIP3) which serves as docking site (through pleckstrin homology domains)
for several signaling molecules such as PLCγ, VAV, the Burton’s tyrosine
kinase (BTK) and AKT. While PLCγ phosphorylation leads to Ca++ influx
and PKC activation, as described earlier, AKT mediates the activation of the
mammalian target of rapamycin (mTOR) pathway by inactivating the neg-
ative regulator of mTOR tuberin106. Active mTOR forms two macromolec-
ular complexes: the rapamycin-sensitive mTOR complex 1 (mTORC1) and
the rapamycin-insensitive mTORC2, both sensitive to inhibition by the tuber-
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Figure 2.1.7: Signaling in FcRI-induced activation. A. The “fundamental”LYN-SYK signaling cascade. After FcRI aggregation (not shown) LYN asso-ciates with receptor ITAM and activates SYK. Both LYN and SYK promote thephosphorylation of LAT which serves as a scaffold for several signaling proteins.Here, PLCγ induces the activation of PCK and the influx of intracellular calcium,while SOS and VAV promote RAS activation and RAF-dependent activation ofthe MAPK pathway. B. The “complimentary” FYN-GAB2-PI3K signaling cas-cade. FYN- and GAB2-dependent phosphorylation of PI3K catalyzes a furtherCa++ influx which sustains the initial PLCγ-dependent Ca++ influx and the ac-tivation of the AKT/mTOR pathway which leads to cytokine production. Adaptedfrom Gilfillan and Tkaczyk 95.
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ous sclerosis complex (TSC). It was demonstrated that during MC activation,
both mTORC1 and mTORC2 are activated and finely regulated by TSC1 and
TSC2, and that TSC deficiency led to increased cytokine production107. In-
terestingly, the activation of PI3K is not fundamental for the initiation of MC
degranulation as it was demonstrated that its role is to maintain the signals
induced by the “canonical” PLCγ activation108. This effect could be due to
the activation of nonselective Ca++ channels such as TRPC-1104. Seen that
FYN-mediated PI3K activation is independent on the presence of LAT, it has
been proposed that a similar transmembrane protein, NTAL (also know as
LAT2), might be the key adaptor molecule for the assembly of the macro-
molecular signaling complex necessary for FYN signaling109.
Toll-like receptors.
TLRs are a family of evolutionarily conserved receptors profoundly in-
volved in early host defense against pathogens. Since 1997 (when the first
TLR was defined to be a pathogen recognition receptor - PRR) up to 13
different TLRs have been described in mammals110. TLRs are membrane-
spanning receptors composed by an extracellular, a transmembrane and a
cytoplasmic domain. The extracellular domain (responsible for pathogen
recognition) contains blocks of 24-29aa repetitions called leucine-rich repeats
(LRR) which fold in a horseshoe structure (Fig. 2.1.8A). The cytoplasmic tail
present a conserved region known as the Toll/IL-1R (TIR) domain, which
interacts with adaptor molecules for downstream signaling. The specificity
of binding with different TIR-containing adaptor proteins is mediated by the
exposed side chains close to the BB loop. The main TIR-domain-containing
adaptor molecules involved in TLR signaling are: Myeloid differentiation
primary response 88 (MyD88), TIR-domain-containing adaptor protein
(TIRAP), TIR-domain-containing adaptor protein inducing IFN-β (TRIF) and
TRIF-related adaptor molecule (TRAM). After ligand biding, TLRs undergo
dimerization and a subsequent conformational change required for the bind-
ing of adaptor and signaling molecules.
TLR signaling comprises a complex network of signaling molecules but
the MyD88-dependent and MyD88-independent pathways are of particular
relevance.
myd88-dependent pathway The signaling cascade begins with ligand
binding, the dimerization of TLRs and the association of MyD88 through
the TIR domain (Fig. 2.1.8B). MyD88 present a N-terminal death domain
(DD) which interacts with the same residue on the N-terminus of the kinase
IRAK4. This leads to the recruitment and phosphorylation of the kinase
IRAK1 which in turn induces further auto-phosphorylation of IRAK1 and
the recruitment of TRAF6. At this point, the IRAK1-TRAF6 complex dis-
engages the receptor and interact with the plasma membrane through the
proteins TAK1, TAB1, TAB2 and TAB3. Phosphorylation of TAK1 and TABs
induces IRAK1 degradation and subsequent translocation of the remaining
complex to the cytosol. Here the complex is bound by the ubiquitin ligases
UBC13 and UEV1A, leading to K63-polyubiquitination of TRAF6 and acti-
vation of the MAPKKK TAK1. TAK1 in turn is able to phosphorylate and
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activate both MAP kinases and the IKK complex. The IKK complex then
phosphorylates IκB, leading to its ubiquitination and degradation allowing
the transcription factor complex NF-κB to translocate to the nucleus. On the
other side, activation of the MAP kinase signaling pathway leads to phos-
phorylation of p38, JNK and ERK1/2, finally resulting in the activation of
the transcription factor complex AP-1111,112. Such pathway of activation is
shared by most TLRs (namely, TLR2, TLR4, TLR5, TLR7 and TLR9) and
induces the expression of pro-inflammatory cytokines such as TNF-α and
IL-6111.
myd88-independent, trif-dependent pathway The existence of a
TLR signaling independent on MyD88 was determined on the basis that
MyD88-deficient macrophages fail to produce inflammatory cytokines in re-
sponse to TLR4 triggering by lipopolysaccharide (LPS) but appear to acti-
vate both NF-κB and MAPK with delayed dynamics. On the other side, the
same cells showed unaltered IRF3 activation and release of type-I IFN after
TLR4 and TLR3 triggering113,114. The MyD88-independent activation of TLR
signaling is dependent on the TIR-domain-containing adaptor protein TRIF.
This protein is known to induce IRF3 and NF-κB activation via three mech-
anisms (Fig. 2.1.8C). At first, TRIF is able to bind the kinase TBK1 which in
turn interacts with the IKK kinase IKKe and phosphorylate IRF3. Upon ac-
tivation, IRF3 quickly migrates in the nucleus and recruits the co-activators
p300 and CBP, inducing the expression of type-I IFNs. On the other side
TRIF is able to activate the NF-κB pathway by the interaction with TRAF6
(at its N-terminus) and RIP1 (at its C-terminus). TRAF6 and RIP1 are both
able to induce NF-κB activation and to promote IFN-β expression111.
tlr4 TLR4 mediates response mainly against bacterial LPS and, among
others, against VSV glycoprotein G, Candida albicans mannan and Cryptococ-
cus neoformans glucuronoxylomannan116. TLR4 is expressed on the cellular
surface and LPS-mediated triggering of this receptor induces the activation
of both MyD88-dependent and MyD88-independent, TRIF-dependent path-
ways (Fig. 2.1.9). The “classical” MyD88-dependent activation is mediated
by MyD88 but also by the TIR-domain-containing protein TIRAP, which was
shown to interact with MyD88 and to be required for the early production
of inflammatory cytokines in response to LPS117,118. On the other side, the
MyD88-independent, TRIF-dependent activation requires the presence of
the TIR-domain-containing adaptor molecule TRAM which associates with
TRIF and TLR4119. TRIF-deficient mice showed impaired activation of IRF3
and reduced expression of type-I IFNs in response to TLR4 ligands120. No-
tably, in vivo studies on TRIF- and TRAM-deficient mice demonstrated that
both TRAM and TRIF are required for the production of inflammatory cy-
tokines despite showing normal levels of IRAK1 and early-phase NF-κB ac-
tivation119.
TLR4 also requires the cooperation of two co-receptors in order to fully ac-
tivate downstream signals: MD2 and CD14. MD2 is associated with the
cytoplasmic tail of TLR4 and it is fundamental for LPS recognition and
activation since TLR4 alone fail to induce NF-κB activation after LPS chal-
lenge121. CD14, on the contrary, is not fundamental for TLR4 activation but
2.1 why do we have mast cells? 21
Figure 2.1.8: TLRs structure and activation pathways. A. TLR structure. TLRextracellular domain is deputed to the recognition of non-self products via itshorseshoe structure composed by repeated LRR. The cytoplasmic tail present theTIR domain, which interacts with adaptor molecules (as MyD88) for downstreamsignaling. B. Myd88-dependent activation pathway. After ligand binding, TLRsdimerize and the adaptor protein MyD88 associates to the TIR domain. Thisleads to the recruitment of the kinases IRAK1 and IRAK4 which became activatedand in turn recruit TRAF6. At this point the IRAK1-TRAF6 complex disengagesthe receptor and interact with TAK1 and TAB proteins, finally leading to IRAK1degradation (not shown). The complex now is free to move to the cytoplasm whereTRAF6 undergoes polyubiquitination and activates TAK1 which in turn promotesMAPK and canonical NF-κB activation. C. MyD88-independent activationpathway. After the activation of TLR3, TRIF is recruited and activated. Threekinases are then recruited at the C-terminus and N-terminus of TRIF: TBK1activates IKK and phosphorylate IRF3, which quickly migrates into the nucleusand promotes type-I IFNs expression; TRAF6 and RIP1 are able to induce latephase activation of NF-κB which promotes IFN-β expression. Adapted fromAkira and Takeda 111 and Gay et al. 115 .
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its presence can increase the responsiveness of cells to TLR4 ligands by sev-
eral mechanisms. For instance, LPS is known to bind the soluble protein
LBP (LPS-binding protein), which is normally present in serum, and this
complex is then able to bind CD14 and to activate TLR4/MD2122. CD14
can also activate TLR4 in a LBP-independent manner by favoring the endo-
cytosis of TLR4, by enlarging the spectrum of LPS chemotypes recognized
by the receptor, incrementing the sensitivity to LPS (i.e. being responsive to
lower doses of the ligand) and allowing the MyD88-independent activation
of TLR4123–125. Moreover, it was proposed that the main function of CD14
might be to catalyze the transfer of LPS from the extracellular environment
to the cellular membrane where it interacts with a plethora of receptors in-
volved in LPS binding (i.e. TLR4, HSP70, HSP90 and CXCR4)126.
As discussed in the above paragraph, TLR triggering leads to the activa-
tion of both the NF-κB and the MAP kinase pathways by the action of TAK1
kinase. Notably, TLR4 can also interact with PI3K through a non-canonical
PI3K-binding site on the C-terminus of MyD88127. The TLR4-induced activa-
tion of PI3K leads to the activation of NF-κB and production of IL-1β, TNF-α
and MIP-2 by murine macrophages128. Stimulation with LPS can also result
in the activation of the calcineurin/NFAT pathway in dendritic cells (DCs)
(Fig. 2.1.9). After LPS binding, CD14 is supposed to cluster in lipid rafts,
leading to the activation of SFKs which in turn phosphorylate PLCγ2. Once
active, the phospholipase PLCγ2 catalyzes the hydrolysis of PIP2 to IP3 and
DAG. IP3 is then able to induce the opening of IP3-dependent Ca++-channels
on the cell membrane, triggering the influx of extracellular Ca++. Ca++ influx
induces calcineurin activation and subsequent NFAT dephosphorylation and
nuclear translocation129,130. This process relies exclusively on CD14 seen that
TLR4-, MD2-deficient DCs, as well as MyD88/TRIF double deficient DCs
show normal NFATc activation upon LPS stimulation131.
Mast cells express TLR4 and are able to respond to LPS in a TLR4/MD2-
dependent manner132. LPS stimulation induces the release of IL-1β, TNF-α,
IL-6 and IL-13 but does not induce MC degranulation133–135. In addition,
BMMC stimulation with LPS also induced the release of IL-10, IL-5, and the
chemokines CCL3 and CXCL2136,137. The expression of CD14 on MC is quite
controversial since different authors demonstrated the expression mCD14
transcripts but none succeeded to demonstrate the presence of the protein
on MCs’ surface133,138–140. Huber et al. demonstrated that MCs activation
by LPS is dependent on the molecular structure of LPS141. Smooth-LPS (or
S-form LPS) is composed by lipid A, a core oligosaccharide region and a
region composed of repeated O-polysaccharide units, whilst rough-LPS (or
R-form LPS) lacks the O-oligosaccharide chain. While R-form LPS induced
the release of TNF-α and IL-6 from BMMCs in a TLR4/MD2-dependent
manner, S-form LPS failed to induce cellular activation141. Further analy-
ses on macrophages and DCs confirmed that S-form LPS requires CD14 for
the activation of both MyD88-dependent and MyD88-independent signaling
cascades at least at low doses, while R-form LPS leads to the activation of
MyD88-dependent signals also in the absence of CD14141,142. In addition,
MCs lack a complete TRIF-TRAF signaling cascade and thus can respond to
LPS triggering by producing pro-inflammatory cytokines under the control
of the MyD88-dependent pathway but not producing Type-I IFN143,144. This
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Figure 2.1.9: TLR4 signaling. TLR4 triggering can activate both the MyD88dependent and the MyD88-independent, TRIF-dependent signaling pathways.TRIF requires the adaptor molecule TRAM in order to induce the activation ofIRF3 and NF-κB. On the other side, MyD88 requires a further adaptor, TIRAP, toassociate with the TLR4 TIR domain in order to start downstream signaling. PI3Kcan promote further activation of NF-κB by interacting with MyD88 through anon-canonical binding site. Moreover, LPS activation of DCs can lead to aCD14-dependent activation of NFAT through the action of the phospholipasePLCγ2 which catalyzes the hydrolysis of PIP2 to IP3 which in turn triggers theinflux of extracellular Ca++.
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could be explained by the quite low expression of TRAM by MCs or by the
fact that MCs fail to internalize TLR4 after LPS challenging, probably due to
the lack of membrane-bound CD14123,143,144.
tlr2 TLR2 is a peculiar TLR since can oligomerize with TLR1 or TLR6
for the recognition of triacetylated or diacetylated lipopeptides respectively.
In addition, TLR2-TLR6 oligomerization can occur after binging to lipote-
ichoic acid (LTA) and zymosan (an insoluble glucan composed of β-1,3
glucose chains)116. TLR2 triggering activates the MyD88-dependent signal-
ing pathway and, as TLR4, requires the collaboration of the adaptor pro-
tein TIRAP118. It is worth of note that TLR2 signaling often cooperates
with C-type lectin receptors (CLRs) for the recognition of fungal pathogen-
associated molecular patterns (PAMP).
Murine and human mast cells express TLR2, TLR1 and TLR6137,145–147.
Even though it is supposed that BMMC express a truncated version of TLR2
which lacks the intracellular TIR domain, stimulation with TLR2 ligands
induces MCs activation and the production of a greater range of mediators
compared to TLR4 stimulation134,148.
Stimulation of BMMC with bacterial peptidoglycan (PGN), a TLR2-TLR6
ligand, induced the release of TNF-α, IL-4, IL-5, IL-6, and IL-13 in a TLR2–
dependent manner132,134. In addition, peritoneal cell-derived mast cells
(PDMCs) stimulated with LTA and MALP-2 (a synthetic ligand of TLR2-
TLR6) released a broader spectrum of cytokines: TNF-α, IL-1, IL-6, IL-10, IL-
17, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IFN-
γ148. PDMCs are considered to be more mature than BMMCs and this could
reflect their increased ability to respond to TLR2 stimulation. Human MCs
also behave similarly: stimulation of cord blood-derived mast cells (CBMC)
with PGN or zymosan resulted in the production of TNF-α, IL-1β, IL-5, GM-
CSF and cysteinyl leukotrienes149.
MCs degranulation in response to TLR2 ligands is still matter of debate.
Two studies reported that both BMMCs and human CBMCs were able to
degranulate in response to PGN while a third one reported that zymosan
and Pam3CSK4 (a synthetic TLR1-TLR2 ligand) but not PGN were able to in-
duce human CBMCs degranulation134,135,146. On the other side, other groups
were unable to demonstrate BMMCs and PCMCs degranulation in response
to TLR2 stimuli such as PGN and LTA137,140,148.
intracellular tlrs Intracellular TLRs (TLR3, TLR7, TLR8, and TLR9)
are involved in the response to virus and certain bacteria by the recognition
of foreign nucleic acids. Triggering of these receptors with their cognate
ligands results in the production of pro-inflammatory cytokines and type-I
IFNs150. With the exception of TLR3, the activation of downstream signal-
ing after ligand binding is, at least in part, dependent on MyD88. Activation
of the MyD88-dependent pathway leads to the nuclear translocation of AP-
1 and NF-κB and thus to the transcription of pro-inflammatory cytokines
as TNF-α. On the other side, TLR3 signals through the MyD88-independent,
TRIF-dependent pathway to promote IRF3 activation and type-I IFN produc-
tion (Fig. 2.1.8C)111,150. Furthermore, activation of TLR7 and TLR9 leads to
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the MyD88-dependent activation of IRF and IRF7 which contributes to the
expression of TNF-α, IL-12 and type-I IFNs150.
MCs are able to recognize nucleic acids via intracellular TLRs as TLR3
(dsRNA), TLR7 (ssRNA) and TLR9 (CpG-DNA). BMMCs, PCMSs and fe-
tal skin-derived MCs (FSMC) respond to polyI:C stimulation by releasing
IFN-α, IFN-β, TNF-α, IL-6, and the chemokines CCL2, CXCL2 and CCL5
in a TLR3-dependent manner137,145. Matsushima et al. demonstrated that
stimulation with the synthetic TLR7 agonist R848 induced the secretion of
IL-6, TNF-α, CCL2, and CXCL2 from FSMCs but not BMMCs. Also syn-
thetic oligonucleotides rich in CpG regions (which are recognized by TLR9)
induced murine MCs to release pro-inflammatory cytokines137. In most of
the cases, FSMCs responded more robustly than BMMCs, suggesting again
that BMMCs may represent an immature phenotype of mast cells137,151.
C-type lectin receptors.
C-type lectin receptors (CLRs) comprise a superfamily of proteins which
are responsible for the recognition of both self- and non-self-ligands. Of pe-
culiar interest for the purposes of this thesis, some CLRs are involved in the
recognition of several carbohydrates such as mannose, N-acetylglucosamine
and β-glucan. Among this family of receptors, much attention has been
given to the mannose receptor (CD206), the DC-specific ICAM3-grabbing
non-integrin (DC-SIGN), dectin-1, and dectin-2152,153.
Figure 2.1.10:Dectin-1 structure.The receptor is com-posed by a singleextracellular CDR, astalk region and anintracellular ITAM-like motif whichmediates dectin-1signaling.
dectin-1 Dectin-1 has a single extracellular carbo-
hydrate-recognition domain (CRD) which specifically
recognize particulate β-1,3- and β-1,6-linked glucans
that are found mainly in the cell walls of fungi and
certain bacteria154. The CRD is kept separated from
the cellular membrane by a stalk region and is con-
nected to a cytoplasmic tail through a transmembrane
domain. Dectin-1 activation can mediate a signaling
cascade independently on the cooperation of adaptor
molecules thanks to the presence of an ITAM-like mo-
tif on its cytoplasmic tail (Fig. 2.1.10)155. Upon bind-
ing to β-glucans, the YxxL motif (where “x” identi-
fies any amino acid) became phosphorylated by the
action of SRC kinases and two phosphorylated recep-
tors cooperate for the recruitment and activation of
the kinase SYK156,157. SYK phosphorylation leads to
the formation of a complex comprising CARD9, Bcl-
10, and MALT1, which then activate IKKβ and subse-
quently the canonical NF-κB pathway (Fig. 2.1.11)158.
The CARD9–Bcl-10–MALT1 complex can also be acti-
vated by PKCθ through the SYK-dependent phospho-
rylation of PLCγ2. Phospholipase PLCγ2 activation
also leads to IP3–dependent Ca++ influx and subse-
quent NFAT nuclear translocation152,159. In addition to the canonical NF-
κB pathway, dectin-1 triggering can also lead to the activation of the non-
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Figure 2.1.11: Dectin-1 signaling network. Dectin-1 engagement induces thephosphorylation of its cytoplasmic ITAM. Two activated receptors can clustertogether causing the recruitment and activation of the key kinase SYK whichmediates downstream signaling. SYK phosphorylates PLCγ which in turn ac-tivates PKCθ and leads to the formation of a CARD9–Bcl-10–MALT1 complexand the activation of ERK. The CARD9–Bcl-10–MALT1 complex mediates theactivation of the canonical NF-κB pathway, while ERK induces the activationof the NLRP3 inflammasome. The hydrolysis of PIP2 to IP3 and DAG due toPLCγ2 activity, causes an influx of intracellular Ca++ and subsequent NFATnuclear translocation. SYK-dependent activation of the kinase NIK promotesalso the processing of the NF-κB subunit p100 to p52, leading to the nucleartranslocation of the non-canonical p52-RelB. Finally, NF-κB transcription fac-tor activity is modulated by the SYK-independent, Ras-dependent control of p65S276 phosphorylation. Adapted from Plato et al. 152 .
canonical NF-κB pathway. IKKα activation by the NIK kinase, promotes
the processing of the NF-κB subunit p100 to NF-κB p52 and the consequent
formation of a p52-RelB complex which translocates into the nucleus and
initiate gene transcription160.
In addition to the CARD9- and NIK-dependent NF-κB activation, dectin-1
engaging induces the phosphorylation of the kinase RAF1 through the ac-
tion of RAS proteins which then induces NF-κB phosphorylation at S276.
This modification fine-tunes NF-κB activity by altering the balance between
the different subunits and their DNA-binding affinity, resulting in increased
or reduced TLR-induced cytokine expression160. This mechanism is of par-
ticular interest since dectin-1 is known to cooperate with TLRs for the recog-
nition of distinct microbial components. For example, dectin-1 activation in
DCs stimulated with zymosan particles enhances TLR2-, CD14- mediated
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NF-κB activation and production of cytokines such as TNF-α and IL-12161.
Other studies on macrophages demonstrated that the collaboration between
dectin-1 and TLR2 during β-glucan recognition is dependent on Syk and
MyD88 as the deficiency in either one of the two proteins completely abol-
ished synergistic TNF-α, CXCL2 and CCL3 release162.
SYK-CARD9 activation in response to C. albicans and A. fumigatus also
leads to the activation of the NLR family, pyrin domain containing (NLRP3)
inflammasome. NLRP3 is able to catalyze the cleavage of pro-IL-1β to its
active form IL-1β through the action of caspase I163,164. Recently, it has been
proposed that dectin-1–dependent SYK activation induces the formation of a
complex composed of CARD9, RAS-GRF1 and H-RAS which leads to down-
stream activation of ERK and subsequent release of TNF-α, IL-1β, IL-6 and
IL-12165.
Albeit being only poorly described, mast cells express dectin-1 and can re-
spond to fungal antigens. For example, murine BMMC express dectin-1 on
cell surface and stimulation with zymosan up-regulates dectin-1 levels and
induce reactive oxygen species (ROS) production in a TLR2–independent
manner166. A more recent work by Nieto-Patlan et al. showed that MCs
stimulation with C. albicans induced BMMC and PMC degranulation, and
production of TNF-α, IL-6, IL-10, CCL3, and CCL4167. Blockade of dectin-1,
but not TLR2, partially reduced the release of TNF-α during C. albicans chal-
lenge, indicating that this receptor plays an important role in fungal recogni-
tion167. Human MCs also express functional dectin-1. Stimulation of CBMC
with both PGN and zymosan resulted in the release of leukotrienes LTB4
and LTC4 while the addition of the dectin-1 inhibitor laminarin resulted in
reduced release of leukotrienes during zymosan but not PGN stimulation149.
Other receptors
complement receptors. The complement system is composed by a
great number of plasmatic proteins which interact with pathogens in order
to opsonize and kill it. Mast cells are known to interact with the comple-
ment system proteins with the complement receptor 3 (CR3; also known as
CD11b-CD18), the CR4 (CD11c-CD18), and the receptors for C3a (C3aR) and
C5a (C5aR; also known as CD88)168. MCs are generally activated to degran-
ulate in response to complement peptides, and the C3a protein can induce
the production of the chemokines CCL2 and CCL5 in human MCs169,170. In
addition, both C3a and C5a are chemotactic factors for MCs171. Interest-
ingly, CR3 recognize also non-opsonized ligands including β-glucans, but
this ability has not been demonstrated in MCs yet.
2.1.3 MCs (social) networks: crosstalk with other immune system cells.
The fact that mast cells are able to modulate their phenotype depending
on their physiological context together with their ability to release a wide
plethora of mediators and to express many membrane-bound costimulatory
molecules, suggest that these cells are deeply involved in cell-cell interac-
tions172. In fact, MCs have been described to interact with members of both
the innate and the adaptive arm of immunity. As can be expected, often the
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interaction through MCs’ costimulatory molecules is bi-directional, meaning
that both MC and the interacting cell can be influenced173.
mcs and dendritic cells. Soluble mediators released by MCs (as his-
tamine and TNF-α) have been described to modulate DCs behaviour by fa-
voring their recruitment at the site of infection, enhancing their maturation
and migration into draining lymph nodes and by promoting their ability to
activate T-cells174–177. On the other side, little is known about the direct inter-
action between MCs and DCs. In vitro co-culture of MCs with DCs induced
the upregulation of maturation markers on DCs, such as CD80, CD86 and
CD4083. Similar results were obtained in a subsequent work, which demon-
strated that DCs maturation was induced by interaction between lympho-
cyte function-associated antigen (LFA-1) and intracellular adhesion molecule
(ICAM-1) on MCs178.
mcs and monocytes/macrophages. Mast cell interaction with macro-
phages has been described in the context of bacterial infections. During the
infection with Francisella tularensis, which replicates within macrophages,
bacterial replication was inhibited in a contact-dependent manner and re-
quired MC-derived IL-4179. Additional investigation showed that IL-4 is
able to induce macrophage alternative activation, leading to the upregula-
tion of the mannose receptor and to a more efficient bacterial phagocytosis.
Moreover, IL-4 treatment resulted in an increased ATP production in mac-
rophages, which promoted phagosomal acidification180. On the contrary,
MC-derived IL-4 had a detrimental effect on bacterial phagocytosis by mac-
rophages both in vitro and in a murine model of acute sepsis86.
interactions with the adaptive arm of immunity. Interaction be-
tween MCs and T-cells have been described during many inflammatory pro-
cesses such as inflammatory bowel disease (IBD), parasite infections and
allergy181–183. MCs can interact with both CD4+ and CD8+ effector T-cells.
Phagocytosis of different Gram-negative enterobacteria induced MCs to pro-
cess bacterial antigens for presentation through MHC-I molecules to T-cells184.
Interestingly, MC-dependent antigen presentation induced the activation
and proliferation of CD8+ T-cells in vitro and in vivo185. Moreover, MCs inter-
action with Foxp3+ CD4+ regulatory T-cells (Treg) inhibit their suppressive
activity and skew their development into IL-17–producing T-cells (TH17)186.
On the other side, Treg reduce MC degranulation in a contact-dependent
fashion187. Both these processes requires MC- or T-cell–derived cytokines
(e.g. IL-6) and cell-cell interaction through the OX40-OX40L axis.
Mast cells are an important source of cytokines involved in the regulation
of B-cell and express the ligand for CD40 (CD40L) on their surface. Inter-
action of MCs with B-cells through the CD40-CD40L axis, promoted B-cell
survival and differentiation into IgA-secreting CD138+ plasma cells188. An
analogous mechanism which involved the CD40-CD40L axis was also de-
scribed to be fundamental for the expansion of IL-10–competent B-cells by
MCs189.
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2.1.4 Do we really need mast cells? Roles in health and disease.
Until recent years, MCs were kept in the shadow by their well known role
in allergy and anaphylaxis but this circumstance changed completely as dif-
ferent new roles for this cells were reported50,190. Nowadays the scientific
community agrees on the fact that they are involved in the regulation of both
innate and adaptive immune response as well as some non-immunological
process. For instance, MCs have an important role during parasitic infections
of different pathogens such as helminths, bacteria and fungi. Gastrointesti-
nal helminth infections are generally associated with the expansion of MCs The term ”helminth” is
used to describe a group of
unrelated organisms
belonging to different phyla
(Nematoda, Platyhelminthes
and Annelida) which display
similar characteristics.
at the site of infection191,192. In this context, MCs are traditionally known for
their role during early- and late-stage induction of a TH2 response, mainly
mediated by interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin
(TSLP)193. Nevertheless, MCs have a direct effect on helminth survival and
proliferation by secreting cytotoxic proteases such as chymase and tryptase,
as well as an indirect role on round-worm expulsion by the action of se-
creted mast cell protease 1 (MCPT1) which disrupts intestinal epithelial bar-
rier integrity194,195. A recent work published by Reitz et al. highlighted the
fundamental role of MMC but not CTMC in the termination of Strongyloides
ratti infection: CPA3Cre mice (which lack both MMC and CTMC) were un-
able to resolve the parasitic infection before 150 days, while MCPT5Cre ×
R-DTA mice (which lack only CTMC) terminated the infection already after
1 month192.
Mast cells have also been implied in bacterial infections. Several papers
published in the last years show that MCs are able to phagocyte in vitro
different bacteria such as Escherichia coli and FimH+ Enterobacteria, Strepto-
coccus faecium, Pseudomonas aeruginosa and Francisella tularensis196–200. After
being recognized by different receptors, bacteria are engulfed in a plasma
membrane-derived vesicle called phagosome. Phagosomes then undergo
subsequent processes of fusion with lysosomes and secretory vesicles re-
sulting in strong acidification and digestion of the engulfed bacteria into
peptides201. Professional antigen-presenting cells (APCs) are then able to
load those peptides on newly synthesized MHC class II complexes and to
redirect them to the plasma membrane in order to be recognized by naïve
CD4+ T cells202. The ability of MCs to behave as antigen-presenting cells
(APCs) is still controversial; however, a study by Kambayashi et al. showed
that LPS and interferon (IFN)-γ stimulation lead to the expression of MHC
class II on BMMCs and PDMCs and allowed them to present antigens di-
rectly to T cells203. Similar results were also recently observed in human
primary MCs isolated from cytomegalovirus (CMV) seropositive patients, in
which ex vivo IFN-γ stimulation induced the expression of human leuko-
cytes antigen complexes (HLA-DR and HLA-DM), CD40 and CD80 by MCs
and allowed them to uptake, process and present antigens to autologous
CD4+ TH1 cells204. Bacterial challenge also induces MCs activation in term
of degranulation and subsequent release of pre-stored and de-novo synthe-
sized mediators. For instance, in vitro co-culture of MCs with Mycobacterium
tuberculosis resulted in cell degranulation, while stimulation of MCs with S.
faecium induced the release of TNF-α198,205. Both murine and human MCs
have been described to respond to in vitro infections with Staphylococcus au-
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reus: murine PMC released IL-3, IL-13 and TNF-α, while human CBMCs
released TNF-α and IL-8206,207. It is worth of note that several commensal
bacteria such as Lactobacillus casei, Enterococcus fecalis and non-pathogenic
E. coli can instead decrease MCs degranulation induced by IgE/Ag or Ca++
ionophores stimulation, most likely by affecting signaling pathways down-
stream of FceRI208–210. It also appears that in vitro stimulation of MCs with
Streptococcus pyogenes and Listeria monocytogenes can induce the release of so-
called “MCs extracellular traps”, namely extracellular structures composed
of DNA, histones, tryptase, and the antimicrobial peptide LL-37211,212.
The role of MCs in bacterial infections has been studied also in vivo with
murine models of MC-deficiency. For example, MCs and MC-derived IL-6
were fund to be important in the survival during Klebsiella pneumoniae infec-
tion and in a murine model of cecal ligation and puncture: KitW-sh/W-sh mice
and KitW-sh/W-sh mice reconstituted with IL-6-/- BMMC showed diminished
survival compared to WT mice and KitW-sh/W-sh mice reconstituted with IL-
6+/+ BMMC. Moreover, using a BALB/c model of MCs deficiency, it was
demonstrated that MCs play an important role in the clearance of L. monocy-
togenes by releasing TNF-α and recruiting neutrophils in the peritoneal cav-
ity during the initial phase of the infection213. On the other side, in a recent
work by Rönnberg et al. MCs were completely dispensable for the resolu-
tion of inflammation during intraperitoneal S. aureus inflammation, since no
difference in bacterial clearance, inflammation or cytokine production were
described between WT and MCPT5Cre × R-DTA mice206.
MCs are also able to recognize and respond to fungal infections. Even
though the topic is still quite controversial (mostly because of the limited
literature), a complete overview on this subject will be given in Section 2.2.4.
The concept that MCs could be involved in tumor biology goes back in
time, as Ehrlich and his student Westphal noticed and described the accu-
mulation of MCs at the periphery of tumors already at the end of the XIX
century2,214. Nowadays it is known that MCs partecipate in the progression
of different tumors but it is controversial whether they play protective rather
than pro-tumorigenic roles. For example, heparin and histamine released
by MCs interfered with the growth of human breast cancer cells and human
primary melanoma cells215,216. On the other side, many MCs mediators
(such as the matrix metalloprotease MMP-9, tryptase and VEGF) are known
to be involved in extracellular matrix (ECM) remodeling and angiogenesis,
and were found to favor tumor progression in different mouse models217–219.
A protective role for MCs in tumor progression has been described also in
a model of colon cancer: APCMin mice backcrossed on a KitW-sh/W-sh back-
ground showed increased tumor size compared to APCMin littermates220.
Conversely, the lack of MCs in the inducible model of Mcpt5Cre/iDTR+ mice
resulted in lower tumor growth of transplanted EL4 T-cell lymphoma221.
MCs are also involved in autoimmunity and have been described to have a
detrimental role in experimental autoimmune encephalomyelitis (EAE) and
rheumatoid arthritis, while being important in the induction of a tolerant
microenvironment during skin grafting222–224 . MCs are also supposed to be
involved in the pathology of celiac disease (CD)225,226, and were found to be
expanded and activated in irritable bowel syndrome (IBS)227,228 and Crohn’s
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disease229. Finally, mast cells are believed to be involved in many other non-
immunological processes such as defense against venoms230, tissue morpho-
genesis231, wound healing232, nociception and pain signaling233,234, depres-
sion and axiety235,236.
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2.2 hold the door! immunity to fungal infec-tions.
Agargantuan number of microorganisms resides in the human bodyand coexist with its host. Although the ratio between the number of
bacterial and human cells is often believed to be around 10:1, a recent report
suggests that this proportion is much closer to 1:1, estimating ∼3.9 × 1013
bacterial cells in a human body237. As such, thousands of studies published
in the last decade revealed that these tiny microbes have a huge impact on
human health (Fig. 2.2.1)238.
Figure 2.2.1: Number of publishedpapers about “microbiota” from1956 to 2017. In the last decade, ahuge number of studies contributedto the understanding of the role ofhuman microbiota. Bars indicatethe number of annual publicationscontaining the word “microbiota”from 1956 to 2017. Source: https:
//www.ncbi.nlm.nih.gov/pubmed
Sequencing of 16S-rRNA genes al-
lowed the identification of the human in-
testinal microbiota composition, which
mainly comprises bacteria belonging to
the Bacteroidetes and Firmicutes phyla.
The ratio of abundance between the two
phyla is important for human health; for
example, Firmicutes are reduced in pa-
tients suffering IBD, while are expanded
in obese individuals239,240. These mi-
croorganism are restrained in the intesti-
nal lumen by a thick and dense mucus
layer which avoid bacteria to contact the
epithelium but also provides a scaffold
for the gut microbiota. However, certain
bacteria (such as short filamentous bacte-
ria (SFB), Proteobacteria and Bacteroides
fragilis) are able to associate with the in-
testinal epithelium241. This close interac-
tion is fundamental for the promotion of
beneficial immunosuppression in the in-
testine and IgA production242. Lymphoid-tissue-resident commensal (LRC)
bacteria are subset of microorganisms which typically colonize the Peyer’s
patches and the mesenteric lymph nodes of healthy individuals. Their in-
teraction with DCs induce the release of cytokines which modulate type-3
innate lymphoid cells (ILC3) and TH17 response promoting gut-associated-
lymphoid tissue (GALT) maturation, IgA production and intestinal-tissue
repair238. Together with direct contact-dependent modulation of the im-
mune response, commensal bacteria can release several metabolites with
immunomodulatory properties. Fermentation of non-digestible polysaccha-
rides by anaerobic bacteria leads to the accumulation of short-chain fatty
acids (SCFA), including butyric acid and propionic acid, which behave as po-
tent anti-inflammatory and help in the maintenance of intestinal homeosta-
sis243. In a similar way, metabolization of dietary tryptophan by commen-
sal bacteria generate indole ligands of the Aryl-hydrocarbon receptor (AHR).
For example, indole-3-aldehyde derived from Lactobacillus reuterii was shown
induce the release of IL-22 from ILC3 in a AHR-dependent manner, resulting
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Figure 2.2.2: The human mycobiota. The pie charts indicate the proportion be-tween different fungal genera identified in healthy humans. Noteworthy, mucosalpopulations are rather diversified compared to skin. Adapted from Underhill andIliev 245 .
in the expansion of L. reuterii and promoting resistance to Candida albicans
colonization244.
Albeit the majority of the investigations on human microbiota focused
exclusively on the bacterial community, recent sequencing of the internal-
transcribed-spacer regions ITS-1 and ITS-2 of the fungal ribosomal DNA
uncovered the presence of a great community of fungi among mammalian
microbiota – named the mycobiome. This community comprises several
genera and change profoundly depending on the anatomical localization
but Candida, Saccharomyces and Cladosporium are among the most common
in the gut (Fig. 2.2.2)245. Fungal and bacterial communities interact and
influence each other. Studies on germ-free mice and on mice undergoing
prolonged antibiotic treatment, demonstrated that these animals are highly
susceptible to Candida infections246,247. This is believed to be true also for
humans, since administration of broad-spectrum antibiotics to adult cancer
patients induced an increased gastrointestinal colonization by yeasts248. A
recent paper by Sokol et al. showed that mycobiota composition was skewed
in patients affected by IBD, with an expansion of Basidiomycota over As-
comycota, and a more prominent colonization by C. albicans compared to
healthy individuals249. As reported above for L. reuterii, specific members
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of the bacterial community can hinder fungal colonization. A further ex-
ample is Bacteroides thetaiotaomicron, whose presence prevents C. albicans ex-
pansion by inducing the production of the antimicrobial peptide CRAMP250.
On the other side, C. albicans can actively promote mucosal tolerance by
skewing mucosal T-cell response and favoring the establishment of an anti-
inflammatory/tolerogenic state251. In a similar way, Malassezia spp. can
induce an anti-inflammatory state in normal skin through the induction of
TGF-β1 and IL-10, but is also responsible for disease exacerbation in patho-
logical skin252. Fungi are also used as probiotic, as in the case of Saccha-
romyces boulardii. This yeast inhibits the growth of different pathogens as
Salmonella typhimurium, Yersinia enterocolitica and C. albicans, even under in-
flammatory conditions. Moreover, the administration of S. boulardii in pa-
tients with Crohn’s disease and ulcerative colitis resulted in the ameliora-
tion of the pathology253,254. Taken together, these evidences suggest that the
host-mycobiome interaction resides on a tight equilibrium between commen-
salism and pathogenesis.
Disturbance of this equilibrium by different means can lead to a patho-
logical and uncontrolled proliferation of fungal species. Albeit being only
poorly considered as a public health concern, over 800 million people world-
wide suffer from life-threatening fungal-related diseases and 1.6 million of
them die annually255. Moreover, it has been proposed that global warming
will increase the prevalence of fungal infections in mammals, highlighting
the need for novel therapies and vaccination strategies256.
2.2.1 Candida albicans.
Candida spp. are commensal fungi that colonize mucous membranes and
the skin of healthy individuals (Fig. 2.2.2) and among all the species, C. al-
bicans is the most common in human mycobiota. However, they can cause
severe invasive diseases in patients hospitalized in intensive care units, with
solid tumors or hematological malignancy, undergoing surgery or being
treated with broad-spectrum antibiotics257. It is estimated that C. albicans
is responsible for more than one half of the cases of candidaemia, whichCandidaemia is a
bloodstream infection caused
by Candida spp. which can
develop into invasive
candidiasis when the fungus
reaches different organs and
tissues.
mortality rates in Europe vary between 28% and 59%257.
candida albicans biology Among Candida species, C. albicans is the
only one able to grow as a unicellular yeast and as a filamentous hyphal and
pseudohyphal forms (Fig. 2.2.3A)258. Generally, the growth of hyphal forms
requires a temperature of 37◦C and is induced in response to the presence
of CO2 and serum259. This property is rather important as C. albicans hyphal
growth is an important virulence factor and represent a key step for tissue-
invasion processes260.
An important feature for fungal biology and for their recognition by the
host immune system is the fungal cell wall composition. C. albicans cell wall
is composed of a strong structural core and a more plastic layer of proteins.
The structural core is quite common to all fungi and is composed by β-(1,3)-
glucans covalently linked with β-(1,6)-glucans and chitin (Fig. 2.2.3B). The
outer part of the cell wall is mainly composed by highly-glycosylated pro-
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Figure 2.2.3: Morphology and structure of Candida albicans. A. Morphologyof C. albicans biological forms. C. albicans can grow as a unicellular yeast or asfilamentous hyphal and pseudohyphal forms. While hyphae form long, thin, andtube-like structures, pseudohyphae are wider and present constrictions at thesites of septation. Scale bars in the main panels are 5µm and 1mm in the inset.Adapted from Sudbery 258 . B. Molecular structure of C. albicans cell wall. C.albicans cell wall is composed of an inner core with structural functions composedof β-(1,3)- and β-(1,6)-glucans, and a thick outer layer mainly composed ofmannoproteins. Adapted from Netea et al. 261 .
teins anchored to glucans or chitins. These proteins contain long chains of
carbohydrates and mannans (mannose-containing polysaccharides) further
stabilized by O-linked mannan side chains261. Most importantly, this thick
proteic layer masks perfectly the underlying β-glucans in both yeasts and
hyphae, except for the “bud scars”(the scars left on the mother yeast cell
after the separation of the budding yeast cell) preventing the recognition of
these polysaccharides by the host’s immune system262. Interestingly, small
differences in the cell wall architecture (as the glycosylation status) can lead
to a delayed migration and phagocytosis of C. albicans by macrophages263.
2.2.2 Innate sensing
The immune response to C. albicans (and, more generally, to fungal patho-
gens) begins with the recognition of specific PAMPs by the innate arm of the
immune system. The recognition of fungal PAMPs is mediated by several
PRRs, including C-type lectin receptors (CLRs), Toll-like receptors (TLRs)
and intracellular NOD-like receptors (NLRs)252.
CLRs
CLRs are the most important receptors for fungal recognition. As deeply
reviewed before (cfr. 2.1.2), dectin-1 is the best characterized CLR and is
fundamental for the recognition of β-glucans and subsequent production of
pro- and anti-inflammatory cytokines.
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C. albicans hyphae β-glucans are completely shielded by the mannopro-
teins layer, preventing its recognition by dectin-1262. However, it has also
been hypothesized that dectin-1 may be responsible for the recognition of
hyphal β-glucans perhaps due to the thinning of mannan fibrils264. More-
over, structural differences between the β-glucans of C. albicans yeasts and
hyphae induce different responses upon dectin-1 binding which, in some
cases, can also fail to recognize specific strains of C. albicans265,266.
Mannans and mannoproteins are recognized by several CLRs including
the mannose receptor (CD206), the DC-specific ICAM3-grabbing non-integrin
(DC-SIGN), MINCLE and dectin-2. The mannose receptor is primarily ex-
pressed on macrophages and recognize N-linked mannans and α-glucans.
Its binding and activation induce a potent expression of IL-17, thus playing
a fundamental role in the promotion of TH-17 anti-fungal responses267. N-
linked mannans are recognized also by DC-SIGN on DCs and macrophages.
Similarly to the mannose receptor, activation of DC-SIGN promotes the re-
lease of cytokines involved in TH cell activation268. Dectin-2 is expressed
on DCs, macrophages and neutrophils and recognize α-mannan. Dectin-2
couples with the Fc receptor γ-chain FcRγ in order to activate downstream
signaling pathways leading to the expression of pro-inflammatory cytokines
and the production of ROS during C. glabrata phagocytosis252,269.
TLRs
TLR2, TLR4 and TLR6 are the main TLRs that are involved in the recogni-
tion of the fungal cell wall mannoproteins. For example, C. albicans O-linked
mannosyl residues are recognized by TLR4 and induce the expression of
pro-inflammatory cytokines (TNF-α, IL-6) as well as the expression of the
anti-inflammatory IL-10 in human mononuclear cells. Moreover, TLR2 coop-
erated with dectin-1 to boost cytokine expression in response to β-glucans270.
In recent years it has been proposed that also the intracellular TLR3 and
TLR9 are involved in the recognition of C. albicans. In a clinical study on pa-
tients affected by chronic mucocutaneous candidiasis, a mutation in the
TLR3 gene (L412F) increased the susceptibility to Candida infections due to
an impaired activation of NF-κB and IFN-γ production271. On the other side,Chronic mucocutaneous
candidiasis is characterized
by persistent or chronic
infections (typically
occurring in the oral and
genital mucosae, skin and
nails) generally caused by C.
albicans272.
TLR9 is able to recognize chitin and possibly fungal DNA, and induce the
release of the anti-inflammatory IL-10 in both mice and humans273,274.
NLRs
NOD-like receptors are a family of cytosolic proteins which ligation in-
duces the activation of the inflammasome and the production of several
pro-inflammatory cytokines. Activation of NOD-, LRR- and pyrin domain
(PYD)-containing protein 3 (NLRP3) inflammasome in response to C. albicans
hyphae, induces the activation of caspase-1 which in turn cleaves pro-IL-1β
and pro-IL-18 to their bioactive forms275. As a result, mice lacking NLRP3
are more susceptible to candidiasis163.
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Figure 2.2.4: Recognition of Candida by innate immune cells. Engagement ofextracellular TLRs induces the expression of pro-inflammatory cytokines, whilebinding of nucleic acids and chitin to intracellular TLRs induces the productionof IFN-γ and IL-10. The dectin family of CLRs are involved in the recognitionof β-glucans and mannans and play a fundamental role in the phagocytosis andkilling of the fungus. CR3 is important for the recognition of unopsonized Candidawhile FcγR recognize opsonized fungi. The signaling cascade activated by themannose receptor is still not clear but its engagement induces the production ofpro-inflammatory cytokines and IL-17. Finally, galectin 3 and MINCLE are twopoorly studied receptors but their activation by Candida leads to the release ofdifferent cytokines. Adapted from Netea et al. 268 .
2.2.3 Innate immunity to fungal infections
After the recognition of fungal PAMPs, different immune and non-immune
cells participate to the clearance of Candida albicans. Fundamental players of
this process are the components of the innate arm of immunity and, more
specifically, myeloid phagocytes (Fig. 2.2.4).
Immunity at the epithelial barrier
The first line of defense against fungi is the epithelial barrier, which serves
as a mechanical barrier to contrast tissue invasion by fungi. As reported ear-
lier, tissue invasion by C. albicans is strictly dependent on the morphological
change from yeast to hyphae which allows the fungus to actively penetrate
the epithelial barrier260. Besides, Candida can interact with epithelial cell
proteins such as E-cadherin and human epidermal growth factor receptor 2
(Her2), triggering its endocytosis276. Candida hyphae overgrowth allows its
recognition by epithelial cells and the activation of the MAPK partway lead-
ing to the c-Fos–dependent release of pro-inflammatory cytokines and of an-
timicrobial peptides such as β-defensins and cathelicidin277. Moreover, dis-
ruption of the epithelial barrier induces the release of alarmins (e.g. S100B),
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matrix metalloproteases, chemokines and growth factors that concomitantly
recruit effector cells as neutrophils and promotes tissue remodeling and bar-
rier repair278.
Neutrophils
Neutrophils are the most important effector cells in host defense against
Candida. As a matter of fact, neutropenia is one of the major risk factors
for invasive fungal infections in both mice and humans279,280. Neutrophils
are recruited to the site of infection by the chemokines released by activated
epithelial cells and tissue resident macrophages. Recognition of Candida by
FcγR leads to the clearance of the fungus through the production of ROS.
On the other side, triggering of CR3 induces the killing of Candida via a
non-oxidative effector mechanism281. This latter mechanism rely on the
production of antimicrobial factors as β-defensins, cathepsin-G, lactoferrin
and lysozyme. Moreover, neutrophils are able to release neutrophil extra-
cellular traps (NETs), which are composed of chromatin mesh associated
with granule-derived antimicrobial peptides and enzymes such as elastase,
cathepsin-G, and myeloperoxidase282. Importantly, human neutrophils are
able to inhibit the germination of C. albicans yeasts to hyphae268.
Monocytes and macrophages
Tissue-resident macrophages produce pro-inflammatory cytokines and che-
mokines with recruit other immune cells (among all, neutrophils) to the site
of fungal infection261. Macrophages can phagocyte both C. albicans yeast
and hyphae and thus exert potent candidacidal activity283. Similarly to neu-
tropenia, lack of macrophages in vivo cause accelerated fungal proliferation
and increased mortality284. Albeit being thought to be less effective than
neutrophils in controlling bloodstream Candida infections, circulating mono-
cytes are recruited to the site of infection in a CX3CR1-dependent fashion
and participate in fungal clearance after developing into macrophages285,286.
Dendritic cells and T-cell activation
DCs are able to phagocyte and kill Candida but their activity is less ef-
fective compared to neutrophils and macrophages287. However, DCs are
fundamental players during fungal infections. For example, their produc-
tion of IL-23p19 upon recognition of C. albicans is fundamental to enhance
neutrophil activity through the release of GM-CSF by natural killer (NK)
cells288.
Most importantly, DCs are the main cells responsible for the processing
and presentation of fungal antigens to TH cells. Their wide expression of
PRR together with their plasticity to activate distinct signaling pathways
confer DCs the ability to affect the balance between CD4+ effector T cells and
Treg cells, thus setting the threshold between commensalism or infection252.
DCs recognition of fungi by TLR and CLR induce the activation of a TH1
response and the subsequent release of INF-γ by activated CD4+ T-cells289.
Interestingly, INF-γ– and IL-18–deficient mice fail to induce an effective TH1
response and thus are more susceptible to disseminated candidiasis290,291.
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TH17 responses are predominantly activated in response to DCs activation
through the mannose receptor252. The release of IL-17 and IL-22 is important
for the recruitment and activation of neutrophils as well as the release of
antimicrobial peptides by epithelial cells292. Moreover, patients harboring
mutations in members of the IL-17 axis or with defects in TH17 activation
are more susceptible to mucosal candidiasis, while mice with IL-17 signaling
deficiency are susceptible also to systemic candidiasis293,294.
TH2 commitment by IL-4 and IL-13 has detrimental roles during fungal
infections by dampening TH1 responses and favoring fungal survival and
disease relapse252,295. In agreement, IL-4 depletion make mice more resistant
to C. albicans infection but at the same time fail to promote the development
of a protective TH1 response during re-infection296.
2.2.4 Are mast cells playing the game?
Despite their potential role during fungal infections, interactions between
mast cells and fungi have been only poorly investigated and published data
are often contradictory.
Gastrointestinal colonization with C. albicans induced mast cell infiltration
and degranulation, and promoted the sensitization against food antigens
by increasing the permeability of the gastrointestinal mucosa297,298. Two
studies showed that rat peritoneal MCs as well as murine BMMCs were
able to phagocytose heat killed and opsonized live C. albicans yeasts, in a
mechanism involving both TLR2 and dectin-1299,300. Interestingly, BMMCs
were not able to kill phagocytosed yeasts but instead efficiently killed the
un-opsonized yeasts in the extracellular environment299. Phagocytosis of
heat killed yeasts was found to be dependent on the recognition of fungal
PAMPs by TLR2 and dectin-1. Moreover, triggering of these receptors by
Candida or zymosan particles resulted in the production of nitric oxide (NO)
but not ROS300. On the contrary, a recent study demonstrated that BMMCs
released ROS in response to in vitro stimulation with C. albicans yeasts and
hyphae. Fungal challenge also induced BMMCs and PDMCs degranulation,
the activation of the NF-κB pathway and the secretion of TNF-α, IL-1β, IL-
6, IL-10, CCL3 and CCL4. Interestingly, TNF-α release could be partially
reduced after the neutralization of dectin-1 but not TLR2 signaling167.
Human MCs also respond to Candida challenge. Lopes et al. demonstrated
that C. albicans challenge of the human mast cell line HMC-1 induced de-
granulation (at high multiplicity of infection - MOI) and the release of pro-
and anti-inflammatory cytokines. Interestingly, a two-phased response was
observed, characterized by an early secretion of IL-8, and a later release of
IL-16 and IL-1ra. Supernatants of infected MCs induced the chemoattrac-
tion of neutrophils but not monocytes, confirming the important role of IL-8
in neutrophil recruitment. Moreover, MCs were transiently able to release
tryptase-containing MC-extracellular traps and to kill Candida in the early
phase of infection. However, at the late stage of infection C. albicans potently
triggered MCs death, also by the outgrowth of internalized yeasts301.
As already discussed, mast cells can be also activated by dectin-1 ligands
which mimic the fungal cell wall such as zymosan and curdlan. Stimula-
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tion of BMMCs with zymosan resulted in the generation of ROS and the
upregulation of dectin-1 expression166. A similar study on human CBMC
reported that zymosan stimulation induced LTB4 and LTC4 production in a
SYK-dependent manner149. Recently, it has been shown that curdlan stimu-
lation was able to induce BMMCs degranulation but not the release of LTC4,
IL-6 nor CCL-2302.
As a matter of fact, deciphering the interaction between MCs and Candida
remains a challenging effort.
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2.3 innate immune memory: bridging the innateand adaptive arms of immunity.
It is common knowledge that the vertebrate immune system is composedof two arms: the innate and the adaptive immunity arms. Innate immune
responses are mainly mediated by the recognition of non-self molecules by
myeloid cells (as monocytes/macrophages, neutrophils, and DCs), which
culminates with the eradication of the invading pathogens. Current opinion
is that innate responses are primitive, nonspecific and unable to induce im-
munological memory. On the contrary, adaptive immunity rely on the slower
activation of B and T lymphocytes which specifically recognize pathogens’
antigens and give rise to antibody-mediated humoral responses. Upon sec-
ondary infections with the same specific pathogen, memory-B and T cells
rapidly expand promoting faster and more effective humoral- and cellular-
mediated responses303.
Despite this widely accepted dichotomy between innate and adaptive re-
sponses, there is an increasing body of evidence suggesting that innate
immune processes might be more sophisticated than what is currently be-
lieved. A first clue is given by the Regnum Vegetabile: plants that have
been locally infected can develop an enhanced, systemic, long-lasting resis-
tance to reinfections, a condition referred to as systemic acquired resistance
(SAR)304. Moreover, several studies published in the last 40 years demon-
strated that immune responses of several invertebrates such as cockroaches,
shrimps, beetles, mosquitoes and clams (which all lack adaptive immune re-
sponses) could be enhanced upon reinfection305–312. This phenomenon has
been termed “innate immune memory” or “trained immunity” and is com-
plementary to the phenomenon of tolerance, in which an infectious episode
can lead to a refractory responce to secondary infections (Fig. 2.3.1)313.
Innate immune memory differs from the classical adaptive memory from
several point of view. Fist of all, this process exclusively involves innate
cells as myeloid cells, NK cells and ILCs, which are not involved in the
classical immunological memory. Second, contrarily from adaptive immune
mechanisms it does not depend on permanent genetic mutations or recombi-
nations but rather on the epigenetic rewiring of the transcription programs.
As such, the increased responsiveness upon reinfection is not specific for a
Figure 2.3.1: Proposedmodel of differentialprogramming of innateimmunity. Innate immuneresponse to infections(priming) can induceimmunological repro-gramming, leading to anenhanced (training) ora refractory (tolerance)status. Adapted fromQuintin et al. 314 .
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Figure 2.3.2: Classical immunological memory and innate immune memory.A. Classical immunological memory relies on the somatic recombination of theloci encoding for immunoglobulins and the T-cell receptor (TCR) after the firstencounter with the pathogen. This process confers a long-term, pathogen-specific protection. B. The recognition of microbial-associated molecular pat-terns (MAMPs) by cells belonging to the innate immune system induces theirepigenetic reprogramming. Trained cells display enhanced inflammatory andantimicrobial properties, and thus are able to mount a prompter non-specificresponse during reinfection. Adapted from Netea et al. 316 .
specific pathogen or ligand (Fig. 2.3.2). Last but not the least, this enhanced
or repressed status lasts for a shorter period of time compared to adaptive
immunity315.
2.3.1 Innate immune memory in vertebrates.
The discovery of memory mechanisms in plants and invertebrates raised
the question whether this phenomenon was confined to lower taxa or also
functional in vertebrates. This hypothesis is supported by the great number
of studies published in the last years, showing that also mice and humans
posses innate immune memory in vivo.
Stimulation with the bacterial protein flagellin induces the cross-protection
against Streptococcus pneumoniae and also against rotavirus infections, in a
mechanism dependent on DCs activation317,318. Similarly, β-glucan stimula-
tion afforded protection against infections with S. aureus319,320. Also ligands
for intracellular PRRs are able to induce trained immunity in mice, as the
treatment with CpG and muramyl dipeptide (MDP, a component of PGN
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recognized by intracellular NOD receptors) confer resistance to E. coli sepsis
and Toxoplasma infection, respectively321,322. It is interesting to note that also
cytokines can be directly involved in the induction of innate immunological
memory. For example, survival of mice infected with P. aeruginosa was im-
proved in animals that were injected with recombinant IL-1β 3 days before
the bacterial infection323.
Further proofs of trained immunity in vertebrates come from in vivo stud-
ies on animals primed with pathogens rather than purified PAMPs. Mice
that were infected with the attenuated strain PCA-2 of C. albicans (which is
unable to germinate hyphae) were protected against the reinfection with the
virulent C. albicans strain CA-6324. Importantly, this mechanism was found
to be independent on B and T lymphocytes activation, as the protection was
induced also in athymic and Rag1-deficient mice (which are unable to de-
velop mature B and T lymphocytes)325,326. Infections with the helminth Nip-
postrongylus brasiliensis induced the expansion of neutrophils with a peculiar
transcriptional profile, which in turn activated M2 macrophages, conferring
a long-lasting protection from reinfection. Interestingly, adoptive transfer
of primed macrophages from infected to nai¨ve animals was sufficient to en-
hance protection against N. brasiliensis327. Viral infections also seem to have
similar biological activity. Challenge with murine CMV induced the activa-
tion of Ly49H+ NK cells which persisted within different organs. Upon CMV
reinfection these “memory” NK cells were able to rapidly expand and de-
granulate, finally sustaining a strong protective immune response328. More-
over, it has been shown that herpesvirus latency increased the resistance to
L. monocytogenes and Yersinia pestis by promoting the production of IFN-γ by
activated macrophages329.
Interestingly, immunization of mice with the tuberculosis vaccine bacillus
Calmette-Guérin (BCG) induces a T cell-independent protection against sec-
ondary infections with C. albicans or the trematode Schistosoma mansoni330,331.
This phenomenon could also be observed in humans, as immunization with
BCG was found to alter the functional status of circulating monocytes, en-
hancing their response to M. tuberculosis, C. albicans and S. aureus. Macro-
phage response was still markedly enhanced after 3 months from the vacci-
nation and returned only partially similar to the baseline 12 months after the
immunization332. The hypothesis that BCG immunization might offer non-
specific beneficial effects was validated by epidemiological studies and clin-
ical trials on children and newborns BCG vaccination in West Africa. These
studies demonstrated a nonspecific protection of the vaccine against unre-
lated pathogens, resulting in a lower overall mortality333,334. Moreover, many
other epidemiological studies suggested that live vaccines other than BCG
(as measles and polio vaccines) protect against nonspecific pathogens335. It
is thus tempting to say that these beneficial effects may rely on the induction
of innate immune memory.
2.3.2 Endotoxin tolerance: the other side of the coin?
Although inflammation is crucial for a proper eradication of pathogens,
uncontrolled inflammation can lead to excessive tissue damage and to the
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development of pathological states as chronic autoimmune diseases, degen-
erative diseases and cancer. As such, a number of mechanisms evolved in
order to restrain excessive activation of inflammatory processes336.
Endotoxin tolerance (ET) is a well known (albeit not completely under-
stood) mechanism to restrain inflammation and protect the host against
endotoxin shock. ET is defined as a process in which cells already exposedEndotoxin shock is a
complex pathology that arise
from a severe inflammatory
response towards Gram-
bacteria. Patients typically
present fever and
hypotension, which generally
evolves in multiorgan failure
and death337.
to LPS enter a transient state of unresponsiveness against further challenges
with LPS, making them tolerant to re-stimulation. These tolerant cells re-
spond to LPS restimulation with a less robust release of pro-inflammatory
mediators and a sustained production of anti-inflammatory mediators338.
This phenomenon was initially described during rabbit vaccination with the
typhoid vaccine (an attenuated strain of the Gram- Salmonella enterica), as
it was noticed that the vaccine-induced fever was gradually reduced after
recurring injections of the vaccine339. In vivo studies demonstrated that the
injection of a sublethal dose of LPS in mice protected them against a subse-
quent lethal dose of LPS. This phenomenon was ascribed to monocytes and
macrophages and particularly to their tolerant status which was responsible
for the attenuated response to the second challenge of LPS340,341. Several
in vitro studies on endotoxin-tolerant macrophages demonstrated a dras-
tic reduction of the expression and release of pro-inflammatory cytokines
such as TNF-α, IL-1β, IL-6, IL-12 together with the chemokines CCL2, CCL4
and CXCL10 both in mice and humans. On the contrary, these tolerant
cells showed a marked upregulation of anti-inflammatory cytokines such as
TGF-β, IL-10, IL-1ra together with cell surface receptor as the macrophage
receptor with collagenous structure (MARCO) and CD64342–346. These mac-
rophages phenotypically resemble the “alternatively-activated” M2 macro-
phages, also demonstrating an improved phagocytosis and an impaired abil-
ity for antigen presentation345.
On the other side, it has been reported that the stimulation with a very
low dose of endotoxin had a completely opposite effect, potentiating the
response to subsequent LPS challenge. This effect was also true in vivo, as
mice that received a super low dose of LPS showed higher mortality rates
after a second injection of a high dose of LPS, compared to controls347,348.
Taken together, it appears clear that also LPS priming can induce a strong
immunological memory on monocytes and macrophages. Moreover, the
initial stimulation with LPS is fundamental for the induction of a tolerant
rather than a trained phenotype, depending on the dose. From this point
of view, tolerance and training can be considered the two sides of the same
coin.
2.3.3 Mechanisms of innate immune memory.
Studies in lower taxa.
The existence of a mechanism of innate immune memory was initially
speculated in plants an invertebrates since both the taxa displayed character-
istics of immune memory albeit lacking adaptive immune responses315.
Upon infections with necrotizing agents, plants often develop an enhanced
resistance to other pathogens also at sites distant from the first infection, a
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phenomenon named “systemic acquired resistance”. It was demonstrated
that SAR induction is dependent on the production of salicylic acid at the site
of the infection, which then act as a signaling molecule to induce resistance
even in remote tissues349. Similarly, the colonization of plant roots with non-
pathogenic fungi and bacteria induce an analogous phenomenon of systemic
resistance which protect the plant against a broad number of pathogens in a
salicylic acid-independent mechanism350. SAR can be induced also by treat-
ment with chemicals: studies on the fungicide Pyraclostrobin demonstrated
that this molecule is able to induce resistance of Tobacco plants to Tobacco
mosaic virus and Pseudomonas syringae infections, as well as long-term protec-
tion of several crops to different pathogens351–353.
Mechanisms responsible for SAR induction were only poorly understood
until a few years ago. It is now hypothesized that this phenomenon is regu-
lated at 4 levels. As described above, release of salicylic acid and pipecolic
acid is fundamental for the induction of SAR and stimulation with salicylic
acid or by its functional analog benzothiadiazole is sufficient to recapitulate
SAR349. Studies on Arabidopsis demonstrated that benzothiadiazole-treated
plants expressed higher levels of transcripts coding for MAP kinases (as
MPK3 and 6). These MAPK represent the second step of regulation: albeit
being normally found in a inactive state (which counted for their name “dor-
mant MAPK”), they rapidly become phosphorylated upon pathogen chal-
lenge and mediate a signaling network that culminates with the expression
of defense genes. As a consequence of their heightened expression, MAPK
activation is much more prominent during SAR354. Together with increased
MAPK expression, SAR plants also display a higher synthesis and secretion
of several PRRs355. Finally, it has been reported that epigenetic modifica-
tions (mainly histone marks) are important regulators of defense genes upon
restimulation. For example, it was described that SAR induced increased
H3K4me3 and H3K4me2 on the transcription factors WRKY6/29/53 promot-
ers, and H3K9ac, H4K5ac, H4K8ac, and H4K12ac on WRKY29 promoter (see
Box 1 for clarifications)356.
Two different mechanism of innate immune memory can be described in
invertebrates. The first mechanism comprises several strategies responsible
for the enhancement of the innate response upon reinfection. For example, in
the European woodlouse Porcellio scaber, in vitro priming of haemocytes with
heat killed bacteria resulted in the increased phagocytosis of the same live
bacteria during reinfections357. Differential responses to reinfection could
also be the consequence of phenotypic changes in the cellular population, as
in the case of Anopheles gambiae in which training by gut microbiota induces
the expansion of granulocytes increasing the protection agains Plasmodium
reinfections311.
On the the other hand, another mechanism involved in invertebrate innate
immune memory is much closer to the specific adaptive memory of verte-
brates and rely on RAG-independent somatic diversification. Two of the
most prominent example are represented by the diversification at genomic
level of fibrinogen-related proteins (FREPs) in the snail Biomphalaria glabrata
and the Down Syndrome Cell Adhesion Molecule (Dscam) in Drosophila
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melanogaster and Anopheles gambiae which confer adaptive and specific recog-
nition of pathogens358–360.
Molecular mechanisms of trained immunity in vertebrates.
It is supposed that induction of innate immune memory in vertebrates
rely on the convergence of different regulatory networks. These includes
chromatin remodeling, the modulation of upstream signaling pathway as
well as the contribution of microRNAs (miRNA) and long non-coding RNAs
(lncRNA). Since we are living in the epigenetics era, much attention has been
given to the epigenetic reprogramming of monocytes/macrophages during
stimulation and it is common belief that this mechanism accounts for the
major features of innate immune memory315.
Box 1 - Epigenetic markersThe basic unit of chromatin is the nucleo-some, which is composed of 147bp of DNAcoiled around an octamer of histone proteins(two of each H2A, H2B, H3 and H4). DNAbases and histone proteins can be covalentlymodified by several enzymes, finally affect-ing chromatin accessibility and gene tran-scription. Methylation of cytosine bases onDNA is linked with gene transcription repres-sion, while the role of histone tails modifi-cation (acetylation, methylation, phosphoryla-tion and ubiquitination) is less clear. Acetyla-tion of histone lysine residues (e.g. H3K27ac)is believed to loose the interaction betweenDNA and histone core proteins, allowing therecruitment of the transcription machinery.On the other side, methylation of histonelysine residues can activate as well as re-press gene transcription. H3K4 methylation(H3K4me), H3K9me, H3K27me and H3K4 tri-methylation (H3K4me3) are linked with genetranscription, while H3K9 di-methylation(H3K9me2), H3K9me3, H3K27me2 andH3K27me3 are known markers of gene repres-sion361,362.
In resting conditions, chromatin
regions encoding for inflammatory
genes are in a repressed status,
showing limited accessibility to
transcription factors (TF), low level
of histone acetylation and absence
of RNA polymerase II (RNA pol II)
activity (Fig. 2.3.3). Upon the first
stimulation, the chromatin structure
of these regions is deeply modi-
fied: histones gain activation marks
(as acetylation and tri-methylation)
thus increasing chromatin accessi-
bility and the recruitment of TF and
RNA pol II, finally leading to gene
transcription. A growing body of
evidence supports the hypothesis
that after the removal of the stimu-
lus, some of these chromatin modifi-
cations remain persistent on specific
promoters and enhances of inflam-
matory genes, allowing a more ef-
ficient transcription during reinfec-
tion363,364. This process is particu-
larly important in the case of latent
or de novo enhancers, which are regulatory regions that gain histone modi-
fication typical of enhancers only upon stimulation365. For example, train-
ing of human monocytes with β-glucan or C. albicans, induced a stable and
global increase in the levels of H3K4me3, especially at the level of the pro-
moters of genes associated with immune signaling pathways (e.g. Myd88,
Raf1, Dectin-1, Tlr4) and of pro-inflammatory cytokines (e.g. Tnf-α, Il-6, Il-
18). Concordantly, total level of endogenous p38 MAPK were increased in
trained monocytes, and its phosphorylation upon restimulation was quicker
and more prominent than controls. On the contrary, trained monocytes did
not show any differences in the global levels of H3K27me3326.
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Similarly, Yoshida et al. demonstrated that in normal conditions, the tran-
scription factor ATF7 is able to repress LPS-induced gene expression by bind-
ing to promoters and driving the deposition of the repressive histone mark
H3K9me2 by action of H3K9 dimethyltransferase G9a. Concomitantly, LPS
treatment of murine peritoneal macrophages induced p38-dependent ATF7
phosphorylation, which led to the release of the TF from promoters and a
marked decrease in repressive H3K9me2 marks. Interestingly, macrophage
memory in vivo was maintained for at least 3 weeks, providing resistance to
S. aureus reinfections366.
Innate immune memory induced by vaccination is also supposed to rely
on similar mechanisms. BCG vaccination of healthy volunteers induced a
long lasting increase in the response against bacterial and fungal pathogens
by circulating monocytes, which persisted for at least 3 months after in-
jection. This training effect relied on the marked increase of H3K4me3 at
cytokines and TLR4 promoters332.
Another proposed mechanism of innate immune memory is based on the
recent finding that monocyte training by β-glucan caused a prominent shift
of the cellular metabolism from oxidative phosphorylation toward anaerobic
glycolysis. This phenomenon was dependent on the activation of a dectin-
1/AKT/mTOR/HIF-1α pathway, as treatment of mice with metformin (an
mTOR inhibitor) prior to β-glucan training prevented the induction of a pro-
tective response against C. albicans infections367. Importantly, the availability
of the Krebs cycle metabolites α-ketoglutarate and succinate is fundamental
for the activity of the JMJ-family of lysine-demethylase and the TET-family
of methylcytosine hydroxylases, two important groups of enzymes involved
in the remodeling of the epigenetic landscape368. As a whole, this hypoth-
esis is supported by the fact that also the two main phenotype of macro-
phages, M1 and the alternatively activated M2, rely on distinct metabolic
pathways369.
Molecular mechanisms of endotoxin tolerance.
Albeit endotoxin tolerance have been studied for over 60 years, many as-
pects of the molecular mechanisms governing this phenomenon remain enig-
matic. As for immune training, the induction of ET is dependent on many
factors such as the modulation of signaling networks, the reprograming of
gene expression via chromatin remodeling and the effect of miRNA and
autocrine signaling370.
A great number of studies demonstrated that this phenomenon is not de-
pendent of the expression level of any of the proteins involved in LPS recog-
nition (e.g. TLR4, CD14, MD2 or LBP)371. On the contrary, ET macrophages
(i.e. tolerant macrophages as a result of LPS exposure) showed an impaired
formation of both the TLR4-MyD88 and MyD88-IRAK1 complexes together
with the decreased kinase activity of IRAK1, suggesting that ET was rather
characterized by an impaired intracellular signaling372,373. It is known that
LPS stimulation induces the activation of the MAPK pathway, leading to the
activation of the TF AP-1 and NF-κB374. Consistent with the hypothesis of
an impaired signaling during ET, it was demonstrated that LPS-treated cells
were refractory to a secondary LPS challenge due to their reduced levels of
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Figure 2.3.3: Epigenetic regulation of innate immune memory. Initial stimula-tion induces the acetylation of histone H4 and H3K4me3 on the promoters ofpro-inflammatory genes. In the case of trained immunity, activation marks suchas H3K4me are retained on the promoters and enhancers of pro-inflammatorygenes which facilitate the recruitment of the transcription machinery and chro-matin modifiers upon a second stimulation. On the contrary, during ET histonemodifications are lost after the removal of the stimulus and chromatin becomeagain poorly accessible. Upon restimulation, “tolerizeable” genes fail to gain hi-stone activation marks and are not be transcribed. Adapted from Alvarez-Erricoet al. 362 .
ERK1/2, JNK and p38 phosphorylation during restimulation371,375,376. This
impaired activation of MAPK signaling was also correlated with the defec-
tive activity of both AP-1 and NF-κB346,374.
With regard to NF-κB activation, it is worth of note that LPS stimulation
mostly induce the activation of the canonical NF-κB pathway, which cul-
minates with the nuclear translocation of the p65/p50 heterodimer377. As
previously described, a key step required for NF-κB activation is the protea-
somal degradation of its inhibitor IκB112. Several authors reported that the
impaired NF-κB activation during endotoxin tolerance was correlated with a
reduced IκB-α and IκB-β degradation after LPS restimulation, possibly due
to both an impaired proteasomal degradation and to a more rapid turnover
of the inhibitory subunit346,374,378,379. Another interesting feature of NF-κB
in ET macrophages is it plasticity to undergo homo- and heterodimerization.
It has been shown that in LPS-treated cells the NF-κB subunit composition is
shifted from the canonical p65/p50 heterodimer to the p50/p50 homodimer.
Notably, p50 homodimers lack the transactivation domain and are unable
to trigger the transcription upon binding to gene promoters: by competing
with the p65/p50 heterodimers for DNA binding is then able to inhibit gene
transcription380,381. In agreement, ET was not induced in macrophages de-
rived from p50-/- mice382.
As reported for trained immunity, macrophages are subjected to substan-
tial gene-expression reprogramming during endotoxin tolerance (Fig. 2.3.3).
A study by Foster et al. identified two classes of genes modulated in murine
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macrophages after induction of ET343. The first class of genes (named ‘to-
lerizeable”) comprised mostly inflammatory genes which were drastically
downregulated upon LPS restimulation (e.g. Il-6, Il-1b, Mmp13). On the
contrary, the second class of genes included genes encoding for antimicro-
bial mediators that were upregulated or remained inducible after the second
LPS challenge and were named “non-tolerizeable”. Notably, albeit the first
LPS stimulation induced H3K4 acetylation of the promoters for both the
tolerizeable and non-tolerizeable genes, histones of non-tolerizeable genes
failed to be re-acetylated upon a further LPS challenge. Also H3K4me3 was
induced on the promoters of both classes during the initial stimulation: al-
beit being rapidly lost on tolerizeable promoters, it was stably maintained
on non-tolerizeable promoters343.
With regard to chromatin remodeling, a previous study reported that af-
ter LPS priming, the NF-κB subunit RelB was able to bind to the promoter
regions of TNF-α and IL-1β, directing the di-methylation of H3K9 and si-
lencing gene transcription383.
2.3.4 MASTer memory: a changing concept in mast cell biology.
In recent years several studies reported that also mast cells show classical
traits of immunological memory. Albeit being only poorly investigated, the
topic is of relevant importance since mast cells are long lived cells and their
priming might affect tissue homeostasis.
Initially it has been reported that LPS stimulation induced endotoxin tol-
erance in BMMCs. This phenomenon was due to the upregulation of the
phosphatase SHIP (but not of SHIP2 nor PTEN) by the autocrine effect of
LPS-induced release of TGF-β. In agreement, SHIP-/- MCs and Mϕ did
not display ET and SHIP-/- mice succumbed quickly after injection of low
doses of LPS384. More recent studies further demonstrated the ability of
MCs to respond to LPS by releasing pro-inflammatory TNF-α and IL-6 in a
p38-dependent manner, and that the release of these cytokines was severely
decreased upon a secondary stimulation with LPS or with TLR2 agonists,
suggesting that endotoxin tolerance could induce also cross tolerance against
different stimuli385,386. Interestingly, TLR4-dependent LPS stimulation am-
plified the release of TNF-α and IL-6 induced by IgE/Ag cross linking. This
effect was also induced in tolerant BMMCs with a less marked effect due to
the decreased activation of p38 and NF-κB and to the expression of SOCS1
and SOCS3 which are known to be negative regulators of LPS-induced TLR4
activation386. In a similar way, prolonged activation with TLR1/2, TLR2/6,
TLR3 or TLR4 ligands amplified MCs response to IgE/Ag challenge387. On
the other way around, MCs sensitization with IgE alone increased the re-
sponse to LPS stimulation by enhancing IKK-IκB phosphorylation and NF-
κB nuclear translocation. However, IgE sensitization was not sufficient to
abolish ET establishment after LPS stimulation388.
A recent report by Poplutz et al. demonstrated that during ET mast cells
displayed a decreased nuclear translocation and DNA binding ability of the
canonical NF-κB p65/p50 heterodimer. The latter phenomenon was due to
the constitutive presence of the suppressive marker H3K9me3 on the pro-
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moters of TNF-α and IL-6 which inhibited NF-κB binding to the promot-
ers. These repression markers were transiently lost during the initial LPS
stimulation (thus allowing NF-κB binding and gene transcription), but re-
mained unchanged during the second LPS challenge. According to previous
reports, ET tolerance did not affect TNF-α and IL-6 release during IgE/Ag
cross-linking, possibly by the involvement of Ca++-dependent NFAT activa-
tion. The whole process was demonstrated to be mediated by the IκB-family
member BCL3, as BCL3-/- MCs failed to induce ET389.
3 A IM OF THE WORK
Mast cells (MCs) are long lived, tissue resident cells belonging to the in-
nate immune arm of immunity. They are localized in tissues prone to be
colonized by bacteria and fungi and, as such, are among the first immune
cell types which can get in contact with commensals and pathogens. Despite
this potential role, interactions between MCs and the commensal microbiota
have been poorly investigated.
The aim of this project is to unravel the mechanisms of reciprocal influ-
ence between mucosal mast cells and the human commensal Candida albicans.
The first part of this work will focus on the physical interactions between
murine mast cells and the fungus. Additionally, since MCs are known to
promote or restrain the activity of other members of the immune system,
the crosstalk with tissue-resident macrophages during fungal clearance will
be evaluated. The second part of this project will try to depict mast cells’ role
in the wider picture of the mutual interplay with the intestinal microbiota.
Known that tissue-specific stimuli are fundamental for the terminal differen-
tiation of mast cell progenitors, we aimed to determine the long term effect
of microbial ligands on MCs development and response to C. albicans.
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Part II
EXPER IMENTAL STUD IES AND RESULTS

4 RESULTS
4.1 mast cell - candida interactions.
4.1.1 MC - Candida immunological synapse.
To dissect the interaction between MCs and C. albicans, BMMCs were co-
cultured with live C. albicans both in the yeast and hyphal forms. Dectin-1-/-
BMMCs were obtained from in vitro differentiation of dectin-1-/- mice bone
marrow precursors. As expected, the absence of the receptor did not im-
pair BMMCs development since cellular yield as well as c-Kit and FceRIa
expression were comparable between WT and dectin-1-/- cells (Fig. 4.1.1 A).
On the contrary, dectin-1 surface expression was lower in dectin-1-/- BMMCs
compared to WT (C57BL/6) controls (Fig. 4.1.1 B).
Intriguingly, after a few hours of co-culture, MCs were found to tightly
interact with the hyphal form of the fungus in a way that resembled phago-
cytosis. Time-lapse bright field microscopy experiments showed that MCs
interacted with C.albicans as soon as it changed its morphology from yeasts
to hyphae but not with yeasts alone, suggesting that this phenomenon specif-
ically relies on the progression of Candida germination (Fig. 4.1.2 A).
Dectin-1 signaling is known to be activated only when the receptor binds
to particulate β-glucans. This interaction induce the receptor to cluster in
synapse-like structures (called “phagocytic synapses”) to which signaling
molecules are recruited390. Albeit C. albicans hyphae β-glucans are shielded
by a layer of mannoproteins and thus fail to activate dectin-1, it has also been
hypothesized that this receptor may be responsible for the recognition of
hyphal β-glucans probably due to the presence of thinner mannan fibrils264.
Interaction with C. albicans by dectin-1-/- BMMCs was comparable with
WT BMMCs. Immunofluorescence staining showed that phagocytosis of C.
albicans hyphae induced the rearrangement of the α-tubulin cytoskeleton in
Figure 4.1.1: Dectin-1-/- BMMC differentiation. Dectin-1-/- BMMCs were ob-tained from in vitro differentiation of bone marrow progenitors of dectin-1-/- mice.BMMCs were checked for cKit and FceRIa expression (A) and for dectin-1 ex-pression (B). Representative results of two independent experiments.
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Figure 4.1.2: Mast cells can tightly interact with C. albicans hyphae. A: Time-lapse microscopy show MC (stained in red) intimately interacting with C. albicanshyphae after 90 minutes of co-culture, resembling the phenotype of “frustratedphagocytosis”. On the contrary, phagocytosis of yeasts was not observed. B,C: Immunofluorescence images show that mast cells rearrange their α-tubulincytoskeleton during the interaction and accumulate LAMP1+ vesicles at theinterface with the fungus. Dectin-1-/- BMMCs display an identical ability tointeract with C. albicans hyphae. Scale bars: 10µm.
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both WT and dectin-1-/- BMMCs (Fig. 4.1.2 B). 3D-modeling of α-tubulin
stained BMMCs, indicate that BMMCs are able to “wrap” around the fungal
hypha (Fig. 4.1.2 B), resembling the phenotype of the so-called frustrated
phagocytosis391,392.
In order to define whether this behaviour could be ascribed as phago-
cytosis or not, BMMCs were stained for two markers of early- and late-
endosomes. During phagosome maturation, phagosomes acquire different
surface molecules (e.g. Rab GTPases) which play key roles in the process of
maturation. The early-endosome antigen 1 (EEA1) is involved in the initial
stages of the maturation process by binding to PIP3 and mediating endo-
somes fusion. On the other side, the late phase marker lysosomal-associated
membrane protein 1 (LAMP1) is acquired at the late stages of maturation,
after the endosomes has fused with acidic lysosomes393. None of the cells
stained for EEA1 (not shown) while most of them stained positively for
LAMP1. Interestingly, both WT and dectin-1-/- BMMCs stained positively for
LAMP1, suggesting that this receptor is not required for the accumulation
of LAMP1+ vesicles.
4.1.2 MCs degranulation in response to fungal challenge.
Seen that LAMP1 is also considered a marker of degranulation, MCs de-
granulation in response to C. albicans was evaluated. Fungal challenge was
performed in the presence of 10% serum in order to allow C. albicans switch
to the hyphal form, and the release of β-hexoseaminidase and leukotrienes
C4, D4 and E4 was determined after 30 minutes, 1 hour and 2 hours. The
release of β-hexoseaminidase was minimally increased over the control only
after 2 hours of stimulation (7.2% ± 4.4% C. albicans vs. 4.9% ± 1.9% con-
trol, p=0.5262), while leukotrienes levels remained constant at all the time
points (Fig. 4.1.3 A). IgE/Ag stimulation was used as positive control of
MCs degranulation.
Taken together, these data indicate that, in our setup, BMMCs do not de-
granulate upon the encounter of C. albicans. Alternatively, it is possible that
the exocytosed cargo rapidly interacted with the fungus due to the tight
interaction between the mast cell and C. albicans, thus making it barely de-
tectable in culture supernatants.
4.1.3 Cytokine release in response to fungal challenge.
MCs can release a broad range of de novo synthesized mediators which
play an important role in the modulation of the immune response to path-
ogens190. To understand the role of MC-derived mediators during fungal
infections, mast cells were co-cultured with live C. albicans yeast and hyphae
and culture supernatants assessed for different cytokines. After 3 hours
of co-culture it was already possible to detect IL-6 and TNF-α (Fig. 4.1.3
B), while after 24 hours also IL-4 and IL-13 were detected in culture super-
natants (Fig. 4.1.3 C). Interestingly, C. albicans yeasts were more effective
than hyphae in inducing MCs release of TNF-α, IL-6, IL-4 and IL-13. These
data were also confirmed by gene expression analyses that revealed a strong
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Figure 4.1.3: MCs degranulation and cytokine release in response to C. al-bicans. A: BMMCs degranulation in response to C. albicans was evaluated bythe release of β-hexoseaminidase and the synthesis of leukotrienes. No degran-ulation was observed after 30 minutes, 1 or 2 hours. Continues on next page. . .
4.1 mast cell - candida interactions. 59
upregulation of tnf-α, il6, il13 and il4. Again, stimulation with C. albicans
yeasts rather than hyphae induced higher levels of cytokines expression (Fig.
4.1.3 D).
To assess whether dectin-1 plays a role in MCs activation by C. albicans,
dectin-1-/- BMMCs were co-cultured with the fungus and cytokine levels were
assessed after 24 hours. Preliminary results showed an impaired release
of TNF-α, IL-6 and IL-13 by Dectin-1-/- BMMCs compared to WT controls,
both during the stimulation with yeasts and hyphae (Fig. 4.1.3 E). Notably,
cytokine release was only impaired and not completely abolished, in line
with the hypothesis that dectin-1 is not the only receptor involved in C.
albicans recognition.
4.1.4 MCs activation status affects macrophage behaviour.
Clearance of fungal pathogens rely mostly on the activity of phagocytic
cells and especially on neutrophils and macrophages. Fungal clearance by
macrophages is a fundamental step in the resolution of infections, and deple-
tion of mononuclear phagocytes has been described to worsen fungal prolif-
eration and overall survival283. Mast cells interact with many members of
the innate and adaptive immune system (cfr. Section 2.1.3) and can affect
monocyte/macrophage behaviour during infections86,179. Thus, we aimed
to determine how mast cells could induce macrophage migration and affect
their ability to phagocyte C. albicans.
Macrophage crawling is increased in the presence of activated MCs.
Monocyte/macrophage migration to the site of infection is a key step for
an efficient clearance of pathogens. Since MC are known to release chemo-
tactic factors, the ability of mast cells to induce macrophage chemotaxis was
determined with the ibidi R© µ-Slide Chemotaxis. This special microscope
slide allows to observe the migration of adherent cells over a gradient of
the putative chemoattractant. For each experiment, peritoneal macrophages
were purified from C57BL/6 mice peritoneal lavages and checked for F4/80,
CD11b and MHC-II expression by flow cytometry and immunofluorescence
(Fig. 4.1.4). To determine the release of chemotactic factors during C. albi-
cans infections, conditioned media (CM) of BMMCs- C. albicans co-cultures
were collected after 3 hours and used to assess macrophage migration. Con-
ditioned media from C. albicans alone and complete RPMI media were used
as controls.
Figure 4.1.3 (previous page): B, C, D: Stimulation of BMMCs with C. albicansinduced a quick release of TNF-α and IL6 (already detectable after 3 hours) andof IL-13 and IL-4. Interestingly, C. albicans yeasts induced a more prominentcytokine release compared to hyphae. These data were also confirmed by qPCRanalyses. E: Challenge of Dectin-1-/- MCs with C. albicans resulted in animpaired release of TNF-α, IL-6 and IL-13 compared to WT controls. Mean(SD) of two independent experiments.
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Figure 4.1.4: Peritoneal macrophages purification. Peritoneal Mϕ were ob-tained from the peritoneal lavage of C57BL/6 mice and checked for purity. A:Z-stack averaging of confocal images. Scale bars: 10µm. B: Flow cytometrygating strategy to confirm Mϕ purification.
Figure 4.1.5 A shows all the single cells trajectories during 24 hours incu-
bation. Notably, conditioned media from BMMCs + C. albicans co-cultures
induced a more evident movement of macrophages. Forward migration in-
dexes (FMI, represent the efficiency of the migration of cells) were calculated
and showed no significant differences (FMI‖=0.0147 ± 0.0126 and FMI⊥=-
0.0008 ± 0.0228)394. Rayleigh test reported a p-value of 0.5327, thus indicat-
ing that cell endpoints are uniformly distributed. On the other side, macro-
phages incubated with BMMC + C. albicans culture supernatants moved with
higher velocity which resulted in greater accumulated distance compared to
controls (Fig. 4.1.5 B). Taken together, these data indicates that BMMCs do
not release chemotactic factors for macrophages during C. albicans infections
but release soluble factors that increase macrophage crawling. Albeit being
unable to attract tissue resident macrophages, BMMCs might improve mac-
rophage crawling, resulting in a better chance to encounter pathogens even
at distant sites from the infection.
Resting MCs partially inhibit macrophage phagocytosis ability.
Mast cells are known to modulate macrophages’ phagocytosis ability86,180.
To establish whether MC phagocytosis of C. albicans could be responsible
for a better fungal clearance by providing “eat-me” signals to tissue-resident
macrophages, peritoneal Mϕ were co-cultured with BMMCs and C. albicans,
and their phagocytosis ability was determined.
BMMCs were stimulated with CPD-stained C. albicans for 3 hours, in
order to allow phagocytosis of Candida hyphae (from now on, these cells
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Figure 4.1.5: Mast cell activation influence peritoneal macrophage behaviour.A: Single cell tracks during 24 hours chemotaxis experiment. Green tracks indi-cate cells moving towards the conditioned media, red tracks indicate cells movingaway from the chemoattractant. Continues on next page. . .
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will be referred as “activated MCs”), scraped and seeded to peritoneal Mϕ.
Naïve BMMCs + CPD-stained C. albicans (referred as “resting MCs”) or CPD-
stained C. albicans alone were seeded to peritoneal Mϕ as control. After 1
hour of co-culture, the percentage of phagocytosis was determined by flow
cytometry (Fig. 4.1.5 C).
Albeit activated MCs had no effect on the phagocytosis of C. albicans by
Mϕ, resting MCs were able to inhibit Mϕ phagocytosis (Fig. 4.1.5 D).
Impaired phagocytosis of Candida by macrophages is not dependent on MCssoluble mediators.
MC-dependent inhibition of phagocytosis has already been described dur-
ing bacterial infections and appear to be mediated by a quick release of IL-4
from MCs upon bacterial encounter86. To determine whether naïve BMMCs
inhibition of Mϕ phagocytosis was dependent on quickly released IL-4, mac-
rophages were stimulated in the presence of exogenous IL-4 or anti-IL-4
blocking antibody.
Addition of recombinant IL-4 to activated MCs or the neutralization of
IL-4 activity on resting MCs did not affect Mϕ phagocytosis of C. albicans,
suggesting that IL-4 is not involved in the modulation of phagocytosis (Fig.
4.1.5 D). Seen that C. albicans-stimulated MCs release TNF-α already after 3
hours (cfr. Fig. 4.1.3 B), it was hypothesized that TNF-α may be responsible
for the reversion of the phenotype by activated MCs. However, addition of
recombinant TNF-α to resting MCs or neutralizing TNF-α activity in acti-
vated MCs did not revert the phenotype (Fig. 4.1.5 D).
To undoubtedly exclude a role of MC-derived soluble mediators in the
modulation of Mϕ phagocytosis, conditioned media were collected after
3 hours of BMMCs and C. albicans co-culture or from Candida alone, and
added to Mϕ together with resting MCs and C. albicans. Again, phagocy-
tosis inhibition was not reverted, suggesting that this mechanism is soluble
mediators-independent but rather contact-dependent (Fig. 4.1.5 E). This hy-
pothesis is further sustained by the fact that in vitro Mϕ and BMMCs inter-
act during Candida phagocytosis (Fig. 4.1.5 F). Intriguingly, activated MCs
lose the inhibitory activity, indicating that fungal-dependent BMMCs activa-
Figure 4.1.5 (previous page): B: Albeit failing to attract Mϕ, culture super-natants from BMMCs + C. albicans co-culture increase Mϕ crawling ability.C: Gating strategy used for the evaluation of Mϕ phagocytosis. D: C. albicansphagocytosis by Mϕ is impaired by the presence of naïve MCs. Addition ofexogenous IL-4 or TNF-α, nor their neutralization with monoclonal antibodiesrestored of inhibited Mϕ activity. Phagocytosis was assessed by flow cytometryafter 1 hour of co-culture and the phagocytosis index expressed as the fold-change over the phagocytosis percentage of Mϕ stimulated with C. albicansalone. E: Similarly, the presence of conditioned media (CM) did not affect mac-rophage phagocytosis ability. F: Immunofluorescence analyses of Mϕ-BMMC-C. albicans co-cultures indicate that MCs and Mϕ interact during the processof phagocytosis. Scale bar: 10µm.
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tion can somehow down-regulate the expression of putative co-stimulatory
molecules.
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4.2 mast cells training by microbial pamps.
Mast cells are particularly abundant at sites where it is likely their en-
counter with microbial ligands (e.g the gut mucosa) and their terminal dif-
ferentiation is highly influenced by tissue-specific stimuli. For these reasons
we decided to investigate the role of microbial ligands in the modulation
of MCs differentiation and response to inflammatory stimuli50. Different
microbial ligands such as β-glucan, and the PGN components Tri-DAP and
MDP are able to induce trained immunity in monocytes in vitro as well as
in vivo, while LPS and Pam3CSK4 promote tolerance326,343,347. Stimulation
with LPS is known to induce a transient unresponsiveness in MCs while IgE
sensitization was described to increase their responsiveness to LPS. Anyway,
these phenomena have been only described in short-term experiments, with
the cells being restimulated immediately after the washout of the first stim-
ulus384,388,389. To assess whether long-lasting trained immunity or tolerance
could be induced also in MCs, BMMCs were differentiated for 6 weeks in IL-
3 media and then primed by stimulation for 24 hours with LPS, curdlan (a
dectin-1 agonist consisting of β-(1,3)-linked glucose residues), IgE/Ag or left
untreated (RPMI). After the stimulation, cells were washed and put back in
culture in fresh IL-3 media for 6 days in order to allow their recovery. Each
cell subset was then re-stimulated with a 10-fold lower dose of LPS, live C.
albicans yeasts or IgE/Ag for 24 hours (Fig. 4.2.1).
Figure 4.2.1: Schematic representation of the experimental protocol. After 6weeks of in vitro differentiation, BMMCs were stimulated with either LPS (1
µg·ml-1), curdlan (10 µg·ml-1), IgE/Ag (100 ng·ml-1 Ag) or left untreated (RPMI)for 24 hours. Cells were then washed and put back in culture in RPMI completemedium with IL3. At the end of the “resting period”, each BMMCs populationwas subsequently stimulated with low-dose LPS (100 ng·ml-1), C. albicans orIgE/Ag.
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4.2.1 MCs priming affect their response to secondary inflammatory stimuli.
In agreement with previously published data, LPS and IgE/Ag stimula-
tion induced the release of both TNF-α and IL-6 while curdlan induced only
a faint release of TNF-α (Fig. 4.2.2 A)134,302,395. During the 6 days of rest-
ing time, all the cells kept proliferating at a low rate, with a slightly more
marked effect in the cells trained with LPS. Cell vitality (determined by try-
pan blue exclusion) was comparable for all the stimulations (Fig. 4.2.2 B).
As expected, priming with LPS impaired MCs response to a secondary
challenge with LPS as demonstrated by the lower release of TNF-α and IL-
6 which was already evident (although not statistically signficant) 3 hours
after the restimulation. On the other side, priming with curdlan or IgE/Ag
did not affect MCs’ responsiveness to secondary LPS challenge (Fig. 4.2.2
C).
In order to determine if LPS priming could induce cross-tolerance also
against non-TLR4 stimulations, BMMCs were restimulated either with live C.
albicans yeasts or IgE/Ag. Strikingly, priming with LPS induced a stronger
response to Candida compared to RPMI control, enhancing the release of
TNF-α but not of IL-6. As for LPS, the response against C. albicans challenge
by MCs primed with curdlan or IgE/Ag was comparable with the control
(Fig. 4.2.2 D). By contrast, the response to a restimulation with the classi-
cal anaphylactoid stimulation IgE/Ag was comparable between all the four
groups, in terms of release of both TNF-α and IL-6 (Fig. 4.2.2 E). Moreover,
LPS priming did not affect BMMCs degranulation in response to IgE/Ag
nor in response to the Ca++ ionophore ionomycin (Fig. 4.2.2 F).
Collectively, this data suggests that LPS priming induces long-term mem-
ory also in MCs. The fact that LPS priming was responsible for the develop-
ment of both tolerance and training in the context of TNF-α release, suggests
that the regulation of this cytokine may not rely exclusively on epigenetic
mechanisms (as described for Mϕ), but rather on a multi-layered process of
regulation dependent on the secondary stimulus.
4.2.2 MCs training by microbial products does not affect MCs phenotype.
Histochemical comparison.
Tissue-specific stimuli are fundamental during the terminal differentiation
of MCs precursors, driving the expression of surface markers and granule
content of the differentiated cells29. In vitro, certain stimuli (as SCF, IL-9, IL-
10 and IL-33) as well as pathogen challenge can induce MCs reprogramming
in term of protease expression and granule content68–70. In order to define
whether MCs priming was responsible for a strong phenotypic change in
MCs, primed BMMCs were stained with two classical staining techniques:
toluidine blue and alcian blue–safranin.
BMMCs granule content and metachromasia were comparable between
the four conditions. Interestingly, BMMCs that degranulated after the first
challenge with IgE/Ag, recovered most of their granules and stained meta-
chromatically with toluidine blue (Fig. 4.2.3 A). Similarly, all the primed
cells maintained a similar phenotype after the alcian blue–safranin staining:
66 results
Figure 4.2.2: BMMCs priming modulate the response to secondary challenges.A: BMMCs were stimulated for 24h with LPS, curdlan, IgE/Ag or left untreated.Supernatants were collected and screened for TNF-α and IL-6 release. B: After6 days of resting, primed-MCs growth and death was evaluated by means ofTrypan blue exclusion. Continues on next page. . .
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BMMCs were all alcian blue positive and showed only little staining for
safranin (with LPS-primed BMMCs being slightly less positive), suggesting
that their granules contained low levels of histamine (Fig. 4.2.3 B). These
data suggest that BMMCs conserved their mucosal-like phenotype, show-
ing toluidine blue metachromatic granules, and little or no safranin positive
granules.
Surface markers expression.
It has been reported that one mechanism involved in innate immune mem-
ory is the regulation of receptors levels on the cellular surface. For exam-
ple, ET macrophages showed ad upregulation of receptors such are CD64,
MARCO and CLEC4A and a marked downregulation of MHC molecules345.
Moreover, it was recently described that macrophages trained with the non-
pathogenic yeast Saccharomyces cerevisiae upregulated dectin-1 levels396. In
a similar report, Garcia-Valtanen et al. demonstrated that β-glucan trained
splenic monocytes differentiated into macrophages but expressed lower lev-
els of F4/80, CD11b and CD11c compared to LPS-trained Mϕ and na’´ive
Mϕ397. Since LPS-primed BMMCs showed both an impaired response to
LPS and an enhanced response during C. albicans challenge, it was supposed
that this phenomenon could be due to a differential expression of the recep-
tors involved in the recognition of LPS and Candida.
Surface expression levels of dectin-1, TLR2, TLR4 and CD14 were eval-
uated by flow cytometry after 6 days from the first stimulation. No dif-
ferences in dectin-1, TLR2 and TLR4 protein expression were detected but
LPS-primed BMMCs presented higher levels of surface CD14 although the
difference was not statistically significant (Fig. 4.2.3 C). This is particularly
interesting since many studies reported that MCs express mRNA transcripts
for CD14 but no one succeeded in demonstrating the presence of a functional
protein on MCs’ surface133,138–141. In agreement, resting “naïve” BMMCs
stained negatively for CD14 (FMI over isotype '1). Intriguingly, CD14 up-
regulation did not enhance MCs responsiveness to LPS stimulation. This
lack of effect could be explained by two mechanism that are not mutually
exclusive. First, the slight expression of CD14 and the -presumed- activation
of its signaling pathway could be too limited to compensate the process of
tolerance activated by the cells. On the other side, endogenous CD14 acti-
vation could be masked by the effect of soluble CD14 (sCD14) commonly
present in the serum135,398–400.
Primed BMMCs were also checked for classical MCs markers. The size of
the cells and their granularity were comparable, as indicated by the almost
identical levels of forward scatter (FSC) and side scatter (SSC). FceRIa levels
were slightly decreases in LPS-primed BMMCs, while cKit levels remained
Figure 4.2.2 (previous page): C-E: Primed-MCs were restimulated with 100ng·ml-1 LPS (C), live C. albicans yeasts (MOI=1, D) or IgE/Ag ( E ). TNF-αand IL-6 levels were detected in culture supernatants after 3 or 24 hours. F:Degranulation of LPS-primed BMMCs and RPMI control cells was determinedby means of β-hexoseaminidase release after IgE/Ag or ionomycin stimulation.
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Figure 4.2.3: MCs phenotype after the conditioning period. After the restingperiod, before the second stimulation, BMMCs phenotype was determined by his-tochemical staining and flow cytometry. A. Toluidine blue staining of cytospinpreparations. Granules were still present in all conditions and stained meta-chromatically. Scale bar: 10µm B. Alcian blue–safranin staining of cytospinpreparations. All the cells stained positively for alcian blue but only weaklyfor safranin red, highlighting a “mucosal-like” phenotype. Scale bar: 10µm C.The level of expression of MCs’ surface markers was analysed by flow cytometry.No differences in the expression levels of dectin-1, TLR2, TLR4 nor cKit weredetected. On the contrary, LPS-primed BMMCs expressed slightly higher levelsof CD14 and lower levels of FceRIa.
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constant after the resting time (Fig. 4.2.3 D). This indicates that BMMCs did
not lost their cellular identity after the priming. Albeit the reduced expres-
sion of FceRIa was not sufficient to significantly reduce LPS-primed MCs
degranulation and release of pro-inflammatory cytokines upon anaphylactic
stimulation (cfr. Fig. 4.2.2 E and F), it is tempting to speculate that prolonged
exposure of MCs to bacterial ligands such as LPS could be fundamental for
the induction of a tolerant MCs phenotype in response to IgE/Ag stimu-
lation and thus may avoid the occurrence of allergies. This phenomenon
is corroborated by several studies demonstrating that bacterial species have
immunoinhibitory properties on MCs, and together would nicely fit in the
greater picture of the hygiene hypothesis209,401–404.
4.2.3 LPS conditioning impairs the PI3K-AKT pathway.
The innate reprogramming by LPS is believed to be mediated by several
factors as the rewiring of the signaling networks and the manipulation of
the epigenetic landscape. Considered the dualistic expression of TNF-α in
LPS-primed BMMCs upon the restimulation with LPS or Candida, we hy-
pothesized that the first LPS stimulation could induce a remodulation of
the signaling networks involved in the response to the two ligands. One
proposed mechanism of ET is based in the modulation of the PI3K-AKT sig-
naling pathway. It has been reported that this pathway played an important
role in the limitation of TNF-α, IL-6 and IL-12 production. Chaurasia et al.
demonstrated that primary macrophages isolated from mice lacking PDK1
displayed a higher release of TNF-α, IL-6 and CCL2 compared to WT mice.
This phenomenon was correlated with the lack of AKT phosphorylation and
with a sustained IKK/NF-κB activation due to enhanced TRAF6 ubiquitina-
tion406. Similarly, PI3K-/- DCs and WT DCs treated with the PI3K inhibitor
wortmannin showed an increased production of IL-12 in response to LPS,
due to the enhanced activation of p38 MAPK407. Moreover, AKT activation
in macrophages was found to inhibit the activity of the transcription factor
forkhead box O1 (FoxO1), which in turn triggered the expression of genes
involved in the TLR4 signalling pathway408.
On the contrary, PI3K is known to be activated after TLR4 engagement
by directly binding to a non-canonical YXXM PI3K-binding site on the C-
terminus of MyD88 and to cooperate with the p38 MAPK to properly acti-
vate the TLR4 signaling cascade127,409. In mast cells, activation of the PI3K
pathway induced the upregulation of TNF-α and IL-6 during TLR-mediated
stimulation410. Moreover, this pathway is of great importance for MCs de-
velopment and for the activation of the complimentary FYN-GAB2-PI3K sig-
naling cascade during IgE/Ag activation105,411.
Seen that PI3K seems to play a dual role depending on the cellular context,
the modulation of PI3K, AKT and p38 MAPK pathways in primed BMMCs
was evaluated. Strikingly, LPS-primed MCs showed a decreased level of to-
tal PI3K p85 and lower levels of PI3K p85 and p55 phosphorylation. This
phenomenon correlated with the expression of a putative isoform (or trun-
cated version) of PI3K with an approximative molecular weight of '65 kDa
(Fig. 4.2.4 A). This putative isoform (from now on referred as PI3K p65) was
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Figure 4.2.4: LPS-primed MCs differentially activate the PI3K-AKT pathway.A: WB analyses of primed-MCs restimulated with 100ng·ml-1 (LPS l.d.) orC. albicans. A '65 kDa PI3K isoform is expressed by LPS-primed MCs. B:Known PI3K splicing variants. The stars indicates the sites antibodies bindingsites (black: endogenous p85; red: phospho Tyr458 and Tyr199). SH: SRC-homology domain; BH: BCR-homology domain; P: proline-rich region; p85-BD:p85 binding domain. Adapted from Thorpe et al. 405 . Continues on next page. . .
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recognized both by the anti-p85 full length antibody (which is specific for
the region surrounding aa 80 of human PI3K p85) and to a lesser extent by
the anti-phospho PI3K antibody which recognize the phosphorylated Tyr458
of p85 and Tyr199 of p55 (Fig. 4.2.4 A). Seen that the protein is recognized
by both the antibodies, it is possible that PI3K p65 conserved both the SH3
and iSH2 domains, the latter being responsible for binding to the catalytic
subunit p110 (Fig. 4.2.4 B).
LPS-primed MCs displayed also a reduced phosphorylation of p38 MAPK
after 30 minutes of low-dose LPS restimulation (Fig. 4.2.4 A). Conversely,
the same cells showed no impairment of p38 phosphorylation after 30 min-
utes of C. albicans challenge. All the cell expressed comparable levels of the
catalytic subunit PI3K p110δ (Fig. 4.2.4 A).
This phenomenon prompted us to compare AKT activation level during
LPS- and C. albicans-induced activation of primed MCs. Control BMMCs
(RPMI) showed a strong activation of AKT already after 60 minutes of stim-
ulation with low-dose LPS, while it was completely abolished in LPS-primed
MCs. AKT activation in control cells correlated with an earlier and more sus-
tained activation of p38 MAPK (Fig. 4.2.4 C). On the other side, C. albicans
failed to induce the activation of AKT in both the cell populations but LPS-
primed MCs displayed an enhanced activation of p38 MAPK. Taken together,
these data suggest that PI3K may be involved in AKT activation in response
to TLR4 stimulation. However, LPS conditioning of MCs caused an impaired
activation of the PI3K-AKT pathway finally leading to a weaker phosphory-
lation of p38 MAPK. This phenomenon could be possibly mediated by a
novel PI3K isoform p65 which is expressed exclusively in LPS-primed MCs.
To further characterize the nature of the ambivalent behaviour of LPS-
primed MCs, we looked at the activation status of the NF-κB transcription
factor p65. Although NF-κB role in TNF-α transcription is quite controver-
sial, it is believed that this transcription factor is involved in the regulation
of TNF-α412. The NF-κB p65-p50 complex is normally restrained in the cy-
toplasm by the interaction with its inhibitor IκB. Upon stimulation, the IKK
kinases promote IκB ubiquitination and proteasomal degradation thus al-
lowing NF-κB to freely translocate into the nucleus413. Preliminary results
showed that already after 30 minutes there was a differential nuclear accu-
mulation of NF-κB p65 in LPS-primed MCs compared to controls. More in
detail, during LPS restimulation NF-κB p65 nuclear translocation was im-
paired in LPS-primed MCs while during C. albicans challenge LPS-primed
cells displayed a more prominent nuclear accumulation of NF-κB p65 (Fig.
4.2.4 D).
Figure 4.2.4 (previous page): C: Time-course WB analyses of primed-MCs res-timulated with 100ng·ml-1 (LPS l.d.) or C. albicans. Numbers indicates theresults of densitometric analyses calculated over endogenous protein expression.D: NF-κB p65 activity in primed-MCs was determined after 30 minutes fromrestimulation. Results are expressed as fold percentage over control (RPMI)translocation. Mean (SD) of two independent experiments.
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Taken together these data suggest that LPS conditioning is able to induce
a profound remodeling of the signaling pathways involved in the response
against TLR4 ligands and invading pathogens. The state of unresponsive-
ness to LPS triggering was mediated by the abrogation of the AKT pathway
activation which resulted in a impaired p38 MAPK activation and down-
stream NF-κB translocation. This phenomenon was possibly mediated by
the presence of a novel PI3K p65 isoform which may be unable to promptly
activate AKT signaling in response to TLR4 triggering. On the other side,
response to C. albicans was independent of the activation of the PI3K-AKT
axis in naïve MCs. Notably, LPS priming allowed a slight activation of the
AKT pathway, which resulted in a more prominent p38 MAPK activation
and NF-κB nuclear translocation.
4.2.4 LPS conditioning modulates TNF-α transcription.
The modulation of the PI3K-AKT and p38 MAPK pathways induced by
LPS priming, resulted in the differential nuclear translocation of NF-κB p65
Figure 4.2.5: TNF-α expression is skewed after LPS priming. Tnf-α (A.) andIl-6 (B.) expression were measured by qPCR on LPS-primed and control MCsafter 3 hours of stimulation with low-dose LPS or C. albicans. Priming withLPS induced a higher basal transcription of Tnf-α, which was '3.3 times higherthan control cells. The same ratio of Tnf-α expression was also induced afterstimulation with Candida. On the contrary, Tnf-α and Il-6 expression weremarkedly reduced in LPS-primed MCs receiving a second dose of LPS. Dataexpressed as mean (SD), n≥3 except for LPS l.d. (n=2). Statistical analyseswere performed with a ratio t-test.
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during LPS and Candida restimulation. Anyway, NF-κB p65 is not the unique
transcription factor involved the control of TNF-α transcription and several
processes can be involved in the regulation of cytokine secretion, indepen-
dently from their transcription412. This is of particular importance in mast
cell seen that the secretion of their granule content is a tightly-regulated
process91–93.
To assess whether NF-κB levels correlated with TNF-α and IL-6 transcrip-
tion, qPCR analyses were performed 3 hours post-restimulation. Concor-
dantly with the protein release detected after 3 and 24 hours, stimulation
with low-dose LPS resulted in a impaired expression of the transcripts for
both TNF-α and IL-6 in LPS-primed MCs (Fig. 4.2.5). Moreover, stimulation
of LPS-primed MCs with C. albicans yeast caused an increased expression of
TNF-α but not of IL-6, again in line with the protein release. Interestingly,
unstimulated LPS-primed MCs showed an increased basal transcription of
TNF-α, '3.3 times higher than controls. Stimulation with C. albicans induced
a '300-fold increase in TNF-α transcription levels in both LPS-primed MCs
and controls, which were found to be '2.7 times higher in LPS-primed cells
(Fig 4.2.5 A). Taken together, this results suggest that LPS-priming induce a
higher basal transcription for TNF-α but not IL-6 and that C. albicans chal-
lenge likely has the same effect on both LPS-primed and control cells. The
heightened release of TNF-α by LPS-primed MCs could be relying only on
the enhanced basal transcription which in turn may be due to an improved
chromatin accessibility on TNF-α regulation regions or due to the presence
of active enhancers/co-activators. On the other side, LPS-primed cells may
be able to override this enhanced TNF-α transcription by modulating up-
stream signaling networks involved in the response to LPS.

5 D ISCUSS ION
Every multicellular organism contain a rich and diverse microbiotaand their interactions profoundly affect the fitness of both the host and
the microbial community. The coexistence of these two entities is based
on a fragile equilibrium between commensalism and pathogenesis which
is maintained by proper mechanisms of activation and suppression of the
immune system. Importantly, the disruption of this stable host-microbiota
equilibrium can lead to pathological consequences414,415. A striking example
is provided by numerous studies which reported a clear reduction in gut
microbiota diversity on patients with autoimmune diseases416.
Candida albicans is the most common member of the human and murine
mycobiota and is found as a commensal especially in the colon and the
vagina. When the equilibrium between the host and the fungus is perturbed
(e.g. during broad-spectrum antibiotics treatment, or in conditions of patho-
logical or pharmacologically-induced immunosuppression) C. albicans can
overgrow and cause severe diseases as recurrent vulvovaginal candidiasis
and invasive candidaemia252,257.
The main effector cells involved in the control of fungal infections are neu-
trophils and macrophages but in recent years several studies reported that
also mast cells might be involved in the outcome of pathological Candida
overgrowth167,268,299,300. This should not be surprising as a growing body
of evidence highlighted the concept that MCs are not mere effector of aller-
gies and anaphylaxis but are rather involved in the maintenance of tissue
homeostasis as well as in many pathological circumstances50,190.
The present study provide novel proofs of the role of mast cells as tissue-
resident sentinels involved in the recognition of fungal infections and in a
wider cross-talk with the commensal microbiota.
Mast cells role in the control of C. albicans infections.
Previous studies demonstrated that MCs respond to fungal infections with
C. albicans but often reported contradictory data. In order to provide addi-
tional elements of the interaction between MCs and Candida albicans we set
up an in vitro co-culture system using murine WT and dectin-1-/- BMMCs.
Time-lapse microscopy experiments showed that MCs tightly interacted with
the fungus only after the switch to the hyphal form, in a way that resembled
frustrated phagocytosis391,392. The formation of this phagocytic synapse was
further characterized by immunofluorescence analyses which revealed that
MCs were able to re-organize their α-tubulin cytoskeleton and to accumulate
LAMP1+ vesicles at the interface with the hyphae. Interestingly, no differ-
ences were observed between WT and dectin-1-/- BMMCs suggesting that
other receptor than dectin-1 might be involved in the recognition of C. albi-
cans. This finding is in line with the current belief that C. albicans is able to
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efficiently shield the β-glucan layer after the germination to the hyphal form,
thus preventing its recognition by dectin-1262.
LAMP1 is also considered a marker of degranulation in MCs but incuba-
tion of BMMCs with C. albicans even in the presence of serum (to allow the
germination of hyphae) did not result in the release of β-hexoseaminidase
nor leukotrienes. A possible explanation is that granules’ cargo was released
directly on the fungal surface due to their close interaction and thus prevent-
ing their detection in the supernatants. It has been demonstrated that MC-
derived β-hexoseaminidase was able to disrupt Staphylococcus epidermidis
cell wall, rendering mice more resistant to bacterial infections417. More-
over, a similar polarized degranulation was recently described and named
“antibody-dependent degranulatory synapse”. Opsonized Toxoplasma gondii
tachyzoites induced FcγR-triggering on mast cells and the localized release
of granule contents at the interface with the pathogen418.
On the contrary, we observed the release of TNF-α, IL-6, IL-13 and IL-
4 during the co-cultures, especially during the stimulation with the yeasts.
This observation might reflect the fact that MCs recognize the morphological
switch from yeasts to hyphae, possibly by discriminating the composition of
the outer layer of the fungal cell wall or through the recognition of cell wall
debris released during the germination.
It was demonstrated that the release of IL-4 during C. albicans infections in
vivo was fundamental for the induction of a protective TH1 response during
reinfection. As such, IL-4-/- mice were more resistant then WT littermates
during the first infection with C. albicans (probably due to the absence of a
TH2 skewing) but failed to survive a secondary infection296. The authors did
not identify the source of IL-4 in this context but our data supports the idea
that MCs may account for most of the release of this cytokine.
Several reports demonstrated that MCs are able to phagocytose bacteria
and fungi, and that in particular conditions they can also present antigens to
autologous T cells185,196–200,299,300. Anyway, their ability to kill phagocytosed
pathogens is much more limited than “professional” phagocytes so we hy-
pothesized that engulfment of C. albicans could be an early line of defense
addressed to recruit tissue-resident macrophages and promote the clearance
of the pathogen. Time lapse chemotaxis experiments revealed that the sol-
uble factors released by MCs during Candida infection failed to induce peri-
toneal Mϕ chemotaxis but instead markedly improved their crawling ability.
This result is in agreement with a previous study by Lopes et al. which re-
ported that C. albicans-infected human MCs were able to recruit neutrophils
but not circulating monocytes301. To assess whether MCs engulfment could
promote macrophage-mediated C. albicans clearance by providing “eat-me”
signals, co-cultures between BMMCs, peritoneal Mϕ and C. albicans were set
up. Interestingly, we found that resting MCs were able to inhibit Mϕ phago-
cytosis of the fungus. A similar phenomenon was described in a model of
severe septic peritonitis, in which a very fast release of IL-4 by MCs upon
bacterial encounter resulted in the inhibition of bacterial clearance by peri-
toneal macrophages86. Anyway, the neutralization of extracellular IL-4, nor
the stimulation with infected MCs conditioned media reversed Mϕ activa-
tion, suggesting that this phenomenon might rely on cell-cell contact. This
should not be surprising since it was demonstrated that MCs modulated T
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and B cells activation through the OX40-OX40L and the CD40-CD40L axes,
respectively186,187,189.
Taken together, this data demonstrate that MCs are able to respond to
fungal infections by tightly interacting with C. albicans hyphae and releas-
ing pro-inflammatory mediators as TNF-α and IL-6. Fungal challenge in-
duced also the release of the TH2 cytokines IL-4 and IL-13. While IL-4 has
been correlated with a protective effect during fungal reinfection, IL-13 is
known to promote intestinal goblet cell hyperplasia and increased mucin
expression during parasitic helminth infections419. Thus, it is possible that
a similar mechanism might be involved in the elimination of C. albicans hy-
phae. Moreover, we demonstrated that MCs-derived soluble mediators can
increase tissue-resident macrophage crawling during the infection. Interest-
ingly, resting MCs were found to limit Mϕ phagocytosis of C. albicans: this
might reflect their ability to restrain effector functions of myeloid cells in
homeostatic conditions, highlighting once more that mast cells are impor-
tant gatekeepers of tissue homeostasis.
Microbial products modulate mast cells response to inflammatory signals.
The fact that mast cells can survive in the tissues for up to 12 weeks and
that their terminal differentiation is highly influenced by tissue-specific stim-
uli, render these cells possibly implicated in innate immune memory29,49.
Several studies on the nature of endotoxin tolerance demonstrated memory-
like traits also in mast cells384,386,389. These studies were based only on short-
term experiments, with the cells being restimulated immediately after the
washout of the first stimulus. Anyway, an important feature of innate im-
mune memory is the long lasting effects induced by the first “priming” stim-
ulation315. To verify whether microbial ligands could induce a long-lasting
immune memory in MCs, and if their priming could affect the response also
against fungal pathogens, we set up an experimental panel which allowed
the cells to “rest” for 6 days between the fist stimulation and the subsequent
restimulation.
As indicated by the impaired release of TNF-α and IL-6, mast cells primed
with LPS became tolerant to a secondary dose of LPS, indicating that endo-
toxin tolerance could be maintained for at least 6 days. Unexpectedly, the
restimulation of LPS-primed cells with C. albicans induced a higher release
of TNF-α but not of IL-6, suggesting that LPS priming could induce both
tolerance and training depending on the secondary stimuli. Moreover, the
response to the classic anaphylactoid IgE/Ag stimulation was not affected by
the priming with LPS, both in terms of TNF-α, IL-6 and β-hexoseaminidase
release.
To exclude that this phenomenon was mediated by the differential expres-
sion of PRRs by “naïve” and primed cells, phenotype and surface markers
expression were compared after the resting period (i.e. just before the res-
timulation). Interestingly, BMMCs phenotype (determined by toluidine blue
and alcian blue–safranin staining) did not change after the priming simula-
tion. Similarly, expression levels of TLR4, TLR2, and dectin-1 were compara-
ble between primed and naïve cells. The unique exception was found in LPS-
primed BMMCs which showed an increased expression of surface CD14 and
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slight decreased level of FceRIa. CD14 expression on MCs is still matter of
debate since many authors reported the presence of a CD14-encoding mRNA
transcript but no one was able to demonstrate the presence of a functional
protein on the cell surface133,138–141. Moreover, LPS-mediated upregulation
of CD14 levels was demonstrated only by two independent studies on the hu-
man monocytic cell line Mono-Mac-6 while many others failed to report any
difference in CD14 expression during ET371,420,421. Notably, increased CD14
levels in LPS-primed MCs did not increase their responsiveness to LPS. This
effect could be explained by: i) a masking effect of the sCD14 present in the
serum; ii) an insufficient activation of the CD14-downstream signaling path-
way; iii) MCs lack of the TRIF-TRAF signaling cascade that is activated (at
least in DCs) after CD14-TLR4 endocytosis123,143,144. On the other side, the
slight downregulation of the FceRIa in LPS-primed cells is in line with pre-
vious reports demonstrating that bacterial ligands as LTA and PGN or the
probiotic Lactobacillus rhamnosus induced FceRIa downregulation on human
MCs402,422. Anyway, this mild downregulation of the receptor did not affect
MCs response to IgE/Ag challenge.
Innate immune memory is supposed to rely on different regulatory net-
works comprising the modulation of intracellular signaling cascades as well
as epigenetic mechanisms of chromatin remodeling. As previously discussed,
the modulation of the PI3K/AKT pathway plays a dual role during the
response to TLR-triggering. On one hand, PI3K is activated in a MyD88-
dependent manner upon TLR4 triggering and, in turn, participates to the
proper phosphorylation of p38 MAPK127,409. On the other hand, PI3K-AKT
activation dampened the expression of pro-inflammatory cytokines in re-
sponse to LPS by inhibiting TRAF6 K63-polyubiquitination and the activity
of FoxO1406,408.
WB analyses revealed that LPS-primed BMMCs expressed lower amounts
of PI3K p85 but presented a putative isoform (or truncated version) of PI3K
with an approximative molecular weight of '65 kDa. Based on the recog-
nition by the antibodies directed against the endogenous and the phospho-
rylated forms, we hypothesize that this putative isoform conserved both the
SH3 and iSH2 domains, the latter being responsible for binding to the cat-
alytic subunit p110. To our knowledge only one PI3K variant with a similar
molecular weight has been described in the literature. This protein was
obtained from a transformed cell line (X-ray–induced murine lymphoma)
and caused the constitutive activation of the PI3K pathway423. Anyway,
this PI3K p65 variant did not exhibit an hyperactive phenotype since LPS-
primed cells failed to activate AKT upon LPS restimulation. On the contrary,
naïve MCs showed a marked AKT phosphorylation which correlated with a
stronger p38 MAPK phosphorylation during LPS restimulation. Moreover,
restimulation with C. albicans failed to promote AKT activation but induced
similar levels of p38 phosphorylation in both the MCs population, with a
slightly more marked effect in LPS-primed cells. These results indicate that
the activation of the PI3K-AKT axis is fundamental for the expression of
LPS-induced TNF-α and IL-6 in MCs. Moreover, the lack of AKT activation,
possibly related to the impaired expression of PI3K, could represent a novel
mechanism of ET tolerance in MCs. These evidences are in agreement with
two reports by Hochdorfer et al. that demonstrated the important role of
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PI3K and p38 in MCs response to LPS. Interestingly, the activation of the
PI3K pathway increased the expression of TNF-α and IL-6 but reduced the
expression of IL-1β upon TLR4 triggering385,410.
Further efforts will be required in order to define the nature of this PI3K
variant, its activity and binding affinity, and its involvement in the induction
of ET. In this regard, PI3K impairment failed to modulate MCs degranu-
lation and cytokine production during IgE/Ag challenge although its well
established role in the complimentary FYN-GAB2-PI3K pathway105.
Although NF-κB role in TNF-α transcription is quite controversial, it is
known that ET tolerance relies also on the impairment of NF-κB p65/p50
dimerization and nuclear translocation377,379,380,412. Preliminary results in-
dicate that already after 30 minutes from the re-stimulation, LPS-primed
BMMCs differentially regulated NF-κB p65 nuclear translocation. The acti-
vation of NF-κB in primed cells was impaired during LPS restimulation but
enhanced upon Candida challenge. Accordingly, Tnf-α mRNA expression in
LPS-primed MCs was reduced upon LPS challenge but increased during C.
albicans infection while Il-6 levels were found to be impaired only during LPS
restimulation. Moreover, Tnf-α basal expression in LPS-primed cells was '3
times higher that in naïve MCs.
Taken together, these data suggest that LPS challenge induce long-term
memory in MCs. Albeit being known that LPS can induce endotoxin toler-
ance or training depending on the dose used for cell priming, here we report
an ambivalent role for LPS in the induction of both tolerance and training
depending on the secondary challenge. This phenomenon is possibly the
result of the combined rewiring of intracellular signaling cascades and of
epigenetic changes in the regulating loci of TNF-α.
On one hand, LPS-priming induced long-term tolerance to endotoxin by
impairing the PI3K-AKT pathway possibly through the modulation of PI3K
p85 expression. The lack of AKT activation correlated with an impaired p38
phosphorylation and NF-κB p65 nuclear translocation, finally leading to a
reduced expression of TNF-α and IL-6. On the other hand, LPS-priming
induced a higher basal transcription of the Tnf-α gene. We believe that
this phenomenon could be the result of improved chromatin accessibility
on TNF-α regulating regions or due to the constitutive presence of active
enhancers/co-activators. The higher release of TNF-α in LPS-primed cells
during stimulation with C. albicans could rely mostly on the enhanced Tnf-α
gene transcription. At the same time, these cells developed a profound rear-
rangement of the intracellular signaling network involved in TLR4 responses
which could override the higher basal TNF-α transcription.
Further proof of this hypothesis is given by the pattern of IL-6 expression:
its reduction during LPS-restimulation indicates that the impaired signaling
pathway controlling TNF-α expression also affects other pro-inflammatory
cytokines. On the other side, restimulation with C. albicans did not affect IL-6
expression in primed cells, suggesting that the control of TNF-α transcription
might be governed by gene-specific chromatin modification rather than by
the rewiring of the signaling cascades activated by the fungus.
Additional efforts will be required in order to elucidate the nature of this
ambivalent phenomenon mediated by LPS. By expanding the signaling path-
way involved in LPS and fungal sensing and characterizing the putative
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epigenetic mechanisms controlling TNF-α expression it will be possible to
describe the roles of mast cells priming in homeostatic and pathological con-
ditions.
Figure 5.0.1: Proposed model of MCs activation during fungal infections. A.MCs recognize and tightly interact with C. albicans releasing pro-inflammatoryand TH2 cytokines involved in many physiological processes. On the other side,resting MCs inhibit Mϕ phagocytosis, highlighting their role in the restriction ofmyeloid cell activation in homeostatic conditions. B. LPS induces ET in MCs byimpairing the PI3K-AKT pathway and NF-κB nuclear translocation. At the sametime, LPS-primed cells show a higher basal transcription of TNF-α, enhancingtheir response to C. albicans infections.
6 EXPER IMENTAL PROCEDURES
Mice
C57BL/6 mice were purchased from Envigo (The Netherlands) and main-
tained at the animal facility of the Department of Medicine, University of
Udine (Italy). Dectin-1-/- femurs and tibiae were kindly gifted by Prof. Gor-
don Brown, University of Aberdeen (Aberdeen, UK). All animal experiments
were performed in accordance with the animal care and experiments were
performed in accordance to institutional guidelines and national law (D.Lgs.
26/2014).
BMMCs generation
Bone marrow derived mast cells (BMMCs) were obtained from 6- to 8-
week-old mice by in vitro differentiation of bone marrow derived progeni-
tors obtained from mice femurs and tibiae. Precursor cells were cultivated
in complete–IL-3 medium (RPMI 1640 medium (Euroclone) supplemented
with 20% FBS (Sigma Aldrich), 100 U·ml-1 penicillin, 100 mg·ml-1 Strepto-
mycin, 2 mM Glutammine, 20 mM Hepes, non essential amminoacid, 1 mM
Sodium Pyruvate (Euroclone), 50 mM β-mercaptoethanol (Sigma Aldrich)
and 20 ng·ml-1 IL-3 (Peprotech)) at 37◦C in 5% CO2 atmosphere. After 5
weeks, BMMCs differentiation was confirmed by flow cytometry by stain-
ing with anti-FceRIa–PE (MAR-1) and anti-cKit–PE-Cy7 (ACK2) conjugated
antibodies (eBiosciences). Data was acquired with a FACScan cytofluorime-
ter (Becton Dikinson) and analyzed with FlowJo software (FlowJo LLC).
BMMCs were usually ≥ 96% cKit+ and FceRIa+.
BMMCs activation
Before all in vitro experiments, BMMCs were starved for 1 hour in IL-
3–free complete RPMI medium (RPMI 1640 medium (Euroclone) supple-
mented with 10% FBS (Sigma), 100 U·ml-1 penicillin, 100 mg·ml-1 Strepto-
mycin, 2 mM Glutammine, 20 mM Hepes, 1X non essential amminoacid, 1
mM Sodium Pyruvate (Euroclone), and 50 mM β-mercaptoethanol (Sigma
Aldrich)).
For IgE-dependent activation, BMMC were sensitized in IL-3–free com-
plete RPMI medium for 3 hours with 1 µg·ml-1 of dinitrophenol (DNP)-
specific IgE, washed twice and challenged with 100 ng·ml-1 DNP (Sigma-
Aldrich).
For C. albicans infections, 106 BMMCs were stimulated with C. albicans
yeast (1:1 ratio) or hyphae (1:10 ratio) at a final concentration of 2×106
cells·ml-1 in IL-3–free complete RPMI medium. In order to limit fungal
growth, amphotericin-B (Sigma Aldrich) was added to each well at a final
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concentration of 10 ng·ml-1. RNA extraction was performed before the addi-
tion of amphotericin-B.
For the stimulation–restimulation panel, BMMCs were differentiated for 6
weeks in complete–IL-3 medium and checked for purity by flow cytometry.
BMMCs were left untreated or stimulated for 24 hours with 1 µg·ml-1 LPS
(LPS from E. coli O55:E5, Sigma Aldrich), 10 µg·ml-1 curdlan (Invivogen),
IgE/Ag (100 ng·ml-1 DNP) in IL-3–free complete RPMI medium. After the
stimulation, supernatants were collected and cells were washed twice with
PBS and put back in culture in fresh complete–IL-3 for 6 days. Each cells
subset was then re-stimulated with 100 ng·ml-1 LPS, live C. albicans yeasts
(MOI=1) or IgE/Ag for 24 hours (Fig. 4.2.1).
BMMCs degranulation assay
BMMCs degranulation response was determined as the percentage of
β-hexosaminidase released. 0.5×106 BMMCs were incubated in Tyrode’s
buffer (10 mM HEPES buffer [pH 7.4], 130 mM NaCl, 5 mM KCl, 1.4 mM
CaCl2, 1mM MgCl2, 5.6 mM glucose, and 0.1% BSA) with or without the ad-
dition of 10% FBS, and stimulated with the same number of C. albicans yeasts
at 37◦ for the indicated time points. As positive control, 0.5×106 BMMCs
were sensitized in complete RPMI medium for 3 hours with 1 µg·ml-1 of dini-
trophenol (DNP)-specific IgE, then washed twice, resuspended in Tyrode’s
buffer and challenged with 100 ng·ml-1 DNP (Sigma-Aldrich). The enzy-
matic activity of the released β-hexosaminidase was assessed by the cleav-
age of its synthetic substrate (p-nitrophenyl N-acetyl- glucosamide, Sigma
Aldrich) in p-nitrophenol and measuring the p-nitrophenol absorbance at
405nm with a plate spectrophotometer. Results are expressed as the per-
centage of β-hexosaminidase released over β-hexosaminidase retained in the
cytoplasm.
Leukotrienes C4, D4 and E4 were measured in the same samples using a
specific detection kit (GE Healthcare) according to manufacturer’s instruc-
tions.
Purification of peritoneal macrophages
The peritoneum of 8- to 12-week-old C57BL/6 mice was lavaged using a
PBS solution containing 100 U·ml-1 penicillin and 100 mg·ml-1 Streptomycin
(Euroclone). Following lavage, the cells were washed, resuspended in com-
plete RPMI medium (RPMI 1640 medium (Euroclone) supplemented with
10% FBS (Sigma), 100 U·ml-1 penicillin, 100 mg·ml-1 Streptomycin, 2 mM
Glutammine, 20 mM Hepes, non essential amminoacid, 1 mM Sodium Pyru-
vate (Euroclone), and 50 mM β-mercaptoethanol (Sigma Aldrich)), plated in
24-well plates at a concentration of 0.5×106 cells/well, and cultured for 6 h
at 37◦C in 5% CO2 atmosphere. Non-adherent cells were removed by wash-
ing the cells twice with PBS, and adherent cells were cultured overnight in
complete RPMI at 37◦C in 5% CO2 atmosphere. Peritoneal macrophages
(Mϕ) purity was confirmed by flow cytometry and immunofluorescence by
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staining with anti-F4/80–APC (BM8), anti-CD11b–FITC (M1/70) and anti-
MHC-II–PE (M5/114.15.2) conjugated antibodies (BioLegend).
Candida albicans cultures
Wild-type Candida albicans SC5314 strain was a kind gift of Prof. Luig-
ina Romani, University of Perugia (Perugia, Italy). Yeast were seeded on
Sabouraud agar supplemented with 50 µg·ml-1 chloramphenicol and incu-
bated at 30◦C for 24 hours. To generate C. albicans hyphae, 107 yeast cells
were resuspended in complete RPMI medium, seeded into T-25 adhesion
flasks and allowed to germinate for 3 hours at 37◦C. Hyphae were harvested
by scraping, centrifuged at 700 ×g for 10 minutes and washed with PBS.
Flow cytometry
0.5×106 cells were harvested, washed with PBS and stained for 30 minutes
at 4◦C in the dark with monoclonal conjugated antibodies. Cells were then
washed twice with PBS and acquired with a FACSCalibur flow cytometer
(Becton Dickinson).
Time-lapse bright-field microscopy
MC-C. albicans interaction was analysed by time–lapse epiluminescent mi-
croscopy using the Leica AF6000LX system (DMI6000-B microscope equipped
with a DFC350FX camera) at a magnification of 40×. Before each experi-
ment, BMMCs were labelled with FAST DiI (Invitrogen) according to manu-
facturer’s instructions. 0.5×106 BMMCs and 0.5×106 C. albicans yeasts (ratio
1:1) were plated on 8-well Permanox R© Chamber Slide (Lab-Tek, Nunc). The
chamber was placed at 37◦C in 5% CO2 atmosphere. Phase contrast im-
ages were recorded every 10 minutes for a total of 12 hours and resulting
video-recorded movies were processed with LAS AF (Leica) and Fiji (ImageJ)
softwares424.
Immunofluorescence
Cells were seeded onto sterile glass coverslip in a 24 well plate and stim-
ulated. Non-adherent cells were gently removed by pipetting, coverslips
washed with PBS and fixed for 20 minutes with 4% formaldehyde (Sigma
Aldrich). Cells were permeabilized for 5 minutes with 0.1% Triton-X100
(Fluka) and incubated for 30 minutes with PBS + 10% FBS (Sigma Aldrich)
to reduce unspecific binding. Coverslips were incubated with primary an-
tibodies (diluted in PBS + 5% FBS) overnight at 4◦C in a humidified cham-
ber. AlexaFluor-488, -546 or -647 conjugated anti-mouse, anti-rabbit or anti-
rat secondary antibodies (Invitrogen) were incubated for 1 hour at room
temperature. Coverslips were washed and mounted on SuperFrost glass
slides (Menzel) with Mowiol 40-88 mounting media containing 2.5% 1,4-
diazobicyclo-[2,2,2]-octane (Sigma Aldrich). Images were acquired with a
with a Leica DM IRBE microscope equipped with a TCS-SP confocal scanner
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head (with 488 nm Ar and 543–633 nm HeNe lasers) at a magnification of
63× and processed with Fiji (ImageJ) software424.
Antibodies (clones, vendors): α-tubulin (DM1A, Sigma Aldrich), Candida
(Abnova), CD11b (M1/70, Thermo Fisher), F4/80 (BM8, BioLegend), FceR β
chain (JRK b), LAMP-1 (1D4B, eBiosciences), TBP (SI-1, Santa Cruz).
Histochemical staining
Histochemical staining were performed based on the protocol reported by
Kovarova 425 .
104 BMMCs were cytospun onto SuperFrost glass slides (Menzel) at 300
×g for 3 minutes and allowed to air-dry overnight. For toluidine blue stain-
ing, slides were incubated for 5 minutes with a solution of 1% toluidine
blue [pH 5] (Sigma Aldrich), rinsed twice in PBS and once in water, than
allowed to air-dry and mounted with Micromount (Diapath). For alcian
blue–safranin staining, slides were incubated for 10 minutes with a solution
of 0.5% alcian blue (Sigma Aldrich) in 0.3% acetic acid [pH 3], rinsed twice in
PBS then incubated for 20 minutes with a solution of 0.1% safranin-O (Sigma
Aldrich) in 0.1% acetic acid [pH 4]. Slides were then rinsed and mounted as
described above.
Images were acquired with a Leica DM750 equipped with a Leica ICC50W
camera at a magnification of 63× and processed with Fiji (ImageJ) soft-
ware424.
Cytokine ELISA assays
Supernatants for cytokine quantitation were collected 3 or 24 hours after
BMMC stimulation. Supernatants were assessed for TNF-α, IL-6, IL-13 and
IL-4 using specific ELISA kits (eBiosciences) according to manufacturer’s
instructions.
Macrophage chemotaxis and migration assay
Chemotaxis of peritoneal Mϕ was evaluated using the ibidi R© µ-Slide Che-
motaxis kit according to manufacturer’s instructions. ∼15000 peritoneal Mϕ
were seeded in the observation area and the slide incubated at 37◦C in 5%
CO2 atmosphere. After cell attachment, non-adherent cells were removed
by washing three times with PBS. 24 hours after cell seeding, reservoirs
were filled with either complete RPMI medium or conditioned media and
the slider were immediately placed at 37◦C in 5% CO2 atmosphere. DIC
images were recorded at 10× magnification every 10 minutes for a total of
24 hours and resulting video-recorded movies were processed with LAS AF
software (Leica). At least 25 cells per condition were manually tracked with
Fiji Software (ImageJ) and resulting data were analysed with the Chemotaxis
and Migration Tool software (ibidi)424.
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Macrophage phagocytosis assay
C. albicans yeasts were resuspended at 2×106 cells·ml-1 in PBS and labelled
for 20 min with 5 µM Cell Proliferation Dye eFluo 670 (CPD, eBioscience) at
37◦C in 5% CO2 atmosphere. Extracellular stain was quenched by the ad-
dition of 10 ml complete RPMI media for 5 minutes, then the cells were
pelleted at 700 ×g for 5 minutes and washed twice with PBS. CPD-labeled
C. albicans was seeded to BMMCs at a 1:1 ratio or plated alone on 24-well
plates, incubated for 3 hours at 37◦C in 5% CO2 atmosphere and harvested
by scraping. Peritoneal Mϕ received BMMCs co-cultured with C. albicans,
na’´ive BMMCs and CPD-labled C. albicans or CPD-labeled C. albicans alone
at a 1:1:1 ratio. As negative control of phagocytosis, some Mϕ were pre-
treated with 1 µM cytochalasin-D for 1 hour. After 1 hour, cells were har-
vested by scraping, washed with PBS and stained with anti-F4/80–PE (BM8,
Biolegend). Flow cytometry was used to quantify the number of F4/80+ cells
that had engulfed CPD-labeled C. albicans. Percentage of phagocytosis was
calculated by subtracting the percentage of double positive cells in presence
of 10 µM cytochalasin-D to the percentage of double positive cells in non-
treated Mϕ. Phagocytosis index was further determined as fold-change over
the phagocytosis percentage of Mϕ stimulated with CPD-labeled C. albicans
alone.
In some experiment, 50 pg·ml-1 recombinant IL-4 (Peprotech), 100 pg·ml-1
recombinant TNF-α (Immunotools), 10 µg·ml-1 anti-IL-4 neutralizing anti-
body (11B11, eBioscience), 10 µg·ml-1 anti-TNF-α neutralizing antibody (MP6-
XT22, Miltenyi Biotec), or conditioned media were used to stimulate peri-
toneal Mϕ together with BMMCs and C. albicans.
RNA extraction and real-time PCR analyses
Cells were lysed with EUROGOLD TriFast (Euroclone) and total RNA ex-
tracted with the phenol-chloroform protocol according to manufacturer’s in-
structions. Total RNA was quantified using a NanoDropTM spectrophotome-
ter (ThermoFischer) and retro-transcribed with the SensiFASTTM cDNA Syn-
thesis kit (Bioline). Quantitative qPCR analyses were performed with SYBR
Green chemistry (BioRad) using a BioRad iQ5 real-time PCR detection sys-
tems. Target genes expression were quantified with the ∆∆Ct method using
G3PDH (glyceraldehyde 3-phosphate dehydrogenase) as normalizer gene.
Cell lysis and western blot analyses
5×106 BMMCs were stimulated with an equal number of C. albicans yeasts
or with the indicated stimuli or left untreated for the indicated times. Cells
were then incubated for 5 minutes on ice to stop the reaction and centrifuged
300 ×g, 5 minutes at 4◦C. Before the lysis, BMMCs were washed twice with
PBS + phosphatase inhibitors (Active Motif). Cell pellet were lysed in 50
µl NP-40 buffer (25 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA,
1% NP-40 and 5% glycerol, 1 mM Na3VO4, 50 mM NaF (Sigma Aldrich),
and COmplete Mini protease inhibitor cocktail (Roche, usage according to
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manufacturer)) for 10 minutes on ice. Lysates were then centrifuged at 12000
×g, 4◦C for 10 minutes and supernatants were collected and stored at -80◦C.
Upon western blot analyses, lysates were diluted with 4× Laemmli buffer
and denatured 7 minutes at 95◦C. Lysates were then separated on SDS 10%
polyacrilamide gels and blotted on a nitrocellulose membrane (Amersham)
at 300 V, 250 mA, 4◦C for 3 hours. Membranes for phosphoproteins were
blocked in TBS-T (20 mM Tris-base [pH 7.6], 150 mM NaCl, 0.05% Tween-20)
+ 5% BSA while membranes for total proteins were blocked in TBS-T + 5%
non-fat dry milk for 1 hour at room temperature. Primary antibodies for
phosphoproteins were diluted 1:1000 in TBS-T + 5% BSA and membranes
probed overnight at 4◦C with gentle agitation. HRP-conjugated secondary
antibodies (Pierce) were incubated for 1 hour at room temperature with gen-
tle agitation. Signals were detected using ECL substrates Luminata forte
(Millipore) or SuperSignal West Femto (Thermo Scientific) and acquired
with a ChemiDoc imaging system (BioRad). Densitometric analyses were
performed with the Image Lab 5.2 software (BioRad).
Probed membranes were stripped twice for 10 minutes at room tempera-
ture in mild stripping buffer (0.2 M glycine, 0.1% SDS (Sigma Aldrich), 1%
Tween20, pH 2.2) than blocked in TBS-T + 5% non-fat dry milk for 1 hour at
room temperature and reprobed overnight at 4◦C with gentle agitation.
Antibodies (clones, vendors): actin (C4, BD biosciences), AKT (BD bio-
sciences), phospho-AKT S473 (D9E, CST), PI3K p85 (CST), phospho-PI3K
p85 p55 Y459 Y199 (CST), p38 MAPK (CST), phospho-p38 MAPK T180 Y182
(CST), PI3K p110δ (A-8, Santa Cruz).
Nuclear-cytoplasmic fractionation
107 BMMCs were were stimulated as indicated, harvested and washed
twice with PBS + phosphatase inhibitors (Active Motif). Cytoplasmic frac-
tions were obtained by lysing the cell pellet with EDG lysis buffer + 0.1%
Triton-X 100 (10 mM Hepes-KOH [pH 8.0], 10 mM KCl, 1.5 mM MgCl2, 0.34
M sucrose, 10% glycerol, 1 mM DTT, 50 mM NaF, 1 mM Na3VO4 (Sigma
Aldrich) and COmplete Mini protease inhibitor cocktail (Roche, usage ac-
cording to manufacturer)) for 5 minutes on ice. Nuclei were pelleted at 500
×g for 10 minutes at 4◦C and washed with EDG lysis buffer. Nuclear pellet
were lysed with complete lysis buffer (Active Motif) on ice for 30 minutes
and cleared by centrifugation at 12000 ×g, 10 minutes, 4◦C. Both fractions
were immediately used for downstream analyses or kept at -80◦C.
NF-κB activity
Nuclear protein fractions were obtained as described above and protein
concentration was measured with the PierceTM BCA Protein Assay Kit (Ther-
mo Scientific). 20 µg of protein extracts were used for the quantification of
NF-κB p65 activity using the TransAMTM NF-κB kit (Active Motif) according
to manufacturer’s instructions.
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Statistical analyses
Unless otherwise indicated, results are expressed as mean (SD) of at least
three independent experiments. Data were analysed using paired on un-
paired Student’s t test, ratio t test, paired or ordinary one-way ANOVA,
paired two-way ANOVA, or Kruskal-Wallis tests (GraphPad Prism v6).
Rayleigh tests were performed with the Chemotaxis and Migration Tool
software (ibidi). A confidence level of 95% was used. *=p<0.05, **=p<0.01,
***=p<0.001, ****=p<0.0001.

Part III
BACK MATTER

L I ST OF ABBREV IAT IONS
APCs Antigen-presenting cells
BMMC Bone marrow derived mast cells
BCG Bacillus Calmette-Guérin
CBMC Cord blood-derived mast cells
CM Conditioned media
CPA3 Carboxypeptidase A3
CTMC Connective-tissue mast cells
cysLT Cysteinyl leukotriene
DAG Diacylglycerol
DCs Dendritic cells
ECM Extracellular matrix
ET Endotoxin tolerance
FceRI High affinity receptor for IgE
GM-CSF Granulocyte-macrophage colony-stimulating factor
IBD Inflammatory bowel disease
IBS Irritable bowel syndrome
IFN-γ Interferon-γ
IgE Immunoglobulin-E
IL Interleukin
IP3 Inositol triphosphate
ITAM Immunoreceptor tyrosine-based activation motif
LPS Lipopolysaccharide
LTA Lipoteichoic acid
Mϕ Macrophages
MOI Multiplicity of infection
MC Mast cell
MCPT Mast cell protease
MDP Muramyl dipeptide
MHC Major histocompatibility complex
MMC Mucosal mast cell
MyD88 Myeloid differentiation primary-response protein 88
NFAT Nuclear factor of activated T cells
NF-κB Nuclear factor κ-light-chain-enhancer of activated B cells
NK Natural killer cells
NLRP3 NOD-, LRR-, and pyrin domain (PYD)-containing protein 3
PAMP Pathogen-associated molecular pattern
PGN Peptidoglycan
PIP2 Phosphatidylinositol 4,5-diphosphate
PIP3 Phosphatidylinositol 3,4,5-triphosphate
PMC Peritoneal mast cell
SAR Systemic acquired resistance
SCF Stem cell factor
SFK SRC family kinase
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TCR T-cell receptor
TF Transcription factor
TH T-helper cell
TIR Toll/Interleukin-1 receptor
TLR Toll-like receptor
TNF-α Tumor necrosis factor-α
TSLP Thymic stromal lymphopoietin
VEGF Vascular endothelial growth factor
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T helper 9 (Th9) cells contribute to lung inflammation and allergy as sources of interleukin-9
(IL-9). However, the mechanisms by which IL-9/Th9 mediate immunopathology in the lung
are unknown. Here we report an IL-9-driven positive feedback loop that reinforces allergic
inflammation. We show that IL-9 increases IL-2 production by mast cells, which leads to
expansion of CD25þ type 2 innate lymphoid cells (ILC2) and subsequent activation of Th9
cells. Blocking IL-9 or inhibiting CD117 (c-Kit) signalling counteracts the pathogenic effect of
the described IL-9-mast cell-IL-2 signalling axis. Overproduction of IL-9 is observed in
expectorates from cystic fibrosis (CF) patients, and a sex-specific variant of IL-9 is predictive
of allergic reactions in female patients. Our results suggest that blocking IL-9 may be a
therapeutic strategy to ameliorate inflammation associated with microbial colonization in the
lung, and offers a plausible explanation for gender differences in clinical outcomes of patients
with CF.
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nnate lymphoid cells (ILCs) perform a variety of immune
functions at barrier surfaces1. Three types of ILCs have been
reported, which differ on the basis of the cytokines produced.
ILC1 encompass natural killer cells and interferons (IFN)-g-
releasing cells; ILC2 release IL-5, IL-9 and IL-13, and ILC3 release
IL-17A and IL-22. ILC2 preferentially localize to the interface
between the host and the environment (lung, intestine and skin)
and perform a variety of biological functions in mice2 and
humans3. In the lung, ILC2 and their cytokines play pro-
inflammatory roles in allergic inflammation2,4,5, but also
protective roles in airway epithelial cell repair and control of
tissue inflammation linked to pathogens6,7. Thus, ILC2 may affect
the course of airways diseases, resulting in either pathological or
protective outcomes. Lung ILC2 rapidly produces IL-5 and IL-13
on exposure to IL-33 (ref. 5), an effect potentiated by IL-25 and
thymic stromal lymphopoietin (TSLP)5, and IL-9 on the exposure
to IL-2 (ref. 8). By promoting ILC2 survival8, IL-9 provides a
positive feedback loop that amplifies ILC2 cytokine production
and the ensuing allergic airway inflammation9. However, IL-9
also dampens the pathogenic activities of Th17 cells10 and
mediates tolerance imparted by regulatory T cells (Treg) via mast
cells (MC)11. Produced by MC, in addition to ILC2 and Th9, IL-9
in turn affects the expansion12 and function13 of MC, which are
known to have positive, as well as negative, immunomodulatory
roles in vivo13–16. Thus, IL-9, like ILC2, may have different roles
in lung immune homeostasis.
In patients with cystic fibrosis (CF), the primary source of
morbidity and mortality is due to a vicious cycle of airway
infection and inflammation eventually resulting in lung damage.
The inflammatory response in CF is dysregulated at several levels,
resulting in inefficient microbial clearance and contributing
to lung damage17. This is supported by several studies that
have documented an altered balance of inflammatory/anti-
inflammatory cytokines in CF (ref. 17), providing evidence that
targeting specific inflammatory/anti-inflammatory pathways is a
valid therapeutic strategy in CF (ref. 18). This balance is essential
for the efficient control of Aspergillus fumigatus diseases in CF
(ref. 18), where the colonization by the fungus is common
and may lead to fungal sensitization, bronchitis and allergic
broncho-pulmonary aspergillosis (ABPA)19 as well as worse
forced expiratory volume in the first second (FEV1) (ref. 20). In
CF patients, the expression of IL-9 and IL-9R is increased and is
associated with mucus overproduction, but whether and how IL-9
contributes to immunity and pathology in response to the fungal
infection in CF is not known.
In the present study, we determine the contribution of IL-9 to
Aspergillus infection and allergy in murine and human CF, and
assess the therapeutic effectiveness of targeting IL-9-dependent
pathways and the diagnostic potential of this approach. We find
that IL-9-driven IL-2 production by MC expands CD25þ ILC2,
which in turn activate Th9 cells, leading to an amplified allergic
inflammation. Overproduction of IL-9 is observed in expectorates
from CF patients and a genetic variant of IL-9 shows a
sex-specific association with IgE levels in female patients.
Blocking IL-9 or inhibiting CD117 (c-Kit) signalling counteracts
the pathogenic potential of the IL-9-MC-IL-2 axis, thus providing
a therapeutic angle to ameliorate the pathological consequences
of microbial colonization in CF.
Results
IL-9 production and ILC2-Th9 activation during aspergillosis.
We infected C57BL/6 or Cftr /mice intranasally with
A. fumigatus and measured IL-9 production, ILC2 and Th9 cell
activation in infection. We have already shown that Cftr /mice
are susceptible to Aspergillus infection (from 2.5±0.7 to
3.9±1.0 log colony forming unit (cfu)±s.d. per lung, C57BL/6
versus Cftr /mice, respectively) and allergy (from 9.2±0.7 to
22.4±1.3 ngml 1 total serum IgE in C57BL/6 and Cftr /
mice, respectively). A peak production of IL-9 occurred during
the first week of the infection in C57BL/6 mice to decline
thereafter as opposed to Cftr /mice in which levels of IL-9
were sustained throughout the infection (Fig. 1a). Peak produc-
tion of IL-9 was also observed in Rag1 / , and less in
Rag1 / /Il9R / , mice early but not late in infection (Fig. 1a),
a finding suggesting that early IL-9 production is IL-9R-depen-
dent and late is T-cell-dependent. We looked therefore for the
presence of IL-9þ ILC2 and Th9 cells in infection by character-
izing IL-9-producing Lin and CD4þ T cells in the lung. ILC2
are marked by expression of the IL-33R as well as the common g
chain (gc) cytokine receptors for IL-2 and IL-7 (ref. 2). Flow
cytometry analysis revealed that CD90.2þ ILC2 expressing IL33R
or CD25 were present in the lung of naive C57BL/6 (4.5 and 3.3%
for CD25þ and ST2þ cells, respectively) and Cftr /mice (5.8
and 4.0% for CD25þ and ST2þ cells, respectively; Fig. 1b,c). In
C57BL/6 mice, and similarly in Rag1 / mice (Supplementary
Fig. 1a), ST2þ ILC2 cells decreased early in infection to return to
baseline level 10 days later while CD25þ ILC2 stably decreased
(Fig. 1b,c). In contrast, in Cftr /mice, both types of ILC2
steadily increased throughout the infection (Fig. 1b) along with
the expression of the ILC2 transcription factors, Rora, and Gata3
(Fig. 1d) and the production of ILC2 effector cytokines, IL-5 and
IL-13 (Fig. 1e). IL-9-producing CD90.2þ ILC2 were also expan-
ded in Cftr /mice but not in C57BL/6 (Fig. 1b,c) and
Rag1 / mice (Supplementary Fig. 1a), as revealed by flow
cytometry. In terms of Th9 cell activation, CD4þ IL-9þ T cells
appeared in C57BL/6 mice a week after the infection to decline
thereafter (Fig. 1h), consistent with the short retention of Th9 at
the inflammatory sites21. The expansion was instead sustained in
Cftr /mice (Fig. 1h) along with the expression of Il9, Pu.1
(purine-rich box 1) and Irf4 (interferon regulatory factor 4)
transcription factors (Fig. 1g). These data indicate that
IL-9þ ILC2 and Th9 cells are all increased in Cftr /mice
during A. fumigatus infection.
Given that ILC1 through IFN-g (ref. 22) and ILC3 through
IL-22 (ref. 23) may affect ILC2 expansion, the differential
expansion of ILC2 could reflect the ILCs dynamics in the lung.
However, NKp46þNK1.1þ ILC1 cells producing IFN-g did not
expand and ILC1-promoting cytokines IL-15 and IL-18 were not
produced in Cftr / as opposed to C57BL/6 mice
(Supplementary Fig. 2a,b). Similarly, despite expanded in
Cftr /mice, CCR6þRORgtþ ILC3 produced IL-17A more
than IL-22 (Supplementary Fig. 2c,d). Thus, while confirming the
defective production of IFN-g and IL-22 in Cftr / mice18,
these findings suggest that the expansion of ILC2 in Cftr /mice
is not dependent on ILCs dynamics in the lung but rather on the
production of ILC2 promoting cytokines. This appeared to be the
case, as the levels of cytokines promoting ST2þ ILC2, IL-33 and
CD25þ ILC2, IL-2, were constantly elevated in Cftr /mice
whereas a peak production was only observed at an early time
point in C57BL/6 mice (Fig. 1f).
IL-9 contributes to inflammatory pathology in infection. To
assess the role of IL-9 in A. fumigatus infection and allergy, we
resorted to Il9R /mice that, given the crucial role of the IL-9R,
a member of the gc receptor family, for the survival of lung
ILC2 (ref. 8), also have a decreased ILC2 (ref. 8). Mice were
either acutely infected with Aspergillus conidia intranasally or
subjected to fungal allergy (ABPA) by repeated sensitization with
Aspergillus culture filtrate extracts (5.5±0.7 ngml 1 versus
11±1.0, total serum IgE in Il9R / versus C57BL/6 mice,
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respectively). We found that the absence of IL-9R signalling
conferred resistance to both infection and allergy, as indicated by
the reduced fungal load (Fig. 2a) and decreased inflammatory
lung pathology in infection as well as in ABPA (Fig. 2b). The
numbers of lung CD25þ and ST2þ ILC2 were decreased in these
mice as revealed by immunofluorescence staining (Fig. 2c).
Concomitantly, Th9 and, partially, Th2 cells—revealed by
Stat6 expression and STAT5 phosphorylation (Supplementary
Fig. 1b,c)—were decreased in both infection and allergy
(Fig. 2d,e), while Th17 and Treg cells were unaffected and Th1
cells increased (Supplementary Fig. 3a,b). Corroborating these
findings, IL-9 neutralization in C57BL/6 or Cftr /mice greatly
ameliorated lung pathology in response to the fungus, both in
terms of inflammatory cell recruitment (Fig. 2f) and fibrosis as
shown by Masson’s trichrome staining (insets of Fig. 2f) and
production of TGF-b (Fig. 2g), a mediator of pulmonary
fibrosis24. Together, these results indicate that the IL-9/IL-9R
signalling pathway is required for the expansion of pathogenic
ILC2 and Th9 cells in response to the fungus. However, whether
ILC2 promote Th9 cell activation via IL-9R signalling is not
known. To directly assess this, we did criss-cross experiments in
which CD4þ T cells from either C57BL/6 or Cftr /mice were
assessed for IL-9 production and Th9 transcription factor
expression on co-cultivation in a transwell permeable support
with lung Lin cells exposed to A. fumigatus and either IL-2 or
IL-33. We found that Th9 cell activation was observed upon
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Figure 1 | IL-9 production and ILC2-Th9 cells activation in Aspergillus fumigatus infection. (a) Time course of IL-9 production at various days post
infection (dpi) in mice (six per group) infected intranasally with live A. fumigatus conidia. (b) Detection of CD90.2þCD25þ , CD90.2þST2þ and
CD90.2þ IL-9þ lung type 2 ILCs by flow cytometry (numbers refer to percentages of positive cells) and immunofluorescence staining. (c) Absolute
number of lung ILC2; (d) ILC2–specific transcript on lineage negative lung cells; (e,f) ILC2 effector and activating cytokines; (g) Il9 and Th9-cell specific
transcripts on lung CD4þ T cells and (h) immunofluorescence staining of lung CD4þ IL-9þ T cells. Photographs were taken with a high-resolution
microscope (Olympus DP71) equipped with a 40 objective; scale bar, 100mm. Mean values±s.d. cytokines were determined on lung homogenates by
ELISA, Il9 and transcripts assessed by PCR with reverse transcription. 0, uninfected mice. *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001, knockout
versus C57BL/6 mice (data represent pooled results or representative images from three experiments, Two-way ANOVA, Bonferroni post test). Gata3,
GATA binding protein 3; Irf4, interferon regulatory factor 4; Pu.1, purine-rich box 1; Rora, RAR-related orphan receptor alpha.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14017 ARTICLE
NATURE COMMUNICATIONS | 8:14017 | DOI: 10.1038/ncomms14017 | www.nature.com/naturecommunications 3
Naive Infected ABPA
Na
ive
Inf
ec
ted
AB
PA
Na
ive
Inf
ec
ted
AB
PA
Na
ive
Inf
ec
ted
AB
PA
Na
ive
Inf
ec
ted
AB
PA
Na
ive
Inf
ec
ted
AB
PA
Lo
g 
cf
u/
lu
ng
10
8
6
4
2
**
C57BL/6
pg
 m
l–1
pg
 m
l–1
1,000
800
600
400
200
0
100
80
60
40
20
0
10
8
6
4
2
0
20
16
12
8
4
0m
R
N
A 
fo
ld
 in
cr
ea
se
m
R
N
A 
fo
ld
 in
cr
ea
se
pg
 m
l–1
100
80
60
40
20
0
10
8
6
4
2
0m
R
N
A 
fo
ld
 in
cr
ea
se
pg
 m
l–1
100
80
60
40
20
0
**
**
**
**
** **
**
***
***
*** **
**
**
****
**
*
*
*
10
8
6
4
2
0m
R
N
A 
fo
ld
 in
cr
ea
se
40
32
24
16
8
0
C5
7B
L/
6
Il9R –/–
C57BL/6
Lin– C57BL/6
C57BL/6C57BL/6C57BL/6
Lin– Cftr –/–
Untreated
Untreated
UntreatedαIL-9
αIL-9
αIL-9 C57BL/6
TG
F-
β
pg
 m
l–1
600
480
360
240
120
0
Cftr –/–
Cftr –/–
Il9R –/–Il9R –/–Il9R –/–Il9R –/–Il9R –/–Il9R –/– Cftr –/–Cftr –/–Cftr –/– CD4+CD4+CD4+
None IL-2 IL-33
CD4+
Pu.1 Irf4 Stat6IL-9
Pu.1 Irf4 IL-9 Pu.1 Irf4 IL-9
IL-4
Il9
R
–
/–
C5
7B
L/
6
Il9
R
–
/–
CD90.2 CD25 CD90.2 ST2
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
**
*
*
*
*
*
*
dpi 0 7 14 0 7 14
C57BL/6 Il9R –/– C57BL/6 Il9R –/–
a b c
d e
f g
h
Figure 2 | IL-9R signaling contributes to inflammation and allergy. C57BL/6 and Il9R / mice (six per group) were intranasally infected with live
Aspergillus fumigatus conidia or subjected to ABPA and assessed for (a) lung fungal growth (log10 cfu, mean±s.d.); (b) lung histology (periodic acid Schiff
staining); (c) expression of CD90.2þCD25þ , CD90.2þST2þ lung ILC2 by immunofluorescence; (d,e) Th-cell specific transcripts and cytokine
production. (f) Lung histology (periodic acid–Schiff and, in the inset, Masson’s trichrome staining) and (g) TGF-b production in C57BL/6 or Cftr/ mice
infected as above and treated with IL-9 neutralizing antibody for a week. Days post infection (dpi). (h) Th-cell specific transcripts and IL-9 production of
lung CD4þ T cells from naive mice co-cultured with lung lineage negative (Lin ) cells in the presence of A. fumigatus conidia, IL-2 or IL-33. Photographs
were taken with a high-resolution microscope (Olympus DP71) equipped with a  20 objective; scale bars, 200mm and a 40 objective (insets of f,
scale bars, 100 mm). Results are mean values±s.d., ELISA was done on lung homogenates and culture supernatants for cytokines and PCR with reverse
transcription on CD4þ lung cells. *Po0.05, **Po0.01, ***Po0.001, Il9R / , Cftr/ versus C57BL/6 mice; IL-9-treated versus control isotype-treated
mice; stimulated versus unstimulated (none) cells and Il9R / versus C57BL/6 or Cftr/ CD4þ Tcells. Naive, uninfected mice. Data represent pooled
results or representative images from three experiments, Two-tailed Student’s t-test (a) or Two-way ANOVA (d,e) Bonferroni post test. Gata3, GATA
binding protein 3; Irf4, interferon regulatory factor 4; Pu.1, purine-rich box 1.
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co-cultivation of CD4þ T cells with Lin cells in the presence of
IL-2 more than IL-33, an effect magnified in Cftr / as
compared to C57BL/6 mice (Fig. 2h), and requiring the
presence of IL-9R on responder CD4þ T cells being
significantly negated with Il9R / responder cells (Fig. 2h and
Supplementary Fig. 4). These results indicate that ILC2, and
particularly CD25þ ILC2, may account for the sustained IL-9
production and Th9 activation responsible for pathology in CF.
IL-9 activates mast cells to produce IL-2. The sustained
production of IL-33 and IL-2 in Cftr /mice prompted us to
investigate mechanisms behind this production. IL-33 is
constitutively expressed at epithelial barrier surfaces where it is
rapidly released from cells during tissue injury25. However,
tight regulation of IL-33 following its release to dampen
ST2-dependent inflammation to fungi has also been
described26. This likely occurred in C57BL/6 but not in Cftr /
mice in which the high levels of epithelial damage observed
upon the infection (Fig. 3a) likely accounted for the sustained
IL-33-dependent ST2þ ILC2 expansion. For IL-2, predictably
high in CF, given the sustained NFAT activity27, in addition to
CD4þ T cells8 and dendritic cells28, MC are known to produce it
in the lung7. We looked therefore for MC presence and activity in
the lung of C57BL/6 and Cftr /mice after the infection. MC
were much expanded in Cftr / mice, as seen by flow cytometry
(Fig. 3b) and toluidine staining (Fig. 3c). MC are distinguished by
their granule content whose expression is tissue-dependent29. In
the lung, chymase-positive MC numbers positively correlated
with better lung function30, whereas chymase- and tryptase-
positive MC were expanded in areas of fibrosis in CF lungs and
positively correlated with the degree of fibrosis and lung
function31. Immunohistochemistry revealed that while tryptase-
positive cells could not be detected, chymase-positive MC
were present in C57BL/6 mice (insets of Fig. 3c). In contrast,
chymase-positive and tryptase-positive MC were observed in
Cftr / mice (insets of Fig. 3c).
As MC are known to produce cytokines through different
receptor mechanisms32, we evaluated cytokine production on
magnetically purified c-Kitþ MC (as characterized by
morphometry and MC specific transcripts, Fig. 3d) upon
stimulation with IgE, IL-9 or IL-33. We found that IL-2
production was induced by IL-33 and, more, by IL-9 and not
by IgE, mostly in MC from Cftr /mice (Fig. 3e). As IL-9 also
induced IL-9 production (Fig. 3e) and IL-9þMC could also be
detected in vivo (Fig. 3b), this suggests that an autocrine loop
appears to mediate the IL-9-dependent IL-2 release by MC. As a
matter of fact, IL-2 production (39±6 ng/ml versus 127±22,
IL-2 in lung homogenates at 3 dpi in Il9R / versus C57BL/6
mice, respectively) and IL-2þMC (Fig. 3f) were greatly reduced
in Il9R /mice, thus contributing to the defective expansion of
CD25þ ILC2 in these mice. Of interest, IL-9 stimulation also
induced TGF-b in MC from Cftr /mice but not IL-6 (Fig. 3e),
a finding suggesting that the autocrine IL-9 stimulation appears
to be specific for IL-2 and TGF-b (Fig. 3e). These data indicate
that MC may contribute to IL-2 production eventually leading to
CD25þ ILC2 expansion in Cftr /mice. This appears to be the
case, as IL-2þMC, more than IL-2þCD90.2 or IL-2þCD4þ
T cells, were expanded in vivo, early in infection, particularly in
Cftr /mice (Fig. 3f).
To directly prove this, we assessed susceptibility to inflamma-
tory allergy of MC-deficient C57BL/6-KitW/W-v mice or Cftr /
mice treated with the tyrosine kinase inhibitor imatinib known to
inhibit IL-9-driven mastocytosis in the lung12. Airway
mastocytosis was reduced in MC-deficient KitW/W-v mice
(Fig. 4a) along with reduced levels of IgE, IL-2, IL-9 and
TGF-b (Fig. 4b). Concomitantly, the number of CD25þ ILC2
were also decreased in the lung but promptly restored upon MC
engraftment or exogenous IL-2 administration (Fig. 4a). Thus,
MC appear to be able to control CD25þ ILC2 expansion in the
lung during the infection via IL-2. Similar results were obtained
upon treatment of Cftr / mice with imatinib. Both
inflammation (Fig. 4c), collagen deposition (insets of Fig. 4c),
IL-2, IL-9 and TGF-b production (Fig. 4d) and Th9 cell activation
(Fig. 4e) were attenuated. Interestingly, imatinib apparently
increased early inflammation in C57BL/6 mice (Supplementary
Fig. 5), a finding suggesting that c-Kitþ cells could contribute to
pathogen resistance early in infection. As a matter of fact, MC-
deficient KitW/W-v mice displayed increased susceptibility to the
infection as compared with C57BL/6 mice, as indicated by the
increased fungal load (Supplementary Fig. 6a), neutrophils
recruitment (Supplementary Fig. 6b) and a degree of lung
inflammation (Supplementary Fig. 6c).
CFTR deficiency contributes to inflammation. The above
results suggest that a circuit involving IL-33, IL-2 and IL-9 and
different types of cells is pathogenically amplified in Cftr /
mice. The finding that IL-33, IL-2 and IL-9 are also elevated in CF
patients33,34 prompted us to evaluate the contribution of cystic
fibrosis transmembrane conductance regulator (CFTR)
dysfunction on the activation of the inflammatory circuit.
Given that CFTR dysfunction on both epithelial and myeloid
cells impacts on lung inflammation35, we assessed chimeric mice
with CFTR unresponsive myeloid or epithelial cells for lung
damage and inflammation, production of IL-33, IL-2 and IL-9
and MC/ILC2 activation upon Aspergillus infection. We found
that epithelial cell damage and lung inflammation (Fig. 5a), levels
of cytokines and IgE (Fig. 5b), MC and ILC2 expansion (Fig. 5c)
were all attenuated or decreased in condition of CFTR deficiency
in epithelial cells but CFTR sufficient myeloid cells, a finding
suggesting that myeloid, and perhaps lymphoid, deficiency could
contribute to the activation of the inflammatory circuit in CF.
This seems to be the case as the opposite findings were observed
in recipient C57BL/6 mice receiving CFTR deficient myeloid cells
(Fig. 5a,c) These mice, however, showed an intermediate
inflammatory phenotype as compared to Cftr / mice, a
finding suggesting that, although to a different extent, CFTR
deficiency on epithelial and myeloid cells may predispose to lung
inflammation in response to microbial and non-microbial stimuli.
The IL9 rs2069885 SNP correlates with high IgE levels in CF
females. To assess whether IL-9 may contribute to allergy in CF
patients, we determined the effect of the non-synonymous IL9
p.Thr117Met (c.350C4T, rs2069885) polymorphism, known to
be associated with lung function and sensitization36,37 on total
and Aspergillus-specific IgE levels in CF patients (Supplementary
Table 1). Previous association studies demonstrated the existence
of sex dimorphism linked to this polymorphism36,37. Therefore,
we carried out association testing separately in males and
females. The distribution of the total IgE was skewed but after
natural logarithmic transformation, the distribution adequately
approximated a normal distribution. IL9 rs2069885 genotype
distribution did not deviate from Hardy–Weinberg equilibrium
(w2 test, P¼ 0.776) and it displayed a minor allele frequency of
0.129, comparable to the European population from 1000
Genome Consortium, minor allele frequency¼ 0.128 (ref. 38).
IL9 rs2069885 genotype distribution did not differ between males
and females (w2 test, P¼ 0.243), but a significant rs2069885-sex
interaction on total IgE levels was found (general linear model,
P¼ 0.004), where female T allele carriers showed high IgE
levels (linear regression: females, b¼ 0.624, P¼ 0.043; males,
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b¼  0.666, P¼ 0.034; Fig. 6a). In a subset of CF patients
(N¼ 114; 57 males and 57 females), Aspergillus-specific IgE were
also significantly higher in IL9 rs2069885-T carriers (general
linear model, P¼ 0.002; Fig. 6b). Notably, in line with the results
obtained on total IgE, the association of IL9 rs2069885-T allele
with higher Aspergillus-specific IgE levels was observed in females
(linear regression, b¼ 1.417, P¼ 0.002) more than males
(linear regression, b¼ 0.489, P¼ 0.279). We also tested other
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Figure 3 | IL-9 activates mast cells to produce IL-2. C57BL/6 or Cftr/ mice (six per group) infected intranasally with live A. fumigatus conidia were
evaluated at different days after infection (dpi) for (a) deposition of DNA on lung epithelial cells by TUNEL, resulting in bright DNA staining; (b) detection
of c-KitþFceRþ and c-Kitþ IL-9þ lung mast cells (MC) by flow cytometry (numbers refer to percentages of positive cells); (c) toluidine blue, relative MC
number mm 2 and, in the inset, immunohistochemical staining for chymase- and tryptase-positive MC in lung section. Photographs were taken with a
high-resolution microscope (Olympus DP71) equipped with a 40 objective and (in the inset) a  100 objective and with EVOS FL Color Imaging System
with a  60 objective (immunohistochemical staining). (d) Toluidine blue stain and transcription factors expression (PCR with reverse transcription) of
c-Kitþ cells magnetically isolated from lung of uninfected C57BL/6 mice and pulsed with live A. fumigatus conidia. (e) Cytokine production (mean
values±s.d., ELISA on culture supernatants) by purified lung c-Kitþ cells, pulsed with A. fumigatus and stimulated with IgE, IL-9 and IL-33; (f) detection of
c-Kitþ IL-2þ , CD90.2þ IL-2þ and CD4þ IL-2þ lung cells by flow cytometry (numbers refer to percentages of positive cells). *Po0.05, **Po0.01,
***Po0.001, ****Po0.0001, conidia-pulsed versus unpulsed c-Kitþ cells, stimulated versus unstimulated c-Kitþ cells and Cftr/ versus C57BL/6
c-Kitþ cells (data represent pooled results or representative images from three experiments, Two-way ANOVA, Bonferroni post test). Mcpt1, mast cell
protease 1; Mcpt6, tryptase beta 2; Rorc, retinoic acid receptor–related orphan receptor C; Rora, RAR-related orphan receptor alpha; Tbet, T box expressed in
T cells; Tph1, tryptophan hydroxylase 1.
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Figure 4 | IL-9 activates mast cells to produce IL-2. MC-deficient C57BL6-KitW/W-v mice (six per group) were infected intranasally with live A. fumigatus
conidia, engrafted intravenously with wild-type bone marrow-cultured mast cells (BMMC) or treated intraperitoneally with IL-2 for a week and assessed for
(a) c-KitþFceRþ lung mast cells (MC) and CD90.2þCD25þ lung ILC2 by flow cytometry (numbers refer to percentages of positive cells) with relative
cell number and (b) IgE and cytokine production. (c) Lung histology (periodic acid–Schiff and Masson’s trichrome staining, in the insets); (d) cytokine
production and (e) Th9-cell specific transcripts expression in Cftr/ mice infected as above and treated with imatinib intraperitoneally for a week.
Photographs were taken with a high-resolution microscope (Olympus DP71) equipped with a  20 objective, scale bars, 200mm and a 40 objective
(insets of c, scale bars, 100 mm). Results are mean values±s.d., ELISA on lung homogenates for cytokines and PCR with reverse transcription on lung
CD4þTcells. *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001, MC-deficient C57BL6-KitW/W-v versus C57BL/6 mice or imatinib-treated versus untreated
(none) mice (data represent pooled results or representative images from three experiments, Two-way ANOVA, Bonferroni post test). Irf4¼ interferon
regulatory factor 4; Pu.1¼ purine-rich box 1.
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IL9 tagSNPs (rs2069882, rs31564, rs1859430, rs1799962;
Supplementary Tables 2 and 3), encompassing the whole IL9
gene region, but none associated with IgE levels. Linkage
disequilibrium (LD) analyses of the five SNPs in IL9 failed to
reveal the presence of significant LD blocks (Supplementary
Fig. 7). Haplotype analysis yielded no significant result
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Figure 5 | Epithelial and myeloid CFTR deficiency contribute to the inflammatory phenotype. C57BL/6, Cftr/ and chimeric C57BL/6 and Cftr/
mice (10 per group) received 10 106 viable bone marrow cells 4 weeks before the intranasal infection with A. fumigatus. Chimeric mice were evaluated 7
days after the infection for (a) lung histology (periodic acid–Schiff and, in the insets, Masson’s trichrome and TUNEL staining); (b) cytokines and IgE levels
(mean values±s.d., ELISA on lung homogenates); (c) detection of c-KitþFceRþ mast cells, CD90.2þCD25þ and CD90.2þST2þ type 2 ILCs by flow
cytometry (numbers refer to percentages of positive cells in the lung). Photographs were taken with a high-resolution microscope (Olympus DP71)
equipped with a  20 objective; scale bars, 200mm and a 40 objective (insets of panel a, scale bars, 100mm). *Po0.05, **Po0.01, ***Po0.001,
Cftr/ versus C57BL/6, chimeric C57BL/6 versus C57BL/6, chimeric Cftr/ versus Cftr/ mice, Two-way ANOVA, Bonferroni post test.
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(Supplementary Table 4), although the most common haplotype
C–A–A–C–A (frequency 43.2%) turned out to be associated with
higher IgE levels in males (linear regression, b¼ 0.567,
P¼ 0.022).
We next determined whether the reported sex-specific
associations could be attributable to a differential expression of
IL9 and its receptor, which is located on the pseudoautosomal
region Xq/Yq, between males and females. A significant IL9
rs2069885 by sex interaction was found when analysing the
IL9/IL9R expression ratio (general linear model, P¼ 0.025) where
T allele carriers showed opposite effects according to sex (linear
regression, females, b¼ 0.375, P¼ 0.116; males, b¼  0.426,
P¼ 0.375; Fig. 6c) paralleling the finding on specific IgE (Fig. 6a)
and on IL-9 levels in expectorates (Fig. 6d). No significant
difference was noticed between males and females when IL9 or
IL9R gene expression levels were analysed independently.
Although these results are to be considered with caution given
the small sample size–despite the sufficient power (b¼ 0.20,
Power¼ 0.8; Supplementary Table 6)—which demands for a
definitive validation using a larger new cohort of CF patients, the
present findings confirm the existence of a sex dimorphism at IL9
and IL9R loci, as already reported in several respiratory-related
human phenotypes36,37.
Discussion
We have shown that IL-9 may expand pro-inflammatory CD25þ
ILC2/Th9 cell in CF, an activity involving the production of IL-2
by MC. Human MC co-localize near ILC2 in the human lung and
could directly promote ILC2 responses in vitro39. We found here
that, in addition to CD4þ T cells, known to contribute to
CD25þ ILC2 expansion via IL-2 (ref. 8), lung MC may also affect
the expansion of CD25þ ILC2 thought to contribute to chronic
inflammation through multiple mechanisms3. Failure to expand
CD25þ ILC2 occurred indeed in MC-deficient mice or mice
treated with imatinib.
MC hyperplasia during chronic allergen challenge is associated
with remodeling of airways40. In a mouse model of ovalbumin-
induced airway inflammation, the influx of MC into lung peaks
early after allergen challenge to mature over 14 days into cells
expressing lower level of c-Kit, FceRI and integrins41. MC
hyperplasia was observed in the lung of Cftr /mice along with
the detection of tryptase-positive and chymase-positive MC,
known to be expanded in asthmatic patients42 and in disease
areas of CF lung31. Tryptases and chymases contribute to
inflammation and tissue remodeling through the selective
proteolysis of matrix proteins and the activation of protease-
activated receptors and matrix metalloproteinases29. Consistent
with the finding that MC from CF patients are not high in FceR1
expressing43, we found that lung MC from these mice poorly
responded to IgE in terms of IL-6 production but released IL-2, in
addition to TGF-b, in response to IL-9.
IL-9 is a pleiotropic cytokine that has multiple effects on
structural as well as numerous hematopoietic cells, which are
central to the pathogenesis of asthma44,45. The important role for
the IL-9-MC axis in the pathology associated with chronic allergic
inflammation has been already described46. IL-9 not only
stimulates MC growth and expansion but also stimulates
changes in gene expression that might alter responsiveness to
other stimuli47. In vivo, IL-9 governed allergen-induced MC
numbers in the lung, and anti-IL-9 antibody-treatment protected
from airway remodeling, decreased expression of the profibrotic
mediators TGF-b and improved lung function48. The correlation
between a reduction in MC numbers and decreased airway
remodeling, after IL-9 inhibition, is consistent with reports that
MC-deficient mice demonstrate significantly attenuated fibrosis
and inflammation after silica49, ozone50, or bleomycin injury51.
We found that not only were IL-9 production and MC
expansion significantly increased in CF mice but that the
IL-9-MC axis contributed to the expansion of CD25þ ILC2
leading to Th9 cell activation that further contributed to the
allergic inflammatory pathology (Fig. 7). IL-9 promoted IL-2
production by lung MC from Cftr /mice, a finding that may
explain the increased and persistent expansion of CD25þ ILC2 in
these mice. CD25þ ILC2 were indeed not expanded in condition
of IL-9 ablation or MC-deficiency, a finding suggesting that the
IL-9/MC/IL-2 axis drives the expansion of CD25þ ILC2. In
addition, as IL-2 stimulated lung CD25þ ILC2 to produce IL-9
(ref. 9), this may have a positive feedback effect on ILCs, since
lung ILCs cultured with IL-9 increased the production of type 2
cytokines9 and up-regulated the anti-apoptotic protein BCL-3,
thereby promoting ILC2 survival8. Of great interest, Lin cells
from CF lung also promoted Th9 cell activation in vitro, an
activity that required IL-9R expression on responding CD4þ T
cells. Thus, the pathogenic role of IL-9 in promoting allergic
inflammation may go beyond CD25þ ILC2 expansion to include
the activation of Th9 cells. That Th9 cells are a major source of
IL-9 in models of allergic inflammation and play an important
role in MC accumulation and activation has been reported52. By
producing IL-9, Th9 cells may in turn serve as a positive loop
amplifying the IL-9/MC/ILC2 axis, promoting a deleterious
vicious circle in which the production of profibrotic TGF-b by
IL-9-stimulated MC plays a plausible important role. The
presence of TGF-b dependent signalling in areas of prominent
fibrosis in CF has been already documented24 along with its
inhibition of chloride channel activities53 and the association of
the TGF-b genetic variants with more severe lung disease54.
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Of note, together with IL-4, is able to promote Th9 cell
development in vitro55, a finding highlighting the potential role
of TGF-b in reinforcing Th9 activity in vivo. However, TGF-b
production by MC in response to IL-9 may also serve a
regulatory, anti-inflammatory role11,56.
In addition to IL-9, IL-33 is also a crucial regulator of MC
functions and both IL-33 and MC have been influentially
associated to the pathophysiology of allergic diseases and
inflammation57. IL-33 is expressed in epithelia from patients
with CF and potentiates neutrophil recruitment58 as well as in
type-2 pneumocytes on allergic lung inflammation59. In this
study, IL-33 was increased in CF mice and likely correlated with
the expansion of ST2þ ILC2. At variance with IL-2, IL-33 did not
stimulate MC for IL-9/TGF-b production, a finding indicating a
minor contribution of the IL-33/MC axis in promoting
inflammatory allergy and pathology in response to the fungus.
As a matter of fact, the IL-33/MC/IL-2 axis was found
to suppress, rather than promote, papain-induced allergic
inflammation by promoting Treg7.
Airway inflammation and recurrent pulmonary infections play
a central role in the progression of CF lung disease. It is still an
open question whether CFTR deficiency per se may enhance the
inflammatory response to the different environmental cues60. Our
data would suggest that CFTR dysfunction on both epithelial and
myeloid cells may impact on the inflammatory circuit leading to
the activation of the inflammatory IL-9/Th9 pathway: namely,
among others35, on both epithelial damage eventually leading to
overproduction of IL-33 and on the MC propensity to respond to
IL-9 with IL-2. However, PU.1 translocation into the nucleus has
also been shown to be significantly higher in CF monocytes than
in controls61. It seems that defective CFTR impacts on the
mechanisms of communication between innate and adaptive
immune response.
The potential contribution of IL-9 to CF pathogenesis in
humans is unknown. Elevated levels of IL-9 were observed in the
expectorates from CF patients, likely accounting for the
expansion of TGF-b-producing MC in diseased lung areas31. It
is of interest that in human asthmatic lung tissue, MC were the
main IL-9R expressing population46. It seems therefore that the
IL-9/MC/IL-2 axis may have a pathogenic role in CF patients and
that its targeting could lead to a reduction in chronic
inflammation and improved lung function of these patients.
Studies have indeed highlighted the importance of Th9 cells in
allergic lung inflammation by promoting epithelial alterations,
goblet-cell hyperplasia, mucus production and infiltration of MC
and eosinophils46. Considering that the costimulatory signal
OX40 is required for Th9 activation62, it is intriguing that OX40
ligand was critical in driving Th2-allergic responses to A.
fumigatus in peripheral CD4þ T cells isolated from CF patients
with ABPA (ref. 63). It is clear that the inflammatory response in
the lung involves different Th cell types whose specific role in CF
remain unclear. Intriguingly, there are conditions where
promoting IL-9 might be therapeutically beneficial11 and ILC2
and MC could be exploited for pathogen immunity and tissue
repair64. In this regard, the fact that imatinib apparently
exacerbated signs of inflammation during infection points to a
some beneficial role c-Kitþ cells may have in the control
of Aspergillus infection. MC indeed exhibited conidiocidal
activity (Supplementary Fig. 6d), a finding suggesting that MC
could serve as tissue sentinels modulating antifungal immune
responses, as suggested65.
In conclusion, IL-9 and MC may have an important role in
the pathogenesis of lung disease and inflammation in CF.
Considering the inherent resistance to steroids of MC in
asthmatic patients66, a better understanding of cellular and
molecular pathways leading to inflammation and impaired lung
functions may inspire new treatment avenues in patients with CF.
Our study would suggest that imatinib, known to inhibit lung
fibrosis67, could be therapeutically exploited in CF patients with
an exalted IL-9/Th9 responses. In addition, it is of great interest
that the IL9 rs2069885 polymorphism, linked to high IgE levels,
was associated with females more than males with CF, a finding
offering an explanation for the, as yet unexplained, ‘gender gap’ in
mortality between females and males in CF68 and fostering
gender medicine in CF.
Methods
General experimental approaches. Mice were randomized and assigned to group
allocation at the time of purchase to minimize any potential bias. No blinding was
applied on harvesting cells after the treatments.
Mice. C57BL/6 (wild-type, WT), Rag1 / and MC-deficient C57BL/6-KitW/W-v
mice, 6–8 week old, of both sexes, were purchased from Charles River (Calco,
Italy). Genetically engineered homozygous Cftr / mice69 were bred at the
CF core animal facility at San Raffaele Hospital, Milan, Italy. Il9R / and
RagIl9R / mice were from the Ludwing Institute for Cancer Research, Brussells.
Fungal infection allergy and treatments. Anaesthetized (by inhalation of 3%
isoflurane (Forane Abbot) in oxygen)) mice were infected by the intranasal
instillation of 2 107 resting conidia/20 ml saline. For allergic broncho-pulmonary
aspergillosis, A. fumigatus culture filtrate extract in incomplete Freund’s adjuvant
A. fumigatus
IL-33
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Figure 7 | Proposed model for the role of IL-9 in promoting a mast
cells/ILC2/Th9 fibrotic pathway in CF. IL-9, produced by IL-33-expanded
ILC2, activates MC for IL-2 production leading to the expansion of
CD25þ ILC2 that promote Th9 cell activation. The resulting increased
production of IL-9 further amplifies the inflammatory loop by promoting
ILC2 survival and type 2 cytokines production and by activating MC for the
production of fibrotic TGF-b. IL-9 ablation or MC inhibition (imatinib) are
potential drugable pathways through which inflammation and allergy could
be restrained in CF. EC, epithelial cells. aIL-9, IL-9 neutralizing antibody.
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(Sigma-Aldrich) was given (100 mg) to intact mice intraperitoneally (i.p.),
subcutaneously and then intransally (20mg), twice a week apart. A week after
the last intranasal challenge, mice received 107 Aspergillus resting conidia and
evaluated a week later. Murine monoclonal anti-IL-9 antibody (MM9CI from
BioXcell), or control isotype IgG, were administered i.p. at the dose of 500 mg kg 1
for a week starting the day of the infection. The levels of IL-9 after antibody
treatment were 65±15 versus 295±16 pgmg 1 for C57BL/6 and 103±27 versus
719±14 pgmg 1 for Cftr / mice, treated versus untreated mice. IL-2 at the
dose of 1 mg per mouse was given i.p. for a week. Imatinib mesylate (Glivec, ST1571
Novartis, Basel) were administered i.p. at the dose of 1mg kg 1 for a week starting
the day of the infection.
Mast cell engraftment. Selective engraftment of MC in MC-deficient C57BL/
6-KitW/W-v mice was performed as follow. Briefly, bone marrow cells derived from
6-week-old female C57BL/6 mice were cultured in WEHI-3–conditioned medium
(ATCC number TIB-68), as a source of IL-3, for 4–5 weeks to obtain MC
populations (BMCMC) which purity was higher than 95%. Via the tail vein,
5 106 BMCMC were injected into each mouse, and the recipients were used
for experiments 4 weeks later.
Generation of bone marrow chimeras. Femurs and tibias were removed
aseptically from donor C57BL/6 and Cftr / euthanized mice. Bone marrow was
retrieved by flushing with cold Dulbecco’s modified Eagle’s medium supplemented
with 10% heat-inactivated foetal calf serum and 2mM L-glutamine (Invitrogen).
Cells were washed twice with PBS without calcium and magnesium supplemented
with 1% foetal calf serum. Recipient C57BL/6 and Cftr / mice were irradiated
with 9Gy and reconstituted no later than 6 h after the last irradiation with
10 106 T cells by intravenous injection. Mice were given sulfamethoxazole
(150mgml 1) and trimethoprim (30mgml 1) in drinking water for the first 3
weeks of reconstitution. Mice were used no earlier than 4 weeks after transplan-
tation. Before use in experiments, all mice were bled from the retro-orbital plexus,
and the peripheral blood lymphocytes were analysed for the stable donor-type
chimerism by reverse transcription-PCR of Cftr.
In vivo staining analysis. For histology, paraffin-embedded tissues were stained
with Periodic acid-Schiff, Masson’s trichrome or Toluidine Blue staining to
investigate inflammation, collagen deposition and MC infiltration, respectively. For
immunofluorescence, lungs were incubated at 4 C with phycoerythrin-conjugated
(PE) anti-CD25 (Miltenyi Biotec clone 7D4, 1:60), anti-T1-ST2 (BioLegend clone
DIH9, 1:400), anti-IL-9 (Milenyi Biotec clone RM9A4, 1:60) and fluorescein iso-
thiocyanate-conjugated (FITC) anti-mouse CD90.2 (Miltenyi Biotecclone 30-H12,
1:60) and anti-CD4 (BioLegend clone GK1.5, 1:1,000). Nuclei were counterstained
with 4,6-diamidino-2-phenylindole. Immunostaining with appropriate irrelevant
antibodies did not give positive staining of the lung. For immunohistochemistry,
the lung sections were incubated overnight with polyclonal anti-chymase (Bioss,
1:100) or monoclonal anti-tryptase (Abcam clone EPR8476, 1:500) followed by the
secondary biotinylated antibodies. Cells were counterstained with haematoxylin.
Photographs were taken using a high-resolution Olympus DP71 microscope with a
 20 and  40 objective or EVOS FL Color Imaging System with a  60 objective.
For immunoblotting, blots of lung lysates were incubated with polyclonal
antibodies against STAT5 and phospho-STAT5 (both from Cell Signaling, 1:1,000)
and normalized on b-actin (clone AC-15 from Sigma). The ChemiDocTM
XRSþ Imaging system (Bio-Rad) was used to detect chemiluminescence on the
addition of the LiteAblotPlus chemiluminescence substrate (Euroclone S.p.A).
Quantification was done by densitometry image analysis using Image Lab 5.1
software (Bio-Rad). The uncut blot is shown in Supplementary Fig. 8.
TUNEL assay of lung sections. Sections of lungs fixed in 4% buffered
paraformaldehyde, pH 7.3, for 36 h and embedded in paraffin, were deparaffinized,
rehydrated, treated with 0.1M citrate buffer, pH 6.0, washed and blocked in 0.1M
Tris-HCl buffer, pH 7.5, supplemented with 3% bovine serum albumin and 20%
foetal calf serum. The slides were then incubated with fluorescein-coupled dUTP
and terminal deoxynucleotidyltransferase–mediated deoxyuridine triphosphate
nick-end labelling (TUNEL) enzyme (Roche Diagnostics) in the presence of
terminal deoxynucleotidyltransferase. Unspecific binding was removed by washing
with phosphate-buffered saline for 10min at 70 C. The sections were mounted and
analysed by fluorescence microscopy, using a  40 objective.
Cell isolation and culture. Lungs were finely minced, digested in 16mgml 1
Collagenase P (Roche) for 30min and meshed through a 70-mm cell strainer. ILCs
were isolated from total lung cells by magnetic depletion of Lineage Positive cells
(Miltenyi Biotec). CD4þ T cells and c-Kitþ cells were purified from total lung
cells after incubation of CD4 microbeads and with PE-labelled anti-c-Kit followed
by anti-PE MicroBeads respectively (both from Miltenyi Biotec). FcERIa-APC
and c-Kit-PE (Miltenyi Biotec) staining and morphological examination after
toluidine blue staining on the cytospin slides were used fir c-Kitþ cell phenotyping.
For Lin -CD4þ T cell co-culture, 2 106 CD4þ T cells were co-cultured with
1 106 Lin cells with or without 50 ngml 1 recombinant IL-33, 40 ngml 1
recombinant IL-2 and pulsed with A. fumigatus conidia. Three days later, IL-9
levels in culture supernatants were analysed by ELISA and Th9 transcription
factors by real-time PCR. To separate Lin and CD4þ T cell, we used the
Transwell culture system (Costar, 0.4 mm pore size; Corning) with CD4þ T cells in
the lower wells and Lin in the upper wells7. For c-Kitþ cells culture, 5 105 cells
were cultured overnight in RPMI medium and pulsed with A. fumigatus conidia
with or without 10 mgml 1 IgE, 100 ngml 1 IL-33 and 100 ngml 1 IL-9.
Flow cytometry. Flow cytometry on enriched Lin cells was performed with a
combination of the following fluorescence-conjugated mAbs (all from Miltenyi
Biotec unless specified otherwise): APC-conjugated anti-NKp46 (29A1.4.9),
anti-CD90.2 (30-H12), anti-Rorg (t; REA278), anti-FcRIa (MAR-1), anti-CD4
(GK1.5); PE-conjugated anti-NK1.1 (PK136), anti-CD25 (7D4), anti-T1-ST2
(DIH9, from Biolegend), anti-CD117 (3C11), anti-IL-9 (RM9A4) and anti-IL-2
(JES6-5H4). For intracellular staining, phorbol 12-myristate 13-acetate (PMA)/
ionomycin-stimulated cells were added of brefeldin, and then permeabilized with
the CytoFix/CytoPerm kit (BD Biosciences) for intra-cytoplasmic detection of IL-9
and IL-2. Flow cytometry was done at 4 C on cells first exposed to Fc receptor
mAb (2.4G2). Cells were analysed with a BD LSRFortessa flow cytometer equipped
with BD FACSDiva 7.0 software.
ELISA and real-time PCR. The levels of cytokines and IgE in lung homogenates,
culture supernatants or expectorates were determined by ELISA kits (R&D
Systems) following manufacturer’s instructions. Real-time PCR with reverse
transcription was performed using CFX96 Touch Real-Time PCR Detection
System and SYBR Green chemistry (Bio-Rad) on total RNA reverse transcribed
with the cDNA Synthesis Kit (Bio-Rad). The PCR primers were as listed in
Supplementary Table 5. Amplification efficiencies were validated and normalized
against Gapdh. The thermal profile for SYBR Green real-time PCR was at 95 C
for 3min, followed by 40 cycles of denaturation for 30 s at 95 C and an
annealing/extension step of 30 s at 60 C. The messenger RNA-normalized data
were expressed as relative gene messenger RNA in treated versus untreated groups
or cells.
Human study. A cohort of 347 patients of Caucasian origin with a proven
diagnosis of CF (CFTR genotyping, sweat testing and clinical phenotype) was
enroled in a prospective multicenter longitudinal genetic association study, See
Supplementary Table 1 for clinical data including age, gender, lung function
testing, measures of nutrition, microbiological findings and vital status of the
patients’ cohort.
SNPs selection and genotyping. DNA was isolated from blood with the QIAamp
DNA Mini (Qiagen, Milan, Italy) system and stored at  20 C. IL9 SNPs were
selected based on literature review37 and their ability to tag surrounding variants in
the HapMap-CEU population of the International HapMap project, NCBI build
B36 assembly HapMap phase III (http://www.hapmap.org). Haplotype-based
tagging SNPs were selected by assessing LD blocks from the genes of interest with a
pairwise correlation coefficient r2 of at least 0.80 and a minor allele frequency
higher than 5% in the HapMap-CEU population. Five IL9 SNPs complied with the
selection criteria: rs2069885, rs2069882, rs31564, rs1859430 and rs1799962. The
applied Biosystems 7500 Fast qPCR system (Life Technologies) was used for SNP
genotyping by KASPar assays (KBiosciences, Hertfordshire, UK). Each genotyping
set comprised randomly selected replicates of sequenced samples and negative
controls. Agreement between original and duplicate samples was Z99% for all
SNPs. Laboratory personnel were blind to the sample status.
Statistical analysis. Data are expressed as mean±s.d. Horizontal bars
indicate the means. Statistical significance was calculated by two-way ANOVA
(Bonferroni’s post hoc test) for multiple comparisons and by a two tailed Student’s
t-test for single comparison. The distribution of levels tested by Kolmogorov–
Smirnov normality test turned out to be non-significant. Values of P not 40.05
were considered significant. The data reported are either representative from two
or three experiments (FACS data, histology, immunofluoresce and TUNEL assay)
or pooled otherwise. The in vivo groups consisted of 6 mice per group. Data were
analysed by GraphPad Prism 4.03 programme (GraphPad Software). No statistical
method was used to predetermine sample size. Genetic association testing was
carried out considering additive and dominant models by linear regression
implemented in Plink v1.07 (ref. 70), adjusting for age at sampling. Haplotype-
based association tests were performed by general linear model using Plink v1.07
(ref. 70). LD analysis was performed using Haploview, and defining LD blocks
based on the solid spine of LD algorithm. Analyses were conducted stratifying the
study population according to sex since previous evidence highlighted the existence
of sex dimorphism at IL9 locus36,37. IL9 rs2069885 by sex interaction was tested by
general linear model using SPSS v.21. Two-tail P values are reported. Bonferroni’s
correction for multiple testing was not performed since we are assessing specific
questions on a candidate gene and we are not searching for associations without a
priori hypotheses. Power calculation (using QUANTO v1.2.4) was performed to
determine whether the sample study had sufficient power to detect a significant
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association between IL9 rs2069885 and total IgE levels. Considering sample size
(N¼ 237), allele frequency (13%), dominant genetic model, mean level of IgE and
its standard deviation (131.7±248.2 Uml 1) and a¼ 0.05 two-sided, we could
establish that our sample have sufficient power (b¼ 0.20, Power¼ 0.8) to detect an
association explaining more than 3% of total IgE levels variance (Supplementary
Table 6).
Study approval. All animal experiments were approved by local government
authorities and were in agreement with the Italian Approved Animal Welfare
Authorization 360/2015-PR and Legislative decree 26/2014 obtained from the
Italian Ministry of Health lasting and lasting for five years (2015–2020). Infections
were performed under anaesthesia and all efforts were made to minimize suffering.
Human studies approval was obtained from institutional review boards the
Bambino Gesu` Children’s Hospital (Rome, Italy), Ospedale Maggiore Policlinico,
University of Milan, (Milan, Italy), Innsbruck Medical University, (Innsbruck,
Austria) and Servizio di Supporto Fibrosi Cistica, (Cerignola, Foggia, Italy).
Written informed consent was obtained from the participants, or, in case of
minors, from parents or guardian.
Data availability. The data that support the findings of this study are available
from the corresponding author upon request.
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